Cresco Labs (CRLBF) 40-F 22 Mar 23 2022 FY Annual report (Canada) Financial data

Cover Page

Cover Page	12 Months Ended
	Dec. 31, 2022 shares
Document Information [Line Items]
Document Type	40-F
Document Registration Statement	false
Document Annual Report	true
Entity Registrant Name	Cresco Labs Inc.
Entity Tax Identification Number	98-1505364
Local Phone Number	929-0993
Entity Address, Address Line One	400 W Erie St Suite 110
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
Entity Address, Country	US
City Area Code	312
Annual Information Form	true
Audited Annual Financial Statements	true
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Central Index Key	0001832928
Document Fiscal Period Focus	FY
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	Z4
Entity File Number	000-56241
Document Fiscal Year Focus	2022
Business Contact
Document Information [Line Items]
Local Phone Number	929-0993
Entity Address, Address Line One	400 W Erie St Suite 110
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	312
Contact Personnel Name	Cresco Labs Inc.
Special Subordinate Voting Shares (SSVS)
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	63,868,296
Subordinate Voting Shares (SVS)
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	281,147,586
Proportionate Voting Shares (PVS)
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	100,412
Super Voting Shares (MVS)
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	500,000

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	Marcum LLP
Auditor Firm ID	688
Auditor Location	Chicago, IL, USA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 119,341	$ 223,543
Restricted cash	2,169	2,559
Accounts receivable, net	56,492	43,379
Inventory, net	134,608	136,643
Loans receivable, short-term	447	1,312
Prepaid expenses	9,420	10,665
Other current assets	3,569	3,654
Total current assets	326,046	421,755
Non-current assets:
Property and equipment, net	379,722	369,092
Right-of-use assets	128,264	88,017
Intangible assets, net	407,590	437,644
Loans receivable, long-term	823	505
Investments	1,228	5,912
Goodwill	330,555	446,767
Deferred tax asset	26	6,561
Other non-current assets	9,438	4,210
Total non-current assets	1,257,646	1,358,708
TOTAL ASSETS	1,583,692	1,780,463
Current liabilities:
Accounts payable	28,093	32,278
Accrued liabilities	65,161	95,442
Short-term borrowings	18,812	19,928
Income tax payable	94,842	46,949
Current portion of lease liabilities	26,124	20,792
Deferred consideration, contingent consideration and other payables, short-term	47,834	71,833
Derivative liabilities, short-term	0	1,172
Total current liabilities	280,866	288,394
Non-current liabilities:
Long-term notes and loans payable, net	469,055	465,079
Lease liabilities	156,180	118,936
Deferred tax liability	75,138	85,666
Deferred consideration, long-term	7,770	17,651
Other long-term liabilities	7,000	7,001
Total non-current liabilities	715,143	694,333
TOTAL LIABILITIES	996,009	982,727
COMMITMENTS AND CONTINGENCIES (Note 15)
SHAREHOLDERS’ EQUITY
Share capital	1,704,630	1,597,715
Accumulated other comprehensive loss	(1,393)	(254)
Accumulated deficit	(1,076,198)	(841,907)
Equity of Cresco Labs Inc.	627,039	755,554
Non-controlling interests	(39,356)	42,182
TOTAL SHAREHOLDERS’ EQUITY	587,683	797,736
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 1,583,692	$ 1,780,463

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)		12 Months Ended
		Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares
Super Voting Shares (MVS)
Condensed Balance Sheet Statements
Par value (in dollars per share) | $ / shares		$ 0	$ 0
Authorized (in shares)		500,000	500,000
Issued (in shares)		500,000	500,000
Outstanding (in shares)		500,000	500,000
Subordinate Voting Shares (SVS)
Condensed Balance Sheet Statements
Par value (in dollars per share) | $ / shares		$ 0	$ 0
Issued (in shares)		281,147,586	270,033,270
Outstanding (in shares)		281,147,586	270,033,270
Proportionate Voting Shares (PVS)
Condensed Balance Sheet Statements
Par value (in dollars per share) | $ / shares	[1]	$ 0	$ 0
Issued (in shares)	[1]	20,082,384	20,667,206
Outstanding (in shares)	[1]	20,082,384	20,667,206
Description of stock conversion ratio		0.005
Special Subordinate Voting Shares (SSVS)
Condensed Balance Sheet Statements
Par value (in dollars per share) | $ / shares	[2]	$ 0	$ 0
Authorized (in shares)	[2]	639	639
Issued (in shares)	[2]	639	639
Outstanding (in shares)	[2]	639	639
Description of stock conversion ratio		100,000
[1] 1 Proportionate Voting Shares (“PVS”) presented on an “as-converted” basis to Subordinate Voting Shares (“SVS”) (1-to-200) 2 Special Subordinate Voting Shares (“SSVS”) presented on an “as-converted” basis to SVS (1-to-0.00001)

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [abstract]
Revenues, net	$ 842,681	$ 821,682
Costs of goods sold	435,668	415,335
Gross profit	407,013	406,347
Operating expenses:
Selling, general and administrative	350,653	317,804
Impairment loss	140,655	305,894
Total operating expenses	491,308	623,698
Loss from operations	(84,295)	(217,351)
Other expense, net:
Interest expense, net	(57,837)	(51,211)
Other income, net	15,227	13,031
Loss from equity method investments	0	(1,196)
Total other expense, net	(42,610)	(39,376)
Loss before income taxes	(126,905)	(256,727)
Income tax expense	(88,938)	(40,107)
Net loss	(215,843)	(296,834)
Net income attributable to non-controlling interests, net of tax	(3,796)	22,763
Net loss attributable to Cresco Labs Inc.	$ (212,047)	$ (319,597)
Net loss per share - attributable to Cresco Labs Inc. shareholders:
Diluted loss per share (in dollars per share)	$ (0.71)	$ (1.22)
Basic loss per share (in dollars per share)	$ (0.71)	$ (1.22)
Basic weighted average number of shares outstanding (in shares)	298,161,665	262,326,138
Diluted weighted average number of shares outstanding (in shares)	298,161,665	262,326,138

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statement of comprehensive income [abstract]
Net loss	$ (215,843)	$ (296,834)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation differences, net of tax	(1,139)	393
Total comprehensive loss for the period	(216,982)	(296,441)
Comprehensive income attributable to non-controlling interests, net of tax	(3,796)	22,763
Total comprehensive loss attributable to Cresco Labs Inc.	$ (220,778)	$ (273,678)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Share capital	Accumulated deficit	Accumulated other comprehensive loss, net of tax	Non-controlling interests
Beginning balance at Dec. 31, 2020	$ 575,332	$ 802,264	$ (328,380)	$ (647)	$ 102,095
Exercise of options and warrants	6,947	6,947
Equity-based compensation	28,215	28,215
Employee taxes withheld on certain share-based payment arrangements	11,458	11,458
Income tax reserve	311		311
Payable pursuant to tax receivable agreements	(1,803)	(1,803)
Tax benefit from shareholder redemptions	1,983	1,983
Equity issued related to acquisitions	380,452	380,452
Private placement issuance, net of costs	123,469	123,469
Equity issuances	15,521	15,521
Distributions to non-controlling interest holders	(47,708)	25,877	(1,985)		(71,600)
Cresco LLC shares redeemed	0	203,332	(192,256)		(11,076)
Foreign currency translation	393			393
Net income (loss)	(296,834)		(319,597)		22,763
Ending balance at Dec. 31, 2021	797,736	1,597,715	(841,907)	(254)	42,182
Exercise of options and warrants	698	698
Equity-based compensation	23,761	23,761
Employee taxes withheld on certain share-based payment arrangements	(427)	(427)
Income tax reserve	155		155
Payable pursuant to tax receivable agreements	597	597
Tax benefit from shareholder redemptions	(1,239)	(1,239)
Equity issued related to acquisitions	34,708	34,708
Distributions to non-controlling interest holders	(51,324)	31,379	(5,230)		(77,473)
Cresco LLC shares redeemed	0	17,438	(17,169)		(269)
Foreign currency translation	(1,139)			(1,139)
Net income (loss)	(215,843)		(212,047)		(3,796)
Ending balance at Dec. 31, 2022	$ 587,683	$ 1,704,630	$ (1,076,198)	$ (1,393)	$ (39,356)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (215,843)	$ (296,834)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	51,930	38,640
Amortization of operating lease assets	5,795	6,309
Bad debt expense and provision expense for expected credit loss	1,700	3,544
Share-based compensation expense	23,221	27,536
Loss (gain) on investments	4,615	(930)
Loss (gain) on changes in fair value of deferred and contingent consideration	5,667	(14,775)
Gain on derivative instruments and warrants	(1,184)	(16,663)
Impairment loss	140,655	305,894
Loss on inventory write-offs and provision	7,358	2,669
Change in deferred taxes	(4,643)	(34,931)
Accretion of discount and deferred financing costs on debt arrangements	3,951	11,304
Loss on debt extinguishment	0	10,342
Foreign currency (gain) loss	(940)	730
Loss on disposal of property and equipment	2,635	0
Gain on lease termination and sale and leaseback transaction	(19,630)	0
Other losses, net of gains	0	721
Changes in operating assets and liabilities:
Accounts receivable	(14,776)	(10,964)
Inventory	(2,668)	(18,420)
Other assets	(4,512)	(6,215)
Accounts payable and other accrued expenses	10,700	21,155
Operating lease liabilities	(22,073)	(16,436)
Other current liabilities	0	(90)
Income taxes payable	46,783	1,901
NET CASH PROVIDED BY OPERATING ACTIVITIES	18,741	14,487
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(83,026)	(93,875)
Purchase of intangibles	(3,106)	(3,178)
Proceeds from sale and leaseback transactions and tenant improvement allowances	47,914	33,157
Payment of acquisition consideration, net of cash acquired	(1,135)	(75,814)
Proceeds from disposals of property and equipment	1,322	0
Proceeds from divestiture, net of cash transferred	0	69
Receipts from collections of loans and advances	2,654	2,000
Loans and/or advances for entities to be acquired	(1,200)	(26,292)
NET CASH USED IN INVESTING ACTIVITIES	(36,577)	(163,933)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from January 2021 private placement offering	0	124,105
Proceeds from exercise of stock options, warrants and sell-to-cover shares	3,215	20,096
Proceeds from the issuance of long-term debt	0	387,000
Payment of debt, financing issuance costs and non-extending lender fees	0	(6,461)
Payment of debt prepayment and debt extinguishment costs	0	(16,202)
Repayment of debt	0	(200,000)
Payment of acquisition-related contingent consideration	(4,927)	0
Distributions to non-controlling interest redeemable unit holders	(82,505)	(69,803)
Payments for taxes related to net share settlements of restricted stock units	0	(143)
Principal payments on finance lease obligations	(2,426)	(3,587)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(86,643)	235,005
Effect of exchange rate changes on cash and cash equivalents	(113)	(231)
Net (decrease) increase in cash and cash equivalents	(104,592)	85,328
Cash and cash equivalents and restricted cash, beginning of year	226,102	140,774
Cash and cash equivalents, end of year	119,341	223,543
Restricted cash, end of year	2,169	2,559
Cash and cash equivalents and restricted cash, end of year	121,510	226,102
CASH PAID DURING THE YEAR FOR:
Income tax, net	46,756	73,955
Interest	53,651	39,118
NON-CASH TRANSACTIONS:
Issuance of shares, stock options and warrants under business combinations and acquisitions	0	380,452
Non-cash consideration for business combination	34,708	47,921
Non-controlling interests redeemed for equity	357	11,074
Increase to net lease liability	26,487	28,143
Receivable related to purchase price adjustment	797	0
Liability incurred to purchase property, equipment and intangibles	8,664	7,207
Cashless exercise of stock options and warrants	1,821	3,879
Unpaid declared distributions to non-controlling interest redeemable unit holders	9,896	36,450
Receivable related to financing lease transaction	612	1,117
Liability incurred for debt, financing issuance costs and non-extending lender fees	0	7,000
Liability incurred in accordance with tax receivable agreement	1,053	1,804
Issuance of shares for non-solicitation intangible asset	0	3,000
Issuance of shares for settlement	$ 0	$ 12,790

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2022
Nature Of Operations [Abstract]
Nature of Operations	NOTE 1. NATURE OF OPERATIONS Cresco Labs Inc. (“Cresco Labs” or the “Company”), formerly known as Randsburg International Gold Corp. (“Randsburg”) was incorporated in the Province of British Columbia under the Company Act (British Columbia) on July 6, 1990. The Company is one of the largest vertically-integrated multi-state cannabis operators in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products primarily through Sunnyside* ® , Cresco Labs’ national dispensary brand and third-party retail stores. Employing a consumer-packaged goods approach to cannabis, Cresco Labs’ house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco ® , High Supply ® , Mindy’s TM , Good News ® , Remedi TM , Wonder Wellness Co. ® and FloraCal ® Farms. The Company operates in and/or has ownership interests in Illinois, Pennsylvania, Ohio, California, Arizona, New York, Massachusetts, Michigan, Florida and Maryland pursuant to the Illinois Compassionate Use of Medical Cannabis Program Act and the Illinois Cannabis Regulation and Tax Act; the Pennsylvania Medical Marijuana Act; the Ohio Medical Marijuana Control Program; the California Medicinal and Adult-Use Cannabis Regulation and Safety Act; the Arizona Medical Marijuana Act and the Smart and Safe Arizona Act; the New York Marihuana Regulation and Taxation Act; the Massachusetts Regulation and Taxation of Marijuana Act, the Massachusetts Act for the Humanitarian Medical Use of Marijuana and the Massachusetts Act to Ensure Safe Access to Marijuana; the Michigan Medical Marihuana Act, the Michigan Medical Marihuana Facilities Licensing Act, the Michigan Regulation and Taxation of Marihuana Act and the Michigan Marihuana Tracking Act; the Florida Compassionate Medical Cannabis Act; and the Maryland Medical Cannabis Law, respectively. On November 30, 2018, in connection with a reverse takeover (the “Transaction”), the Company (i) consolidated its outstanding Randsburg common shares on an 812.63 old for one (1) new basis, and (ii) filed an alteration to its Notice of Articles with the British Columbia Registrar of Companies to change its name from Randsburg to Cresco Labs Inc. and to amend the rights and restrictions of its existing classes of common shares, redesignate such classes as the class of SVS and create the classes of PVS and Super Voting Shares (“MVS”). Pursuant to the Transaction, among the Company (then Randsburg) and Cresco Labs, LLC, a series of transactions were completed on November 30, 2018, resulting in a reorganization of Cresco Labs, LLC and Randsburg in which Randsburg became the indirect parent and sole voting unitholder of Cresco Labs. The Transaction constituted a reverse takeover of Randsburg by Cresco Labs, LLC under applicable securities laws. Cresco Labs, LLC was formed as a limited liability company under the laws of the state of Illinois on October 8, 2013 and is governed by the Cresco LLC limited liability agreement (“Pre-Combination LLC Agreement”). The Pre-Combination LLC Agreement was further amended and restated in connection with the completion of the Transaction. The Company trades on the Canadian Securities Exchange under the ticker symbol “CL,” on the Over-the-Counter Market under the ticker symbol “CRLBF” and on the Frankfurt Stock Exchange under the symbol “6CQ.” The Company’s head office is located at Suite 110, 400 W Erie St, Chicago, IL 60654. The registered office is located at Suite 2500, 666 Burrard Street, Vancouver, BC V6C 2X8.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Preparation The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). (b) Basis of Measurement The accompanying consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain equity method investments as well as certain loans receivable, investments, derivative instruments and contingent considerations, which are recorded at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets acquired and the contractual obligation for liabilities incurred. (c) Functional and Presentation Currency The Company’s functional currency and that of the majority of its subsidiaries is the United States (“U.S.”) dollar. The Company’s reporting currency is the U.S. dollar (“USD”). All references to “C$” refer to Canadian dollars. Foreign currency denominated assets and liabilities are re-measured into the functional currency using period-end exchange rates. Gains and losses from foreign currency transactions are included in Other income, net in the Consolidated Statements of Operations. Assets and liabilities of foreign operations having a functional currency other than USD (e.g., C$) are translated at the rate of exchange prevailing at the reporting date; revenues and expenses are translated at the monthly average rate of exchange during the period. Gains or losses on translation of foreign subsidiaries and net investments in foreign operations are included in Foreign currency translation differences, net of tax in the Consolidated Statements of Comprehensive Loss and Accumulated other comprehensive loss on the Consolidated Balance Sheets. (d) Basis of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries with intercompany balances and transactions eliminated upon consolidation. Subsidiaries are those entities over which the Company has the power over the investee, is exposed, or has rights, to variable involvement with the investee; and has the ability to use its power to affect its returns. The following are Cresco Labs’ wholly-owned or controlled entities as of December 31, 2022: Entity Location Purpose Percentage Cresco Labs Inc. British Columbia, Canada Parent Company Cali-AntiFragile Corp. California Holding Company 100% Alta Supply Inc. California Distribution 100% Kaya Management Inc. California Production 100% River Distributing Co., LLC California Distribution 100% FloraCal California Cultivation 100% Cub City, LLC California Cultivation 100% CRHC Holdings Corp. Ontario, Canada Holding Company 100% Laurel Harvest Labs, LLC Pennsylvania Cultivation and Dispensary Facility 100% JDRC Mount Joy, LLC Illinois Holding Company 100% JDRC Scranton, LLC Illinois Holding Company 100% Bluma Wellness Inc. British Columbia, Canada Holding Company 100% CannCure Investments Inc. Ontario, Canada Holding Company 100% Cannabis Cures Investments, LLC Florida Holding Company 100% 3 Boys Farm, LLC (One Plant Florida) Florida Cultivation, Production and Dispensary Facility 100% Farm to Fresh Holdings, LLC Florida Holding Company 100% Cresco U.S. Corp. Illinois Manager of Cresco Labs, LLC 100% Entity Location Purpose Percentage MedMar Inc. Illinois Holding Company 100% MedMar Lakeview, LLC Illinois Dispensary 88% MedMar Rockford, LLC Illinois Dispensary 75% Gloucester Street Capital, LLC New York Holding Company 100% Valley Agriceuticals, LLC New York Operating Entity 100% JDRC Ellenville, LLC Illinois Holding Company 100% CMA Holdings, LLC Illinois Holding Company 100% BL Real Estate, LLC Massachusetts Holding Company 100% Cultivate Licensing LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Worcester, Inc Massachusetts Dispensary 100% Cultivate Leicester, Inc. Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Framingham, Inc. Massachusetts Dispensary 100% Cultivate Burncoat, Inc. Massachusetts Holding Company 100% Cultivate Cultivation, LLC Massachusetts Cultivation and Production Entity 100% Good News Holdings, LLC Illinois Holding Company 100% Wonder Holdings, LLC Illinois Holding Company 100% JDRC Seed, LLC Illinois Holding Company 100% CP Pennsylvania Holdings, LLC Illinois Holding Company 100% Bay, LLC Pennsylvania Dispensary 100% Bay Asset Management, LLC Pennsylvania Holding Company 100% Ridgeback, LLC Colorado Holding Company 100% Cresco Labs, LLC Illinois Operating Entity 58% Cresco Labs Notes Issuer, LLC Illinois Holding Company Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 99% Wellbeings, LLC Delaware CBD Wellness Product Development 100% Cresco Labs SLO, LLC California Holding Company 100% SLO Cultivation Inc. California Cultivation and Production Facility 80% Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100% Cresco Labs PA, LLC Illinois Holding Company 100% Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100% JDC Newark, LLC Ohio Holding Company 100% Verdant Creations Newark, LLC Ohio Dispensary 100% JDC Marion, LLC Ohio Holding Company 100% Verdant Creations Marion, LLC Ohio Dispensary 100% JDC Chillicothe, LLC Ohio Holding Company 100% Verdant Creations Chillicothe, LLC Ohio Dispensary 100% JDC Columbus, LLC Ohio Holding Company 100% Care Med Associates, LLC Ohio Dispensary 100% Cresco Labs Arizona, LLC Arizona Holding Company 100% Arizona Facilities Supply, LLC Arizona Cultivation, Production and Dispensary Facility 100% AFS Maryland, LLC Maryland Production Facility 100% Cresco Labs Tinad, LLC Illinois Holding Company 100% PDI Medical III, LLC Illinois Dispensary 100% Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100% Phoenix Farms of Illinois, LLC Illinois Dispensary 100% JDC Elmwood, LLC Illinois Holding Company 100% FloraMedex, LLC Illinois Dispensary 100% Cresco Edibles, LLC Illinois Holding Company 100% TSC Cresco, LLC Illinois Licensing 75% Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85% (a) Cresco Labs Michigan, LLC is 85% owned by related parties within management of the Company. Cresco U.S. Corp., which is wholly owned by the Company, is the sole manager of Cresco Labs, LLC; Cresco Labs, LLC is the sole owner and manager of Cresco Labs Notes Issuer, LLC. Therefore, the Company controls Cresco Labs Notes Issuer, LLC and has consolidated its results into the consolidated financial statements. Non-controlling interests (“NCI”) represent ownership interests in consolidated subsidiaries by parties that are not shareholders of the Company. They are shown as a component of total equity in the Consolidated Balance Sheets, and the share of income attributable to NCI is shown as Net income attributable to non-controlling interests, net of tax in the Consolidated Statements of Operations and in the Consolidated Statements of Comprehensive Loss. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions. (e) Cash and Cash Equivalents Cash and cash equivalents include cash deposits in financial institutions, other deposits that are readily convertible into cash and cash on hand at retail locations. The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents and mainly consist of certificates of deposits. (f) Restricted Cash Restricted cash represents amounts held in escrow related to investments, acquisitions and building improvements. (g) Accounts Receivable Accounts receivable are recorded net of allowance for doubtful accounts. The Company estimates the allowance for doubtful accounts based on contractual payment terms, actual payment history of its customers, current economic conditions and individual customer circumstances. Accounts receivable are evaluated quarterly and an allowance is recorded as needed. When a receivable is uncollectible, it is written off against the provision. Subsequent recoveries of amounts previously written off are credited to the Consolidated Statements of Operations . See Note 16 for further discussion. (h) Inventory Inventory is primarily composed of raw materials (cannabis and non-cannabis), work-in-process and finished goods. Inventory is recorded at the lower of cost or net realizable value, with cost determined using the weighted average cost method. For manufactured inventory, costs incurred during the growing and production of cannabis and cannabis-based products are capitalized, net of yield adjustments, as incurred to the extent that costs are less than net realizable value. These costs include, but are not limited to, materials, labor, overhead costs, cannabis taxes and depreciation expense on equipment involved in manufacturing, packaging, labeling, inspection and testing. Costs related to purchased finished goods are recorded at cost, including freight. The Company reviews inventory for obsolete, redundant and slow-moving goods and any such inventory is written down to net realizable value. (i) Property and Equipment Property and equipment is stated at cost, net of accumulated depreciation. Land is recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The Company evaluates the recoverability of property, plant and equipment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. In those cases, the assets are assessed for impairment based on the estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying value of an asset exceeds its estimated future undiscounted cash flows, the Company will determine the fair value of the assets within the asset group and record an impairment loss calculated as the excess in carrying value over fair value. Equipment is derecognized upon disposal or when no future economic benefits are expected from its use. Leasehold improvements are amortized over the lesser of the life of the lease or estimated useful life of the improvement. Any gain or loss arising from derecognition or impairment of the asset (calculated as the difference between the net disposal proceeds and the carrying value of the asset) is included in the accompanying Consolidated Statements of Operations. The Company assesses property and equipment for indicators of impairment throughout the reporting period. See Note 4 for additional details. Category Estimated Leasehold Improvements 1 - 15 years Machinery and Equipment 5 - 15 years Furniture and Fixtures 3 - 8 years Vehicles 5 years Website and Software 3 - 7 years Computer Equipment 3 - 7 years Buildings and Building Improvements 5 - 39 years Repairs and maintenance that do not improve efficiency or extend economic life are charged to expense as incurred. (j) Intangible Assets Intangible assets are recorded at cost, less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date or date of consolidation/control. Amortization of definite-lived intangible assets is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. Costs incurred during the year to renew or extend the term of a recognized intangible asset are included within additions and are amortized on a straight-line basis over the useful lives of the permit or license renewal period. See Note 7 for additional details. Intangible assets are amortized over the following terms: Category Estimated Customer Relationships 7 - 19 years Non-Compete Agreements 4 - 5 years Trade Names 10 years Permit Application Fees 1 - 2 years Non-Solicitation Agreements 1 - 2 years The estimated useful lives and residual values are reviewed at each year end and any changes in estimates are accounted for prospectively. Intangible assets that have an indefinite useful life are not subject to amortization. The Company’s indefinite-lived intangible assets consist of licenses which represent the future benefits associated with the Company’s cultivation, processing and dispensary licenses. Absent such license intangibles, the Company cannot continue as a going concern and as such, there is no foreseeable limit to the period over which these assets are expected to generate future cash inflows to the Company. Definite-lived intangible assets are tested for impairment when there is an indication of impairment. Indefinite-lived intangible assets are tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment. For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to reporting units, determined based on the smallest identifiable group of assets that generate cash inflows and outflows that are largely independent of cash inflows from other assets or group of assets. (k) Equity Method Investments The Company determines how to account for investments based on the level of control or significant influence it has over the investee. If the Company determines it has control, then the investee is consolidated. Investees in which the Company has significant influence, but no control, are considered equity method investments. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but without control or joint control over those policies. Investments in equity method investments are accounted for using the equity method of accounting. Interests in equity method investments accounted for using the equity method are initially recognized at cost. The carrying value is then adjusted for the Company’s share of comprehensive loss, additional contributions to the investee and additional distributions from the investee. The carrying value of equity method investments is assessed for impairment at each balance sheet date. The Company’s investments in equity-accounted investees are classified within Investments in the Consolidated Balance Sheets. Investments in which the Company does not have significant influence or control are first recognized at cost. At each reporting period, the investment balances are adjusted to fair value, with changes in value recognized through profit and loss. See Note 6 for additional information. (l) Goodwill Goodwill represents the excess of the purchase price paid for the acquisition of a business over the fair value of the net assets acquired. Goodwill is allocated to the reporting unit or reporting units, which are expected to benefit from the synergies of the combination. Goodwill is not subject to amortization and is tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment may have occurred. For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to reporting units or groups of reporting units representing the lowest level at which the assets generate cash inflow and outflow independent of other assets. An impaired asset is written down to its estimated fair value based on the most recent information available. The Company assesses the fair values of its reporting units using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows. The income approach requires management to estimate a number of factors for each reporting unit, including projected future operating results, economic projections, anticipated future cash flows, discount rates, and the allocation of shared or corporate costs. The impairment review, which is performed October 1 of each year, begins with a qualitative assessment of all reporting units. If the Company determines, based on weighting of all available evidence, that a reporting unit’s carrying value may exceed its fair value at the testing date, the Company performs a quantitative impairment assessment. If the carrying value of these intangible assets or the reporting unit exceeds the fair values, the Company would record an impairment charge based on the excess of the carrying value over the fair value. See Note 7 for additional details. As of December 31, 2022, the Company has no goodwill recorded that is expected to be tax deductible. (m) Income Taxes Tax expense recognized in profit or loss is comprised of the sum of current and deferred taxes not recognized in other comprehensive loss or directly in equity. (i) Current Tax Current tax assets and/or liabilities are comprised of claims from, or obligations to, fiscal authorities relating to the current or prior reporting periods that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. (ii) Deferred Tax Deferred taxes are calculated using the asset and liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realization, provided they are enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are always provided for in full. The measurement of deferred tax assets is reduced through a valuation allowance, if necessary, by the amount of any tax benefits that, based on available evidence, are more likely than not expected to be unrealized. Deferred tax assets and liabilities are offset only when the Company has a right and intention to offset current tax assets and liabilities from the same taxation authority. Changes in deferred tax assets or liabilities are recognized as a component of tax income or expense in profit or loss, except where they relate to items that are recognized in other comprehensive loss or directly in equity, in which case the related deferred tax is also recognized in other comprehensive loss or equity, respectively. As the Company operates in the cannabis industry, the Company is subject to the limits of Internal Revenue Code (“IRC”) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. See Note 20 for additional details. (n) Fair Value of Financial Instruments The Company accounts for assets and liabilities measured at fair value on a recurring basis in accordance with Accounting Standards Codification (“ASC”) 820 Fair Value Measurements . Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the inputs to the fair value measurements. The three levels of the hierarchy are: – Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; – Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; – Level 3 – Inputs for the asset or liability that are not based on observable market data. See Note 16 for additional details. (o) Loans Receivable The Company may provide financing to various related and non-related businesses within the cannabis industry. These loans are classified as held for investment and accounted for as financial instruments in accordance with ASC 310 Receivables . In certain instances, the Company has elected the fair value option in accordance with ASC 825 Financial Instruments ; in these instances, such instruments are labeled as measured at fair value. At each reporting date, the Company applies its judgment to evaluate the collectability of the Loans receivable balance and records a provision based on the assessed amount of expected credit loss (“ECL”). See Note 16 for additional details. (p) Leases The Company has entered into leases primarily for its corporate office, cultivation facilities, processing facilities and dispensaries. At inception of a contract, the Company determines whether the contract includes a lease. A contract contains a lease if it includes enforceable rights and obligations under which the right to control the use of an identified asset is conveyed for a period of time in exchange for consideration. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the commencement date – the date when the asset is available for use by the lessee. The Company assesses at lease commencement whether it is reasonably certain to exercise extension or termination options. The Company reassesses its lease portfolio to determine whether it is reasonably certain to exercise the options if there is a significant event or significant change in circumstances within its control. The extension options which are considered reasonably certain to be exercised are mainly those for which operational decisions have been made that make the lease assets vital to the continued relevant business activities. Liabilities arising from a lease are initially measured at the present value of the lease payments not yet paid, using the Company’s incremental borrowing rate. Lease liabilities include the value of the following payments: (i) Fixed payments, including in-substance fixed payments, less any lease incentives receivable; (ii) The exercise price of a purchase option if the Company is reasonably certain to exercise that option; and (iii) Penalties for early termination of the lease, if the lease term reflects the Company exercising an option to terminate the lease. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is decreased by cash paid net of interest expense incurred. The lease liability is remeasured when there is a change in future lease payments, or if the Company changes its assessment of whether it will exercise an extension, purchase or termination option. ROU assets are measured at cost and are comprised of the following: (i) The amount of the initial measurement of lease liability; (ii) Lease payments made at or before the commencement date less any lease incentives received; (iii) Any initial direct costs; and (iv) An estimate of costs of dismantling and removing the underlying asset, restoring the site on which it is located or the underlying asset, if applicable. The ROU asset is depreciated on a straight-line basis from the commencement date to the end of the lease term. A fixed amount of rent expense is recognized on a straight-line basis over the lease term for operating leases. For finance leases, depreciation expense on the ROU asset and interest expense on the lease liability are recognized over the lease term. The value of the ROU asset is periodically reduced by impairment losses, if any and adjusted for certain revaluations of the lease liability. In accordance with the guidance in ASC 842 Leases , the Company has elected not to recognize ROU assets and lease liabilities where the total lease term is less than or equal to twelve months. The payments for such leases are recognized as rent expense within Selling, general and administrative expenses or Cost of goods sold in the Consolidated Statements of Operations on a straight-line basis over the lease term. See Note 5 for additional information on leases. (q) Revenue Recognition Revenue is recognized by the Company in accordance with ASC 606 Revenue from Contracts with Customers . Through application of ASC 606, the Company recognizes revenue to depict the transfer of promised goods to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. In order to recognize revenue under ASC 606, the Company applies the following five (5) steps: • Identify a customer along with a corresponding contract; • Identify the performance obligation(s) in the contract to transfer goods to a customer; • Determine the transaction price the Company expects to be entitled to in exchange for transferring promised goods to a customer; • Allocate the transaction price to the performance obligation(s) in the contract; and • Recognize revenue when or as the Company satisfies the performance obligation(s). Revenue consists of wholesale and retail sales of cannabis and other cannabis-derived and related products. Wholesale and retail sales are both generally recognized at a point in time when control over the goods has been transferred to the customer and is recorded net of sales discounts. For retail sales, payment is typically due upon transferring the goods to the customer. For wholesale sales, payment is typically due upon transferring the goods to the customer or within a specified time period permitted under agreed-upon payment terms. Revenue is recognized upon the satisfaction of the performance obligation. The Company satisfies its performance obligation and transfers control upon delivery and acceptance by the customer. For some of its locations, the Company has customer loyalty programs where retail customers accumulate points based on their level of spending and use these points for discounts on cannabis and cannabis related products. These points are recorded as a contract liability until customers redeem their points for discounts. In addition, the Company records a performance obligation as a reduction of revenue based on the estimated probability of point redemption, which is calculated based on a standalone selling price and using historical redemption rates. Upon redemption, the loyalty program obligation is relieved and the offset is recorded as revenue. In the event of a product recall, the expected value method is utilized to estimate the financial impact and a reduction of revenue is recorded. See Note 12 for additional information on revenue and loyalty programs. (r) Advertising Costs Advertising costs are expensed as incurred and are included in Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations and totaled $8.1 million and $12.3 million for the years ended December 31, 2022 and 2021, respectively. (s) Excise Tax The Company recognizes excise tax and community benefit fees as Cost of goods sold or Selling, general and administrative expense based on whether the tax is generated on production of cannabis or as part of selling costs, respectively. (t) Share-Based Compensation The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. For awards with performance conditions, compensation expense is recognized over the service period of awards and adjusted for the probability of achievement of performance-based goals. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share-based payments granted to non-employees, the compensation expense is measured at the fair value of the equity instrument on the grant date. For awards where the holder has the election of settling their award in either cash or equity, the fair value of share-based compensation is recorded as a liability and remeasured at the end of each reporting period until the corresponding awards are settled. See Note 9 for additional information on share-based compensation. (u) Earnings (Loss) Per Share Earnings (loss) per share (“EPS”) is calculated by dividing the net earnings or loss attributable to shareholders by the weighted average shares outstanding during the period. The Company presents basic and diluted EPS in the Consolidated Statements of Operations. Basic EPS is calculated by dividing the profit or loss attributable to shareholders by the weighted average number of shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares outstanding for the effects of all dilutive potential shares, which are comprised of redeemable Cresco Labs, LLC shares (“Redeemable Units”); options, warrants and restricted stock units (“RSUs”) issued. Shares with anti-dilutive impacts are excluded from the calculation. The number of shares included with respect to Redeemable Units, options, warrants and RSUs is computed using the treasury stock method. As of December 31, 2022, all warrants that had not previously been exercised have expired. Potentially dilutive shares as of December 31, 2022 and 2021, which were excluded from the calculation of diluted EPS for the periods presented consisted of the following: (in thousands) 2022 2021 Redeemable Units 107,443 115,136 Options 25,528 23,609 Warrants — 9,842 RSUs 4,182 999 Total potentially dilutive shares 137,153 149,586 (v) Variable Interest Entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under ASC 810 Consolidations , where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the financial results of the entity. See Note 17 for additional information on VIEs. (w) Business Combinations and Assets Held for Sale A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for by applying the acquisition method. The total consideration transferred in a business combination is the sum of the fair values of assets transferred, liabilities assumed, equity interests and other consideration issued by the acquirer in exchange for control of the acquiree. The acquisition date is the date on which the Company obtains control of the acquiree. The identifiable assets acquired, and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where ASC 805 Business Combinations provides exceptions to recording the amounts at fair value. Preliminary balances recorded are subject to change during the measurement period which will conclude at the earlier of the date the Company receives the information it was seeking about facts and circumstances that existed as of the acquisition date, learns that more information is not obtainable, or one year following the acquisition date. Acquisition costs of the acquirer are expensed to profit or loss; acquisition costs of the acquiree paid by the acquirer may comprise a portion of consideration transferred. Non-controlling interest in the acquiree, if any, is recognized at fair value. The Company classifies an asset or disposal group as held for sale in accordance with ASC 360 Property, Plant and Equipment, when the following criteria are met: • management, having the authority to

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory [Abstract]
Inventory	NOTE 3. INVENTORY Inventory as of December 31, 2022 and 2021, consisted of the following: ($ in thousands) 2022 2021 Raw materials $ 36,233 $ 38,618 Raw materials - non-cannabis 26,709 22,260 Work-in-process 41,164 26,561 Finished goods 30,502 49,204 Total Inventory $ 134,608 $ 136,643

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2022
Property, plant and equipment [abstract]
Property And Equipment	NOTE 4. PROPERTY AND EQUIPMENT As of December 31, 2022 and 2021, Property and equipment consisted of the following: ($ in thousands) Land and Buildings Machinery and Equipment Furniture and Fixtures Leasehold Improvements Website, Computer Equipment and Software Vehicles Construction In Progress Total Cost Balance as of January 1, 2021 $ 96,526 $ 23,206 $ 17,636 $ 88,369 $ 5,772 $ 1,946 $ 19,197 $ 252,652 Additions 7,873 5,772 4,484 12,339 1,650 921 63,413 96,452 Transfers 4,021 4,923 3,560 39,494 580 65 (52,646) (3) Disposals — (130) (407) (811) (23) (30) — (1,401) Additions from acquisition 39,106 5,279 834 12,448 111 377 12,839 70,994 Effect of foreign exchange and other adjustments (642) (82) 120 939 58 (21) 44 416 As of December 31, 2021 $ 146,884 $ 38,968 $ 26,227 $ 152,778 $ 8,148 $ 3,258 $ 42,847 $ 419,110 Additions 29,826 2,112 1,416 5,691 296 134 45,056 84,531 Transfers 360 3,489 2,645 19,310 1,863 146 (27,813) — Disposals — (1,096) (312) (3,658) (70) (19) (4,583) (9,738) Sale related to sale and leaseback transaction (2,305) (3,333) (2,188) (29,857) — — — (37,683) Measurement period adjustments 1,829 (210) 929 (1,348) — — — 1,200 Effect of foreign exchange and other adjustments — (2) 7 (36) (5) 33 — (3) As of December 31, 2022 $ 176,594 $ 39,928 $ 28,724 $ 142,880 $ 10,232 $ 3,552 $ 55,507 $ 457,417 Accumulated depreciation Balance as of January 1, 2021 $ (2,033) $ (3,235) $ (3,199) $ (12,882) $ (2,006) $ (493) $ — $ (23,848) Depreciation (5,465) (3,603) (4,387) (10,358) (1,882) (588) — (26,283) Disposals — 74 140 297 13 19 — 543 Adjustments — (57) (133) (206) (52) 18 — (430) As of December 31, 2021 $ (7,498) $ (6,821) $ (7,579) $ (23,149) $ (3,927) $ (1,044) $ — $ (50,018) Depreciation (6,469) (6,288) (6,345) (18,293) (2,460) (667) — (40,522) Disposals — 69 24 5,098 — 1 — 5,192 Sale related to sale and leaseback transaction 36 736 950 6,262 — — — 7,984 Adjustments — (275) (2) 1 5 (60) — (331) As of December 31, 2022 $ (13,931) $ (12,579) $ (12,952) $ (30,081) $ (6,382) $ (1,770) $ — $ (77,695) Net book value As of December 31, 2021 $ 139,386 $ 32,147 $ 18,648 $ 129,629 $ 4,221 $ 2,214 $ 42,847 $ 369,092 As of December 31, 2022 $ 162,663 $ 27,349 $ 15,772 $ 112,799 $ 3,850 $ 1,782 $ 55,507 $ 379,722 As of December 31, 2022 and 2021, costs related to construction at the Company’s facilities and dispensaries were capitalized in construction in progress and not depreciated. Depreciation will commence when construction is completed and the facilities and dispensaries are available for their intended use. Land costs at each balance sheet date are included in Land and Buildings. In the second quarter of 2022, the Company determined that approximately $2.4 million of materials held in construction in progress would not be used. The materials were sold in July of 2022 for $0.9 million, with a $1.5 million loss on sale recorded to Selling, general and administrative expenses in the Consolidated Statements of Operations. During the second quarter of 2022, the Company initiated a plan to shut down a cultivation facility and a production facility in California. As a result of this plan, the Company exercised its early termination right to reduce the existing lease terms to 180 days at these locations and determined that the useful life of impacted leasehold improvements had essentially ended. As such, the Company accelerated depreciation on these leasehold improvements to reduce the associated net book value down to $nil, with additional depreciation expense taken on these leasehold improvements in the amount of $2.7 million during the second quarter of 2022. During the year ended December 31, 2022, the Company recorded additional accelerated depreciation on other remaining assets at the facility in the amount of $0.5 million. On September 1, 2022, the Company closed on a sale and leaseback transaction to sell its Brookville, Pennsylvania facility to Aventine Property Group (“Aventine”). Concurrent with the closing of the sale, the Company, entered into a long-term, triple-net lease agreement with Aventine and will continue to operate the facility as a permitted cannabis cultivation and processing facility. In connection with this transaction, the Company disposed of fixed assets with a net book value of $29.7 million and recorded a net gain on sale of assets of $14.7 million to Other income, net, in the Consolidated Statements of Operations. In the fourth quarter of 2022, the Company sold materials held in construction in progress that would not be used. The cost basis was approximately $0.9 million for net proceeds of $0.3 million, with a $0.6 million loss on sale recorded to Selling, general and administrative expenses in the Consolidated Statements of Operations. In addition to the depreciation expense on long-lived assets shown above of $40.5 million, additional depreciation expense was recorded during the year ended December 31, 2022 related to an abandoned construction in progress project of $0.6 million . For the years ended December 31, 2022 and 2021 total depreciation was $41.1 million and $26.3 million, respectively, of which $11.3 million and $6.5 million, respectively, is included in Selling, general and administrative expenses, with the remainder of $29.8 million and $19.8 million, respectively, recorded in Cost of goods sold and ending inventory.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Lease liabilities [abstract]
Leases	NOTE 5. LEASES The Company is the lessee in all of its material leasing arrangements and has entered into leases primarily for its corporate offices, cultivation and processing facilities and dispensaries. The Company has no material lessor arrangements as of and for the years ended December 31, 2022 and 2021. Depending upon the type of lease, the original lease terms generally range from less than 1 year to 20 years. Certain leases include renewal options ranging from less than 1 year to 25 years. The Company is reasonably certain to exercise renewal options ranging from less than 1 year to 10 years on certain leases. As of December 31, 2022 and 2021, the Company’s leases include ROU assets of $128.3 million and $88.0 million, respectively. Total lease-related interest expense of $4.0 million and $4.1 million was recorded for the years ended December 31, 2022 and 2021, respectively. Total finance lease asset depreciation of $2.8 million and $2.6 million was recorded for the years ended December 31, 2022 and 2021, respectively. For the years ended December 31, 2022 and 2021, $2.5 million and $2.3 million, respectively, of leasing depreciation is included in Selling, general and administrative expense with the remainder of $0.3 million and $0.3 million, respectively, recorded in Cost of goods sold and ending inventory. Total rent expense related to operating leases of $17.1 million and $17.7 million was recorded for the years ended December 31, 2022 and 2021, respectively. For the years ended December 31, 2022 and 2021, $9.9 million and $6.5 million, respectively, of rent expense is included in Selling, general and administrative expense with the remainder in Cost of goods sold and ending inventory. The Company has received tenant improvement allowance reimbursements of $3.6 million and $28.6 million across all finance and operating leasing arrangements for the years ended December 31, 2022 and 2021, respectively, and has received tenant improvement allowance reimbursements of $0.6 million and $7.5 million for other financing transactions for the years ended December 31, 2022 and 2021, respectively. The Company expects to receive an additional $5.6 million from lease transactions and $0.8 million from other financing transactions in future periods. Some leases may contain variable lease payments based on an index or rate. These rates are initially measured using the index or rate in effect at lease commencement, and changes to index-based lease payments are recognized in profit or loss in the period of the change and are immaterial. As of both December 31, 2022 and 2021, ending inventory includes $0.1 million of capitalized depreciation and rent expense. For the years ended December 31, 2022 and 2021, $0.3 million and $0.4 million, respectively, of depreciation and rent expense was recorded to Cost of goods sold, which includes $0.1 million and $0.2 million, respectively, related to depreciation and rent expense capitalized to inventory in prior years. The Company has elected not to recognize ROU assets and lease liabilities where the total lease term is less than or equal to twelve months. For these short-term lease agreements, the Company recorded $0.6 million and $2.1 million in rent expense for the years ended December 31, 2022 and 2021, respectively, within Selling, general and administrative expenses. The Company recognizes this expense on a straight-line basis over the lease term. During the second quarter of 2022, the Company initiated a plan to shut down a cultivation facility and a production facility in California. As a result of this plan, the Company has terminated the existing leases at these locations. A termination notice was issued to the landlord of these locations, which included two long-term greenhouse leases and a short-term rental of a housing facility. Due to differences between the carrying amounts of the ROU assets and lease liabilities associated with these leases, a gain on lease termination of $4.9 million was recorded for the year ended December 31, 2022 and is included in Other income, net, in the Consolidated Statements of Operations. On September 1, 2022, the Company closed on a sale and leaseback transaction to sell its Brookville, Pennsylvania, facility to Aventine. Concurrent with the closing of the sale, the Company entered into a long-term, triple-net lease agreement with Aventine and will continue to operate the facility as the permitted cannabis cultivation and processing facility. The selling price for the property was $43.7 million, net of transaction costs and a net gain on sale of assets of $14.7 million was recorded to Other income, net, in the Consolidated Statements of Operations. The lease has a term of 10 years and was recorded as an operating lease which resulted in a ROU asset and lease liability of $29.7 million. During the year ended December 31, 2021, the Company entered into no financing or sale and leaseback transactions. In the fourth quarter of 2022, the Company recorded impairment to ROU assets related to the following: • In the fourth quarter of 2022, Management committed to a plan to restructure certain operations and activities within the California reporting unit. It was determined that this was an indicator of impairment for associated assets. $1.0 million in impairment to ROU assets was recorded to the California reporting unit during the twelve months ended December 31, 2022. • During the annual impairment assessment, which is described in Note 7, Management determined it is more likely than not that the Arizona reporting unit carrying value exceeds its fair value based on updated forecasts and projections. $0.8 million in impairment to ROU assets was recorded to the Arizona reporting units, respectively, during the twelve months ended December 31, 2022. As of December 31, 2022, maturities of lease liabilities were as follows: ($ in thousands) Total Operating Leases Finance 2023 $ 33,027 $ 27,595 $ 5,432 2024 33,465 27,857 5,608 2025 34,289 28,531 5,758 2026 34,715 28,816 5,899 2027 34,949 28,948 6,001 Thereafter 212,253 185,139 27,114 Total lease payments $ 382,698 $ 326,886 $ 55,812 Less: imputed interest (194,752) (169,170) (25,582) Less: tenant improvement allowance (5,642) (4,997) (645) Present value of lease liabilities 182,304 152,719 29,585 Less: current lease liabilities (26,124) (21,850) (4,274) Present value of long-term lease liabilities $ 156,180 $ 130,869 $ 25,311 As of both December 31, 2022 and 2021, the Company had long-term financing liabilities of $87.6 million. During 2022, the Company recorded payments of $12.9 million and interest expense of $11.9 million related to these liabilities. During 2021, the Company recorded payments of $12.6 million and interest expense of $11.6 million. As of December 31, 2022, maturities of financing liabilities were as follows: ($ in thousands) Financing Liabilities 2023 $ 13,204 2024 $ 13,535 2025 $ 13,875 2026 $ 14,223 2027 $ 14,580 Thereafter $ 111,880 Total financing payments $ 181,297 Less: interest $ (84,207) Less: tenant improvement allowance $ (173) Present value of financing liabilities $ 96,917 Less: short-term financing liabilities $ (9,312) Present value of long-term financing liabilities $ 87,605 Other information related to leases as of and for the years ended December 31, 2022 and 2021 was as follows: 2022 2021 ($ in thousands) Operating Leases Finance Leases Operating Leases Finance Leases Right-of-use assets $ 106,127 $ 22,137 $ 62,329 $ 25,688 Lease liabilities (current) $ 21,850 $ 4,274 $ 16,348 $ 4,444 Lease liabilities (non-current) $ 130,869 $ 25,311 $ 92,919 $ 26,017 Weighted average remaining lease term 1 11.9 10.4 4.7 11.2 Weighted average discount rate 14.5 % 13.6 % 13.5 % 13.8 % 1 Note that Weighted average remaining lease term does not include extensions which we are not reasonably certain to enter into. As the interest rate implicit in a lease is generally not readily determinable, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the risk-adjusted rate of interest the Company would have to pay to borrow on a collateralized basis over a similar economic environment and term. Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2022 and 2021 are as follows: ($ in thousands) 2022 2021 Interest paid on finance leases $ 3,877 $ 4,742

Investments

Investments	12 Months Ended
	Dec. 31, 2022
Investment property [abstract]
Investments	NOTE 6. INVESTMENTS The following is a detailed discussion of the Company’s types of investments held: (a) Fair Value Investments The Company has investments in five entities: 420 Capital Management, LLC (“420 Capital”), a cannabis investment company; Lighthouse Strategies, LLC (“Lighthouse”), a diversified cannabis investment company; Infamy Brews, LLC (“Two Roots Brewing Co.”), a non-alcoholic brewing company; IM Cannabis Corp. (“IMC”), a pharmaceutical manufacturer that specializes in cannabis and OLD PAL LLC (“Old Pal”), a cannabis operator/licensor. The 420 Capital, Lighthouse and Old Pal investments are held at fair value and are classified as equity securities without a readily determinable fair value. The IMC investment is classified as a marketable security with a readily determinable fair value. During the year ended December 31, 2022, Lighthouse, in conjunction with a spin-off transaction, issued Lighthouse shareholders a prorated interest in Infamy Brews, LLC, DBA Two Roots Brewing Co. As a result, the Company now holds an 0.8% ownership interest in Two Roots Brewing Co. The investment is held at fair value and classified as an equity security without a readily determinable value. The following is a summary of the investments held at fair value as of December 31, 2022 and 2021: ($ in thousands) 2022 2021 420 Capital $ 68 $ 68 Lighthouse 339 542 Two Roots Brewing Co. 93 — Old Pal 592 592 IMC 136 4,710 Total Investments $ 1,228 $ 5,912 The Company recorded mark-to-market losses of $4.6 million and $7.3 million for the years ended December 31, 2022 and 2021, respectively. (b) Equity Method Investments Upon the acquisition of CannaRoyalty Corp. (“Origin House”) on January 8, 2020, the Company acquired an investment in Trichome Financial Corp. (“Trichome”), a lending entity that focuses its investments on cannabis and cannabis-related companies. At the acquisition date, the Trichome investment had a fair value of $4.3 million. During March 2021, the Company derecognized the Trichome equity method investment as part of an ownership conversion to shares in IMC. At that time, the Company recognized a gain on conversion of $9.3 million in Other income (expense), net, in the Consolidated Statements of Operations as the IMC investment exceeded the carrying value of the Trichome investment on the date of conversion. No distributions were made by the investee to the Company related to investments for any of the respective period s.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2022
Intangible assets and goodwill [abstract]
Intangible Assets and Goodwill	NOTE 7. INTANGIBLE ASSETS AND GOODWILL As of December 31, 2022 and 2021, Intangible assets and Goodwill consisted of the following: ($ in thousands) Customer Relation-ships Trade Names Permit Application Costs Licenses Other Intangibles (a) Goodwill Total Cost Balance at January 1, 2021 $ 70,529 $ 39,700 $ 8,752 $ 89,347 $ 6,390 $ 450,569 $ 665,287 Additions — — 3,169 — 3,002 — 6,171 Additions from acquisitions 24,250 1,400 — 317,200 1,151 212,140 556,141 Impairment (62,900) (39,000) — — (3,783) (215,551) (321,234) Measurement period adjustments — — — (2,240) — (391) (2,631) Disposals — — — — (476) — (476) Balance at December 31, 2021 $ 31,879 $ 2,100 $ 11,921 $ 404,307 $ 6,284 $ 446,767 $ 903,258 Additions — — 3,106 — — — 3,106 Impairment — — — (21,800) — (117,024) (138,824) Measurement period adjustments — — — (1,000) — 812 (188) Balance at December 31, 2022 $ 31,879 $ 2,100 $ 15,027 $ 381,507 $ 6,284 $ 330,555 $ 767,352 Accumulated amortization Balance at January 1, 2021 $ (5,129) $ (3,970) $ (7,118) $ — $ (2,960) $ — $ (19,177) Amortization 932 3,275 (3,330) — (642) — 235 Disposals — — — — 95 — 95 Balance at December 31, 2021 (4,197) (695) (10,448) — (3,507) — $ (18,847) Amortization (3,930) (915) (3,449) — (2,066) — (10,360) Disposals — — — — — — — Balance at December 31, 2022 $ (8,127) $ (1,610) $ (13,897) $ — $ (5,573) $ — $ (29,207) Net book value December 31, 2021 $ 27,682 $ 1,405 $ 1,473 $ 404,307 $ 2,777 $ 446,767 $ 884,411 December 31, 2022 $ 23,752 $ 490 $ 1,130 $ 381,507 $ 711 $ 330,555 $ 738,145 (a) Other Intangibles includes non-compete agreements, non-solicitation agreements and related amortization. License intangible assets of $nil and $317.2 million were acquired from business combinations during the years ended December 31, 2022 and 2021, respectively and are classified as indefinite-lived intangible assets as the Company cannot continue as a going concern without such licenses. See Note 10 for additional details. Amortization of $10.4 million and $15.3 million was recorded for the years ended December 31, 2022 and 2021, respectively, of which $6.9 million and $12.8 million, respectively, of amortization expense, is included in Selling, general and administrative expenses, with the remainder of $3.5 million and $2.5 million, respectively, recorded in Cost of goods sold and ending inventory. During the year ended December 31, 2021, the Company recorded an adjustment to accumulated amortization of $15.7 million as part of the impairment write-down of the trade names and customer relationship intangibles, which is discussed below. During 2021, the Company mutually terminated the agreement for exclusive distribution rights with a third-party vendor which resulted in the impairment of the remaining net book value of the market-related intangible of $0.8 million. Management determined that the Company’s decision to reduce third-party distribution in California was an indicator of impairment for associated assets. Certain trade names and customer relationship intangibles with remaining net book values of $32.2 million and $57.1 million, respectively, were determined to be fully impaired due to updated cash flow projections associated with these assets. Additionally, $215.6 million in goodwill impairment was recorded to the California reporting unit during the twelve months ended December 31, 2021. During the twelve months ended December 31, 2022, the Company recorded impairment to goodwill and indefinite-lived intangible assets related to the following: • In the fourth quarter of 2022, Management committed to a plan to restructure certain operations and activities within the California reporting unit. It was determined that this was an indicator of impairment for associated assets. $89.5 million in goodwill impairment was recorded to the California reporting unit during the twelve months ended December 31, 2022. • During the annual impairment assessment, which is described below, Management determined it is more likely than not that the Arizona, Massachusetts and Maryland reporting units carrying values exceed their fair value due to updated forecasts and projections for those reporting units. $10.1 million and $0.9 million in goodwill impairment was recorded to the Arizona and Maryland reporting units, respectively, during the twelve months ended December 31, 2022. $16.5 million and $21.8 million of goodwill and indefinite-lived intangible impairment, respectively, was recorded to the Massachusetts reporting unit during the twelve months ended December 31, 2022. Annual impairment testing involves determining the fair value, or recoverable amount, of the reporting units to which goodwill and indefinite-lived intangible assets are allocated and comparing this to the carrying value of the reporting units. The measurement of the recoverable amount of each reporting unit was calculated based on the higher of the reporting unit’s fair value less costs to sell or value in use, which are Level 3 measurements within the fair value hierarchy. The calculation of each of the recoverable amounts based on discounting the future cash flows (value in use) was based on the following key assumptions: • Cash flows were projected based on the Company’s long-term business plan for each reporting unit. Cash flows beyond the long-term business plan were projected to grow at a perpetual growth rate, which was estimated to be 3% in most cases. • Discount rates applied in determining the recoverable amount of the reporting units noted above range between 12.5% and 17.5% based on the pre-tax weighted average cost of capital of each reporting unit and other peers in the industry. The values assigned to the key assumptions represent Management’s assessment of future trends in the industries in which the reporting units operate and are based on both external and internal sources and historical trend data. The Company believes a reasonable increase or decrease in the discount rates or perpetual growth rates used in the analysis would not cause the recoverable amount to decrease below the carrying value. As of December 31, 2022 and 2021, ending inventory includes $1.6 million and $1.1 million of capitalized amortization, respectively. For the years ended December 31, 2022 and 2021, $2.9 million and $2.4 million, respectively, of amortization expense was recorded to Cost of goods sold, which includes $1.1 million and $1.0 million, respectively, related to amortization capitalized to inventory in prior years. The following table outlines the estimated annual amortization expense related to intangible assets as of December 31, 2022: ($ in thousands) Estimated Amortization 2023 $ 5,776 2024 4,282 2025 4,093 2026 3,968 2027 3,271 Thereafter 4,693 Total estimated amortization $ 26,083

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2022
Share Capital [Abstract]
Share Capital	NOTE 8. SHARE CAPITAL (a) Authorized The authorized share capital of the Company, which has no par value, is comprised of the following: i. Unlimited Number of Subordinate Voting Shares Holders of SVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of SVS will be entitled to one vote in respect of each SVS held. As long as any SVS remain outstanding, the Company will not, without the consent of the holders of the SVS by separate special resolution, prejudice or interfere with any right attached to the SVS. Holders of SVS will be entitled to receive as and when declared by the directors of the Company, dividends in cash or property of the Company. ii. Unlimited Number of Proportionate Voting Shares Holders of PVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of PVS will be entitled to one vote in respect of each SVS into which such PVS could ultimately be converted (200 votes per PVS). As long as any PVS remain outstanding, the Company will not, without the consent of the holders of the PVS and MVS by separate special resolution, prejudice or interfere with any right or special right attached to the PVS. The holder of PVS have the right to receive dividends, out of any cash or other assets legally available therefore, pari passu as to dividends and any declaration or payment of any dividend on the SVS. iii. 500,000 Super Voting Shares Holders of MVS shall be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company shall have the right to vote. At each such meeting, holders of MVS shall be entitled to 2,000 votes in respect of each MVS held. iv. Unlimited Number of Special Subordinate Voting Shares Holders of SSVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of SSVS will be entitled to a 0.00001 vote in respect of each SSVS held. As long as any SSVS remain outstanding, the Company will not, without the consent of the holders of the SSVS by separate special resolution, prejudice or interfere with any right attached to the SSVS. Holders of SSVS will be entitled to receive dividends in cash or property of the Company, if and when declared by the Board of Directors (the “Board”). v. Redeemable Units As part of the Transaction, unit holders of Cresco Labs, LLC exchanged their units for a new class of Redeemable Units in Cresco Labs, LLC. Each Redeemable Unit is only exchangeable for the equivalent of one SVS in Cresco Labs Inc. (without any obligation to redeem in cash). These unit holders hold an interest only in Cresco Labs, LLC; they participate in the earnings of only Cresco Labs, LLC and not the earnings of the combined entity. (b) Issued and Outstanding As of December 31, 2022 and 2021, issued and outstanding shares and units consisted of the following: (in thousands) Redeemable Subordinate Proportionate Voting Shares (PVS)** Super Voting Shares (MVS) Special Subordinate Voting Shares (SSVS)*** Beginning balance, January 1, 2021 126,338 194,231 29,311 500 1 Options and warrants exercised — 3,030 — — — RSU issued — 351 — — — Issuance of shares related to acquisitions — 35,425 — — — Issuance of shares related to distribution agreements — (249) — — — Cresco LLC redemption (16,897) 16,897 — — — PVS converted to SVS — 8,644 (8,644) — — Issuances related to employee taxes on certain share-based payment arrangements — 173 — — — Share issuances — 11,469 — — — Ending balance, December 31, 2021 109,441 269,971 20,667 500 1 Options and warrants exercised — 1,279 — — — RSUs issued — 337 — — — Issuance of shares related to acquisitions — 5,339 — — — Cresco LLC redemption (3,335) 3,335 — — — PVS converted to SVS — 585 (585) — — Issuances related to employee taxes on certain share-based payment arrangements — 148 — — — Ending balance, December 31, 2022 106,106 280,994 20,082 500 1 *SVS includes shares pending issuance or cancellation **PVS presented on an “as-converted” basis to SVS (1-to-200) ***SSVS presented on an “as-converted” basis to SVS (1-to-0.00001) (i) Share Issuances - Equity Distribution Agreement In December 2019, the Company entered into an agreement with Canaccord Genuity Corp (“Canaccord”) to sell up to C$55.0 million SVS at an at-the-market price. In April 2021, the Company announced a new agreement with Canaccord to sell up to $100.0 million of SVS to replace the prior agreement which was set to expire in August 2021. No shares were issued for the years ending December 31, 2022 and 2021, respectively, under the new agreement which is set to expire in May 2023. (ii) Issuance of Shares - Private Placement In January 2021, the Company closed an offering of 9.9 million SVS at a price of C$16.00 ($12.67) per share. The Company received cash proceeds of $120.7 million, net of $3.4 million in commission and other fees, with a corresponding increase to share capital of $124.1 million. (iii) Issuance of Shares - Arrangement In February 2021, a binding settlement was reached with a former executive of the Company for payment of 1.3 million SVS to the counterparty relating to certain equity awards previously held by the counterparty in exchange for a number of covenants, including non-solicitation, non-hire, certain provisions surrounding voting rights and limitations on future sales of Company shares. See Note 15 for additional information about the arrangement. (iv) Issuance of Shares - Acquisitions During the years ended December 31, 2022 and 2021, the Company issued shares in conjunction with certain acquisitions* as follows: (in thousands) Acquisition date SVS shares issued Replacement shares issued Equity-based consideration Year Ended December 31, 2022: Cultivate - Contingent Consideration September 02, 2021 5,340 — $ 34,708 Year Ended December 31, 2021: Verdant February 16, 2021 127 — $ 2,004 Bluma April 14, 2021 15,061 814 193,310 Cultivate September 02, 2021 4,818 — 46,643 Cure Penn November 24, 2021 6,167 — 54,240 Laurel Harvest December 09, 2021 8,354 — 65,844 *Verdant Creations, LLC (“Verdant”); Bluma Wellness, Inc. (“Bluma”); Cultivate Licensing, LLC (“Cultivate”); Bay, LLC (“Cure Penn”) and Laurel Harvest, LLC (“Laurel Harvest”) (c) Stock Purchase Warrants Each whole warrant entitles the holder to purchase one SVS or PVS of the Company. A summary of the status of the warrants outstanding is as follows: Number of warrants* Weighted average exercise price Balance as of January 1, 2021 6,183 $ 7.80 Bluma replacement warrants 4,665 11.64 Exercised (721) 6.15 Forfeited (285) 11.64 Balance as of December 31, 2021 9,842 $ 9.63 Exercised (12) 4.24 Forfeited (9,830) 9.54 Balance as of December 31, 2022 — $ — *PVS presented on an “as-converted” basis to SVS (1-to-200) During the years ended December 31, 2022 and 2021, the Company recorded $0.1 million and $5.1 million of warrant exercises into share capital, respectively. As of December 31, 2022, all warrants that had not previously been exercised have expired. As part of the Bluma acquisition in the second quarter of 2021, the Company issued 4.7 million Cresco warrants valued at $18.4 million in exchange for Bluma warrants that were issued and outstanding on the acquisition date. The issued warrants were equity-classified. In determining the fair value of the Bluma replacement warrants, key estimates such as the expected life of options, the volatility of the Company’s stock price and the risk-free interest rate are used. In the second quarter of 2021, 0.2 million Bluma replacement warrants were exercised for proceeds of $2.2 million, resulting in an increase to share capital of $2.9 million. (d) Distribution to Non-controlling Interest Holders As of December 31, 2022 and December 31, 2021, the Company accrued for tax-related distributions to 2022 and 2021 unit holders of Cresco Labs, LLC and other minority interest holders of $4.9 million and $36.4 million respectively. These distributions will reduce non-controlling interest upon payment. In accordance with the underlying operating agreements, the Company declared and paid required distribution amounts to 2022 and 2021 unit holders of Cresco Labs, LLC and other minority holders of $83.6 million during the year ended December 31, 2022. Similarly, the Company paid required tax distribution amounts to 2021 and 2020 unit holders of Cresco Labs, LLC and other minority interest holders of $73.6 million, during the year ended December 31, 2021. (e) Changes in Ownership and Non-controlling Interests During the year ended December 31, 2022, redemptions of 3.3 million Redeemable Units occurred which were converted into an equivalent number of SVS. This redemption resulted in a decrease of 1.3% in non-controlling interest in Cresco Labs, LLC. During the year ended December 31, 2021, redemptions of 16.9 million Redeemable Units occurred which were converted into an equivalent number of SVS. This redemption resulted in a decrease of 6.7% in non-controlling interest in Cresco Labs, LLC. As of and for the year ended December 31, 2022, non-controlling interest included the following amounts before intercompany eliminations: ($ in thousands) TSC Cresco, LLC MedMar MedMar Cresco SLO Cultivation Other entities including Cresco Labs LLC 1,3 Eliminations Total Non-current assets $ 4,813 $ 31,151 $ 22,700 $ 16,736 $ 5,376 $ 1,176,870 $ — $ 1,257,646 Current assets 69,844 142,723 232,194 70,693 92,594 88,545 (370,547) 326,046 Non-current liabilities — (10,889) (3,850) (12,515) (2,728) (685,161) — (715,143) Current liabilities (56,341) (127,329) (164,550) (64,479) (126,575) (123,889) 382,297 (280,866) Net assets $ 18,316 $ 35,656 $ 86,494 $ 10,435 $ (31,333) $ 456,365 $ 11,750 $ 587,683 Net assets attributable to NCI $ 4,190 $ 3,979 $ 7,468 $ (32) $ (12,434) $ (42,527) $ — $ (39,356) — Revenue $ 35,302 $ 53,259 $ 88,645 $ 17,834 $ 6,484 $ 670,060 $ (28,903) $ 842,681 Gross profit 23,387 35,485 62,503 1,338 (13,652) 294,993 2,959 407,013 Net income (loss) $ 19,290 $ 13,322 $ 43,500 $ (4,933) $ (16,458) $ (270,564) $ — $ (215,843) Net income (loss) allocated to NCI $ 4,822 $ 1,652 $ 10,875 $ (49) $ (3,292) $ (17,804) $ — $ (3,796) NCI percentage at December 31, 2022 25.0 % 1 12.4 % 2 25.0 % 2 1.0 % 1 20.0 % 1 42.0 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 42.0% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments As of and for the year ended December 31, 2021, Non-controlling interest included the following amounts before intercompany eliminations: ($ in thousands) TSC Cresco, LLC MedMar MedMar Cresco SLO Cultivation Inc. Other entities including Cresco Labs LLC 1,3 Eliminations Total Non-current assets $ 5,208 $ 33,698 $ 22,934 $ 16,093 $ 23,422 $ 1,257,353 $ — $ 1,358,708 Current assets 54,506 95,522 154,929 64,897 97,276 250,029 (295,404) 421,755 Non-current liabilities — (11,213) (3,443) (12,286) (14,071) (653,320) — (694,333) Current liabilities (49,726) (92,049) (124,597) (73,441) (147,993) (107,143) 306,555 (288,394) Net assets $ 9,988 $ 25,958 $ 49,823 $ (4,737) $ (41,366) $ 746,919 $ 11,151 $ 797,736 Net assets attributable to NCI $ 2,850 $ 3,910 $ 6,123 $ 18 $ (9,143) $ 38,424 $ — $ 42,182 Revenue $ 21,549 $ 48,435 $ 84,932 $ 22,661 $ 21,011 $ 663,602 $ (40,508) $ 821,682 Gross profit 13,592 32,020 47,922 10,650 (6,250) 320,419 (12,006) 406,347 Net income (loss) $ 12,387 $ 12,043 $ 30,666 $ (4,627) $ (19,247) $ (328,056) $ — $ (296,834) Net income (loss) allocated to NCI $ 3,097 $ 1,493 $ 7,666 $ (46) $ (3,849) $ 14,402 $ — $ 22,763 NCI percentage at December 31, 2021 25.0 % 1 12.4 % 2 25.0 % 2 1.0 % 1 20.0 % 1 43.3 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 43.3% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangements [Abstract]
Share-Based Compensation	NOTE 9. SHARE-BASED COMPENSATION The Company has a share-based compensation plan (the “Plan”) for key employees and service providers. Under the Plan, options issued have no voting rights and vest proportionately over periods ranging from the grant date to four years from the issuance date. Stock options exercised are converted to SVS. The maximum number of shares issued under the Plan shall not exceed 10% of the issued and outstanding shares. A summary of the status of the options outstanding consisted of the following: (Shares in thousands) Number of stock options outstanding Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value Outstanding – December 31, 2021 23,610 $ 5.54 7.70 $ 53,455 Granted 7,649 3.77 Exercised (1,631) 1.51 Forfeited (4,100) 7.27 Outstanding - December 31, 2022 25,528 $ 5.00 7.54 $ 921 Exercisable - December 31, 2022 14,027 $ 4.32 6.42 $ 921 During the years ended December 31, 2022 and 2021, options were exercised for gross proceeds of $2.9 million and $3.7 million, respectively. The following table summarizes the weighted average grant date fair value and total intrinsic value of options exercised for the years ended December 31, 2022 and 2021: (In thousands, except per share data) 2022 2021 Weighted average grant date fair value (per share) of stock option units granted $2.59 $7.39 Intrinsic value of stock option units exercised, using market price at exercise date $5,106 $21,131 Weighted average stock price of options on the dates on which options were exercised during the years ended December 31, 2022 and 2021 was $4.64 and $10.13 per option, respectively. The fair value of stock options granted under the Plan during the years ended December 31, 2022 and 2021, was determined using the Black-Scholes option-pricing model with the following range of assumptions at the time of the grant: 2022 2021 Risk-free annual interest rate 1.4% to 3.0% 0.4% to 1.2% Expected annual dividend yield 0% 0% Expected stock price volatility 74.9% to 80.4% 67.0% to 82.2% Expected life of stock options 5.5 to 7.0 years 5.0 to 7.0 years Forfeiture rate 7.2% to 28.0% 7.5% to 24.9% Fair value at grant date $1.23 to $4.90 $4.47 to $8.78 Stock price at grant date $1.81 to $6.91 $6.62 to $13.10 Exercise price range $1.81 to $6.91 $6.62 to $13.10 Volatility was estimated by using the average historical volatility of comparable companies from a representative group of direct and indirect peers of publicly traded companies, as the Company and the cannabis industry have minimal historical share price history available. An increase in volatility would result in an increase in fair value at grant date. The expected life in years represents the period of time that options issued are expected to be outstanding. The risk-free rate is based on U.S. treasury bills with a remaining term equal to the expected life of the options. The forfeiture rate is estimated based on historical forfeitures experienced by the Company. Restricted Stock Units The Company has an RSU program to provide employees an additional avenue to participate in the successes of the Company. The fair value of RSUs granted was determined by the fair value of the Company’s share price on the date of grant. A summary of outstanding RSUs is provided below: (Shares in thousands) Number of RSUs outstanding Weighted average fair value Weighted average remaining contractual life (years) Aggregate intrinsic value Outstanding – December 31, 2021 1,093 $ 8.83 3.50 $ 9,657 Granted 4,438 5.36 Vested and settled (452) 5.31 Forfeited (821) 6.46 Outstanding - December 31, 2022 4,258 $ 5.71 4.00 $ 24,330 The following table summarizes the total fair value of RSUs vested for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Total fair value of RSUs vested, using market price at vest date $ 2,396 $ 4,783 Replacement Awards During the second quarter of 2021, the Company granted replacement RSUs in connection with the Bluma acquisition. Upon closure of the acquisition, the Company accelerated the vesting of all replacement RSUs, recognizing $2.1 million in post combination expense. Other Share Issuances During the year ended December 31, 2021, the Company issued replacement shares to existing holders of vested and unissued Bluma RSUs as of the acquisition date and a subscription award as compensation to a former member of key management personnel. A summary of the share movement is provided below: (In thousands, except per share data) Shares issued Fair value Compensation expense Bluma replacement shares 814 $ 12.17 $ 239 Subscription award 62 $ 11.25 $ 694 Expense Attribution The Company recorded compensation expense for option awards in the amount of $13.7 million and $20.7 million for the years ended December 31, 2022 and 2021, respectively. Unrecognized compensation expense as of December 31, 2022 for unvested option awards was $17.4 million and will be recorded over the course of the next four years. The following table sets forth the classification of stock-based compensation expense related to options awards for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Cost of goods sold $ 1,984 $ 2,958 Selling, general and administrative expense 11,749 17,743 Total compensation expense for option awards $ 13,733 $ 20,701 The Company recorded compensation expense for RSU awards in the amount of $10.0 million and $4.6 million for the years ended December 31, 2022 and 2021, respectively. Unrecognized compensation expense as of December 31, 2022 is $8.9 million and will be recognized over the course of the next four years. The following table sets forth the classification of stock-based compensation expense related to RSU awards for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Cost of goods sold $ 2,097 $ 579 Selling, general and administrative expense 7,914 3,985 Total compensation expense for RSU awards $ 10,011 $ 4,563 As of December 31, 2022 and 2021, ending inventory includes $1.7 million and $1.2 million capitalized compensation expense related to both options and RSUs, respectively. For both of the years ended December 31, 2022 and 2021, $3.6 million and $2.5 million, respectively, of compensation expense was recorded to Cost of goods sold, which includes $1.2 million and $0.2 million, respectively, related to compensation expense capitalized to inventory in prior years.

Acquisitions and Dispositions

Acquisitions and Dispositions	12 Months Ended
	Dec. 31, 2022
Business Combinations And Discontinued Operations [Abstract]
Acquisitions and Dispositions	NOTE 10. ACQUISITIONS AND DISPOSITIONS (a) Business Combinations The table below summarizes significant business combinations completed during the year ended December 31, 2021. There were no completed business combinations during the year ended December 31, 2022. ($ in thousands) Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total Total consideration Common shares issued $ 2,000 $ 183,262 $ 46,643 $ 52,610 $ 65,844 $ 350,359 Cash 1,500 — — 33,304 20,480 55,284 Cashless exercise option on loan 10,000 — — — — 10,000 Settlement of leases 90 — — — — 90 Loan settlement 11,414 21,226 1,852 — 3,339 37,831 Warrants issued — 18,415 — — — 18,415 Replacement RSU awards — 10,048 — — — 10,048 Payment of acquisition-related transaction costs on behalf of the acquiree — 3,373 1,001 3,135 331 7,840 Payment of 3rd-party debt on behalf of the acquiree — — 20,125 — — 20,125 Deferred consideration — 1,806 — — 46,677 48,483 Contingent consideration — — 29,642 — — 29,642 Total consideration $ 25,004 $ 238,130 $ 99,263 $ 89,049 $ 136,671 $ 588,117 Net identifiable assets (liabilities) acquired Cash $ 1,360 $ 1,623 $ 2,938 $ 751 $ 937 $ 7,609 Accounts receivable — — 6,494 33 — 6,527 Inventory 1,519 19,244 24,862 2,963 506 49,094 Loans receivable, short-term — 1,600 — — — 1,600 Other current assets 76 1,205 662 134 36 2,113 Property & equipment 996 26,152 30,128 1,845 11,873 70,994 Right-of-use assets 127 13,709 1,304 1,834 859 17,833 Other non-current assets 47 — — — — 47 Customer relationships 1,370 6,700 13,600 2,320 260 24,250 License 16,320 117,000 12,000 70,950 98,690 314,960 Trade name — — 1,400 — — 1,400 Non-compete agreements — — 800 270 80 1,150 Investments — 693 — — — 693 Total identifiable assets acquired $ 21,815 $ 187,926 $ 94,188 $ 81,100 $ 113,241 $ 498,270 Short-term liabilities (1,601) (3,733) (14,585) (1,186) (151) (21,256) Lease liability (127) (13,685) (1,304) (1,834) (859) (17,809) Contract liability-loyalty program — (456) — (355) — (811) Deferred tax liability (3,968) (36,940) (10,597) — (30,753) (82,258) Total identifiable liabilities acquired (5,696) (54,814) (26,486) (3,375) (31,763) (122,134) Net identifiable assets acquired $ 16,119 $ 133,112 $ 67,702 $ 77,725 $ 81,478 $ 376,136 Purchase price allocation Net identifiable assets acquired 16,119 133,112 67,702 77,725 81,478 376,136 Goodwill 8,885 105,018 31,561 11,324 55,193 211,981 Total consideration $ 25,004 $ 238,130 $ 99,263 $ 89,049 $ 136,671 $ 588,117 (i) Verdant On February 16, 2021, the Company completed the acquisition of 100% of the membership interests of Verdant dispensaries in Cincinnati, Chillicothe, Newark and Marion, Ohio. As a result of this acquisition, the Company holds additional licenses to distribute medical cannabis in the state of Ohio, bringing the Company’s dispensary presence in Ohio to five (5), the maximum allowed by the state, as of the date of acquisition. As of December 31, 2021, the Company had recorded estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets acquired and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2021, the Company recorded measurement period adjustments (“MPAs”) related to changes in the valuation of certain intangible assets, lease settlements and deferred taxes, which resulted in a net reduction in goodwill of $0.2 million. The measurement period expired on February 16, 2022, with no further measurement period adjustments recorded during the year ended December 31, 2022. Consideration for the acquisition included 0.1 million SVS issued as of the acquisition date. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (ii) Bluma On April 14, 2021, the Company completed the acquisition of 100% of the membership interests of Bluma, a vertically integrated operator in Florida. As a result of this acquisition, the Company now holds a license to cultivate, process, transport and dispense medical cannabis in the state of Florida, bringing the Company’s dispensary presence in Florida to eight (8), as of the acquisition date. As of December 31, 2021, the Company had recorded preliminary estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets acquired and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2021, the Company recorded MPAs related to RSU awards, short-term loans receivable, inventory and deferred taxes, which resulted in a net increase in goodwill of $0.5 million. During the year ended December 31, 2022, the Company recorded MPAs related to deferred taxes and income taxes payable, which resulted in a net increase in goodwill of $1.8 million. As the measurement period ended April 14, 2022, no amounts are subject to additional adjustments as of December 31, 2022. Consideration for the acquisition included 15.1 million SVS issued as of the acquisition date. The Company recorded transaction costs of $1.5 million in connection with the Bluma acquisition as Selling, general and administrative expenses in the Consolidated Statements of Operations for the year ended December 31, 2021. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (iii) Cultivate On September 2, 2021, the Company completed the acquisition of 100% of the membership interests of Cultivate. As a result of this acquisition, the Company holds additional licenses to cultivate, process, transport and dispense medical and adult-use cannabis in the state of Massachusetts, bringing the Company’s dispensary presence in Massachusetts to four (4), as of the date of acquisition. As of December 31, 2021, the Company had recorded preliminary estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets acquired and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2021, the Company recorded MPAs related to property and equipment, short-term liabilities and deferred taxes, which resulted in a net reduction in goodwill of $0.7 million. During the year ended December 31, 2022, the Company recorded MPAs related to property and equipment, deferred consideration, licenses and deferred taxes, which resulted in a net increase in goodwill of $0.4 million. As the measurement period ended September 2, 2022, no amounts are subject to additional adjustments as of December 31, 2022. Consideration for the acquisiti on included 4.8 million SVS issued as of the acquisition date. The Company recorded transaction costs of $1.6 million in connection with the Cultivate acquisition as Selling, general and administrative expenses in the Consolidated Statements of Operations for the year ended December 31, 2021. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (iv) Cure Penn On November 24, 2021, the Company announced that it had completed the acquisition of 100% of the membership interests of Cure Penn. As a result of this acquisition, the Company holds additional licenses to dispense medical cannabis in the state of Pennsylvania, bringing the Company’s dispensary presence in Pennsylvania to eight (8) as of the date of acquisition. As of December 31, 2021, the Company had recorded preliminary estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2022, the Company recorded an MPA related to a working capital adjustment, which resulted in a net increase in goodwill of $0.1 million. As the measurement period ended November 25, 2022, no amounts are subject to additional adjustments as of December 31, 2022. Consideration for the acquisition included 6.2 million SVS issued as of the acquisition date. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (v) Laurel Harvest On December 9, 2021, the Company announced that it had completed the acquisition of 100% of the membership interests of Laurel Harvest. As a result of this acquisition, the Company holds additional licenses to cultivate, process, transport and dispense medical cannabis in the state of Pennsylvania, bringing the Company’s dispensary presence in Pennsylvania to nine (9) as of the date of acquisition. As of December 31, 2021, the Company had recorded preliminary estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2022, the Company recorded MPAs related to deferred taxes, income taxes payable and a working capital adjustment, which resulted in a net reduction in goodwill of $1.5 million. As the measurement period ended December 10, 2022, no amounts are subject to additional adjustments as of December 31, 2022. Consideration for the acquisition included 8.4 million SVS issued as of the acquisition date. The Company recorded transaction costs of $1.1 million in connection with the Laurel Harvest acquisition as Selling, general and administrative expenses in the Consolidated Statements of Operations for the year ended December 31, 2021. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (vi) Year-of-Acquisition Contributed Revenue and Net Income (Loss) The unaudited table below summarizes contributed Revenue and Net income (loss) for the year ended December 31, 2021: ($ in thousands) Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total Contributed revenue $ 26,547 $ 26,642 $ 29,279 $ 2,966 $ 328 $ 85,762 Net income (loss) 5,352 (8,382) 14,944 (50) (136) $ 11,728 (vii) Unaudited Pro Forma Information - Significant 2021 Acquisitions The following unaudited pro forma financial information reflects the combined results of operations of Cresco Labs Inc. and the pre-acquisition results of entities acquired by Cresco Labs Inc. during the year ended December 31, 2021, as though the acquisitions occurred as of January 1, 2020: For the year ended December 31, 2021 Cresco Labs Inc. Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total ($ in thousands) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) Pro forma revenue $ 821,682 $ 2,677 $ 7,906 $ 39,033 $ 29,281 $ 1,966 $ 902,545 Pro forma net income: Pre-acquisition net income (846) (13,784) 4,550 8,161 (2,121) Pro forma adjustments: (a) Transaction costs 399 1,461 1,555 439 1,081 (b) Post-acquisition share-based compensation — 2,440 — — — (c) Intangible amortization (150) (599) (860) (355) (68) Total pro forma adjustments $ 250 $ 3,302 $ 695 $ 84 $ 1,013 Total pro forma net income $ (296,834) $ (596) $ (10,482) $ 5,245 $ 8,245 $ (1,109) $ (295,531) (a) includes removal of transaction costs as they will be reflected as of the beginning of the earliest period presented (January 1, 2020). These costs were included as Selling, general and administrative expenses in the Consolidated Statements of Operations. (b) includes removal of post-acquisition share-based compensation expense related to warrants issued, replacement shares and replacement RSU awards recorded related to the Bluma acquisition. These costs were included as Selling, general and administrative expenses in the Consolidated Statements of Operations. (c) includes estimated amortization expense on intangible assets acquired. These costs were recorded in Cost of goods sold and Selling, general and administrative expenses in the Consolidated Statements of Operations. For the year ended December 31, 2020 Cresco Labs Inc. Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total ($ in thousands) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) Pro forma revenue $ 476,251 $ 15,195 $ 12,338 $ 22,965 $ 29,119 $ 1 $ 555,869 Pro forma net income: Pre-acquisition net income (1,982) (25,998) 772 8,384 (650) Pro forma adjustments: (a) Transaction costs (399) (1,461) (1,555) (439) (1,081) (b) Post-acquisition share-based compensation — (2,440) — — — (c) Intangible amortization (171) (853) (3,483) (387) (73) Total pro forma adjustments $ (571) $ (4,754) $ (5,037) $ (826) $ (1,153) Total pro forma net income $ (92,771) $ (2,553) $ (30,752) $ (4,266) $ 7,558 $ (1,803) $ (124,587) (a) includes transaction costs related to acquisitions (reflected as of January 1, 2020). (b) includes post-acquisition share-based compensation expense related to warrants issued, replacement shares and replacement RSU awards recorded related to the Bluma acquisition. (c) includes estimated amortization expense on intangible assets acquired. (b) Deferred and Contingent Consideration, short-term The following is a summary of Deferred and contingent consideration balances as of December 31, 2022 and 2021, which are classified as short-term: ($ in thousands) 2022 2021 Cultivate contingent consideration, short-term $ — $ 33,969 Laurel Harvest deferred consideration, short-term 47,821 37,847 Total Deferred and contingent consideration, short-term $ 47,821 $ 71,816 The Company recorded a contingent consideration in conjunction with the acquisition of Cultivate in the third quarter of 2021. The former owners of Cultivate were entitled to an earnout, based on Cultivate’s adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”), a non-GAAP financial measure, of up to $68.0 million. During the first quarter of 2022, the Company remeasured the fair value of the contingent consideration, increasing the value from $34.0 million to $39.6 million. The loss related to the earnout adjustment is included in Other income, net in the Consolidated Statements of Operations. During the second quarter of 2022, the Company paid the former owners of Cultivate a total of $39.6 million, settled in cash of $4.9 million and 5.3 million SVS. In the fourth quarter of 2021, Cresco recorded a $37.9 million short-term deferred consideration and a $9.0 million long-term deferred consideration, for a total of $46.9 million deferred consideration related to the Laurel Harvest acquisition. Total deferred consideration is payable on or before the 18-month anniversary of the acquisition, with accelerated payments required for each of five (5) new dispensaries opened during the 18-month earnout period. In the first quarter of 2022, the Company reclassified $9.0 million of deferred consideration from long-term deferred consideration to short-term due to projected dispensary opening dates and was further adjusted to $47.8 million based on our current expectation of the value of the liability. For the year ended December 31, 2022, $0.9 million of expense was recorded to Interest expense, net in the Consolidated Statements of Operations. (c) Deferred Consideration, long-term The following is a summary of Deferred consideration as of December 31, 2022 and 2021, which is classified as long-term: ($ in thousands) 2022 2021 Valley Agriceuticals, LLC (“Valley Ag”) operating cash flows deferred consideration $ 7,770 $ 8,577 Laurel Harvest deferred consideration — 9,074 Total Deferred consideration, long-term $ 7,770 $ 17,651 As of December 31, 2022, the total estimated liability related to the Valley Ag acquisition of $7.8 million is based on the present value of expected payments associated with the future cash flows of Valley Ag. During the year ended December 31, 2022, the Company recorded the $0.8 million decrease in deferred consideration value to Interest expense, net in the Consolidated Statements of Operations. In the fourth quarter of 2021, the Company recorded $9.0 million of long-term deferred consideration related to the Laurel Harvest acquisition. During the first quarter of 2022, the Company reclassified $9.0 million of long-term deferred consideration to short-term deferred consideration, as noted above. (d) Dispositions On March 30, 2021, the Company completed the divestiture of the 180 Smoke and related intercompany receivables to Spyder Cannabis Inc. and Plant-Based Investment Corp. for approximately $1.1 million, after certain adjustments. The sale resulted in a loss of $0.8 million for the year ended December 31, 2021 and is classified as a component of Other income, net, in the Consolidated Statement of Operations. At the time of sale, the Company recognized an additional loss of $0.3 million for accumulated foreign currency translation loss previously included in Other comprehensive loss, which is included within Other income, net, in the Consolidated Statement of Operations. (e) Pending Acquisitions On March 23, 2022, the Company entered into a definitive arrangement agreement (“Arrangement Agreement”) with Columbia Care Inc. (“Columbia Care”) to acquire all of the issued and outstanding shares of Columbia Care pursuant to a statutory plan of arrangement (the “Arrangement”), in an all-share transaction (the “Columbia Care Transaction”). Under the terms of the Arrangement Agreement, holders of common shares of Columbia Care will receive 0.5579 SVS of Cresco Labs for each Columbia Care share, subject to adjustment. The shareholders of Columbia Care voted in favor of a special resolution to approve the Arrangement on July 8, 2022. The Columbia Care Transaction is expected to close in the second quarter of 2023. The Company continues to work toward successful regulatory approvals to complete the transaction, which are beyond the control of the Company, including required divestitures identified in several states as discussed below. (f) Pending Dispositions While divestitures will be required for state regulatory approvals of the Columbia Care Transaction, the scope and financial impact of any divestitures cannot be quantified at this time. On November 4, 2022, the Company entered into a definitive agreement to divest certain New York, Illinois, and Massachusetts assets (the “Assets”) of Cresco Labs and Columbia Care to entities owned and controlled by Sean “Diddy” Combs, (the “Combs Transaction”) for total consideration of $185.0 million (the “Purchase Price”). The divestiture of the Assets is required for Cresco Labs to close its previously announced acquisition of Columbia Care and is expected to close concurrently with the closing of the Columbia Care Transaction. The purchasing entities will acquire certain Cresco Labs and Columbia Care assets in New York, Illinois, and Massachusetts. A portion of the Purchase Price is payable upon closing of the Combs Transaction, subject to adjustments contained in the definitive agreements, and will be comprised of approximately $110.0 million in cash and approximately $45.0 million of seller notes. The remaining portion of the Purchase Price is payable post-closing of the Combs Transaction upon achievement of certain short-term, objective, and market-based milestones. The following combination of Cresco Labs (“CL”) and Columbia Care (“CC”) assets will be divested in the Combs Transaction: • New York: Brooklyn (CC), Manhattan (CC), New Hartford (CL), and Rochester (CC) retail assets and Rochester (CC) production asset. • Massachusetts: Greenfield (CC), Worcester (CL), and Leicester (CL) retail assets and Leicester (CL) production asset. • Illinois: Chicago – Jefferson Park (CC) and Villa Park (CC) retail assets and Aurora (CC) production asset. The closing of the divestitures noted above is subject to certain closing conditions in the definitive agreements, including the receipt of all required regulatory approvals; clearance under the Hart-Scott-Rodino Antitrust Improvements Act; and the closing of the Columbia Care Acquisition. The divestiture listed do not meet the criteria to be classified as held for sale as of December 31, 2022 due to the closing conditions noted above, many of which are beyond the control of the Company.

Long-term Notes and Loans Payab

Long-term Notes and Loans Payable, Net	12 Months Ended
	Dec. 31, 2022
Borrowings [abstract]
Long-term Notes and Loans Payable, Net	NOTE 11. LONG-TERM NOTES AND LOANS PAYABLE, NET The following table represents the Company’s Long-term notes and loans payable, net balances as of December 31, 2022 and 2021: ($ in thousands) 2022 2021 Senior Loan $ 400,000 $ 400,000 Interest payable 9,500 9,711 Financing liability 96,917 97,797 Total borrowings and interest payable $ 506,417 $ 507,508 Less: Unamortized debt issuance costs (18,550) (22,501) Less: Short-term borrowings and interest payable (9,500) (9,711) Less: Current portion of financing liability (9,312) (10,217) Total Long-term notes and loans payable, net $ 469,055 $ 465,079 (a) Senior Loan and Amended Term Loan On February 2, 2020, the Company closed on a senior secured term loan agreement (the “Term Loan”) for an aggregate principal amount of $100 million, with the option to increase the principal amount to $200 million. Of the $100 million Term Loan commitment, $92.4 million was committed by Tranche A lenders (the “Tranche A Commitment”) and $7.6 million was committed by Tranche B lenders (the “Tranche B Commitment”). The Tranche A Commitment accrued interest at a rate of 12.7% per annum, payable in cash quarterly and had a stated maturity of July 22, 2021. The Tranche B Commitment accrued interest at a rate of 13.2% per annum, payable in cash quarterly and had a stated maturity of January 22, 2022. The Company’s effective interest rates for the Tranche A Commitment and Tranche B Commitment of the Term Loan were 17.0% and 16.1%, respectively. The Company capitalized $5.5 million and $0.4 million, respectively, of borrowing costs related to the Tranche A Commitment and Tranche B Commitment. On December 11, 2020, the Company entered into an amendment to exercise the mutual option to increase the principal amount to $200 million and refinance the existing Term Loan and the Opaskw ayak Cree Nation Loan (the “OCN Loan”), resulting in one amended term loan (the “Amended Term Loan”). As a result of the non-substantial debt modification of the existing Term Loan and the OCN Loan, $0.2 million in financing fees were expensed and $0.8 million of deferred financing fees were written off. Of the $200 million Amended Term Loan commitment, $11.7 million was committed by non-extending lenders (the “ Non-Extending Lenders Commitment ” ), $97.3 million was committed by extending lenders (the “ Extending Lenders Commitment ” ) and $91.0 million was committed by increasing lenders (the “ Increasing Lenders Commitment ” ). The Company accelerated principal repayments of $5.4 million and $1.0 million to the OCN Loan lender and certain exiting Term Loan lenders, respectively. The Non-Extending Lenders Commitment accrued interest at a rate of 12.7% per annum, payable in cash quarterly. The Extending Lenders Commitment and Increasing Lenders Commitment (the “ Extending and Increasing Lenders Commitment”) accrued interest at a rate of 12.0% per annum, payable in cash quarterly. The Company’s effective interest rates for the Non-Extending Lenders Commitment and the Extending and Increasing Lenders Commitment were 17.7% and 15.8%, respectively. On August 12, 2021, the Company closed on an agreement for a senior secured term loan with an undiscounted principal balance of $400 million (the “ Senior Loan ” ) and an original issue discount of $13.0 million. A portion of proceeds from the Senior Loan were used to retire the existing Amended Term Loan, with the remainder to fund capital expenditures and pursue other targeted growth initiatives within the U.S. cannabis sector. As a result of the extinguishment of the Amended Term Loan, loss on debt extinguishment of $18.0 million was recognized in Other (expense) income, net, in the Consolidated Statements of Operations for the year ended December 31, 2021. The Senior Loan accrues interest at a rate of 9.5% per annum, payable in cash semi-annually and has a stated maturity of August 12, 2026. The Company’s effective interest rate for the Senior Loan is 11.0%. The Company capitalized $10.9 million of borrowing costs related to the Senior Loan, of which $7.0 million is payable upon principal repayment of the Senior Loan and thus, is reflected within Other long-term liabilities. The Senior Loan is secured by a guarantee from substantially all material subsidiaries of the Company, as well as by a security interest in certain assets of the Company and such material subsidiaries. The Senior Loan contains negative covenants which restrict the actions of the Company and its subsidiaries during the term of the loan, including restrictions on paying dividends, making investments and incurring additional indebtedness. The Company is also subject to compliance with affirmative covenants, some of which may require management to exercise judgment. In addition, the Company is required to maintain a minimum cash balance of $50.0 million and to ensure that the Fixed Charge Coverage Ratio; defined as the ratio of (a) consolidated EBITDA less unfinanced capital expenditures; restricted payments, as defined by the loan agreement; and federal, state, provincial, local and foreign income taxes to (b) consolidated fixed charges; is not less than 2 to 1. The Company may prepay in whole or in part the Senior Loan at any time prior to the stated maturity date, subject to certain conditions, upon the payment of the outstanding principal amount (plus a specified prepayment premium equal to the present value of all principal and interest payments of the loan remaining until the applicable scheduled maturity date as defined by the loan agreement) and all accrued and unpaid interest and fees. Interest expense is discussed in Note 19. As discussed in Note 10, on March 23, 2022, the Company announced it had entered into the Arrangement Agreement with Columbia Care to acquire all of the issued and outstanding shares of Columbia Care. On March 23, 2022, Cresco entered into a consent agreement with respect to the Senior Loan pursuant to which certain amendments were made to the Senior Loan which are conditional and effective on the closing of the Arrangement (the “Amended Senior Loan”). The Amended Senior Loan permits the Arrangement, Cresco’s assumption of certain Columbia Care debt and certain proposed asset sales in connection with the Arrangement, in each case, on and subject to the terms and conditions of the Amended Senior Loan. (b) Financing Liabilities The Company recognized financing liabilities in relation to sale and leaseback transactions. For the years ended December 31, 2022 and 2021, the incremental borrowing rates range from 11.3% to 17.5% and 11.2% to 17.5%, respectively. The remaining terms were between 10.4 and 17.5 years and between 8.1 and 18.5 years for the same periods. The interest expense associated with financing liabilities is discussed in Note 19.

Revenues and Loyalty Programs

Revenues and Loyalty Programs	12 Months Ended
	Dec. 31, 2022
Revenue [abstract]
Revenues and Loyalty Programs	NOTE 12. REVENUES AND LOYALTY PROGRAMS (a) Revenues The following table represents the Company’s disaggregated revenue by source, due to the Company’s contracts with its customers, for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Wholesale $ 367,222 $ 414,908 Dispensary 475,459 406,774 Total Revenues $ 842,681 $ 821,682 The Company generates revenues, net of sales discounts, at the point in time the control of the product is transferred to the customer, as the Company has a right to payment and the customer has assumed significant risks and rewards of such product without any remaining performance obligation. Sales discounts were 10.7% and 7.0% of gross revenue during the years ended December 31, 2022 and 2021, respectively. The Company does not enter into long-term sales contracts. (b) Loyalty Programs In the states of Illinois, Arizona, Pennsylvania, New York, Florida and Massachusetts; the Company has customer loyalty programs where retail customers accumulate points based on their level of spending. These points are recorded as a contract liability until customers redeem their points for discounts on cannabis products as part of an in-store sales transaction. Loyalty points may be redeemed by customers for a range of $0.01 to $0.10 off of future purchases. The Company records a performance obligation as a reduction of revenue that ranges between $0.01 and $0.04 per loyalty point, inclusive of breakage expectations. Upon redemption, the loyalty program obligation is relieved and the offset is recorded as revenue. As of December 31, 2022 and 2021, there were 126.1 million and 94.1 million points outstanding, respectively, with an approximate value of $2.1 million and $1.3 million, respectively. The Company expects outstanding loyalty points to be redeemed within 1 year.

Other Income , Net

Other Income , Net	12 Months Ended
	Dec. 31, 2022
Other Operating Income (Expense) [Abstract]
Other Income , Net	NOTE 13. OTHER INCOME, NET For the years ended December 31, 2022 and 2021, Other income, net consisted of the following: ($ in thousands) 2022 2021 Unrealized gain on derivative liabilities - warrants $ 1,184 $ 16,669 (Loss) gain on derivative instruments (5,698) 23,909 Gain (loss) on provision - loan receivable 572 (753) Unrealized loss on investments held at fair value (4,609) (7,135) Loss on debt extinguishment — (17,987) Gain (loss) on conversion of investment 22 (880) Gain (loss) on disposition of assets 14,711 (6) Gain (loss) on foreign currency 931 (1,228) Gain (loss) on lease termination 4,876 (43) Other income, net 3,238 485 Total Other income, net $ 15,227 $ 13,031 See Note 11 for additional information on Loss on debt extinguishment. See Note 4 for additional information on Gain (loss) on disposition of assets.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related party transactions [abstract]
Related Party Transactions	NOTE 14. RELATED PARTY TRANSACTIONS (a) Transactions with Key Management Personnel Related parties, including key management personnel, hold 89.9 million Redeemable Units of Cresco Labs, LLC, which is equal to a deficit of $24.7 million of Non-controlling interests as of December 31, 2022. During the years ended December 31, 2022 and 2021, 74.4% and 84.7%, respectively, of required tax distribution payments in accordance with the tax receivable agreement to holders of Cresco Labs, LLC were made to related parties including to key management personnel. (b) Related Parties – Debt On August 12, 2021, the Company closed on a Senior Loan agreement, the proceeds from which were used to retire the then-existing term loan. Upon entering the Senior Loan agreement, the Company had no borrowings with related parties. Prior to the closing of the Senior loan, the Company had borrowings with related parties related to the Amended Term Loan. The balance of the Amended Term Loan as of December 31, 2021 was $nil as payments of $16.6 million were made in the third quarter of 2021 to repay this debt. During the years ended December 31, 2022 and 2021, the Company recorded interest expense related to borrowings with related parties of $nil and $1.2 million, respectively. As of December 31, 2022 and 2021, the Company had no interest payable related to debt with related parties. See Notes 11 and 19 for additional details. Prior to the new Senior Loan agreement, related party lenders included Charles Bachtell, Chief Executive Officer and member of the Board; Robert Sampson, member of the Board; Global Green Debt, LLC which is owned by Randy Podolsky, member of the Board; Calti, LLC which is owned by Joe Caltabiano, owner of 11.8% of the Company’s outstanding Redeemable Units; McCormack Capital which is owned by Brian McCormack, MVS shareholder; CL Debt which is owned by Dominic Sergi, MVS shareholder; a holder of minority interest in MedMar, Inc. (“MedMar”); and Vero Management LLC which is owned by individuals owning 21.9% of the Company’s outstanding Redeemable Units. (c) Related Parties – Leases For the years ended December 31, 2022 and 2021, the Company had lease liabilities for real estate lease agreements in which the lessors have a minority interest in SLO Cultivation, Inc. (“SLO”) and MedMar. The lease liabilities were incurred in January 2019 and May 2020 and were to expire in 2027 through 2030, except for the leases associated with SLO minority interest holders (“SLO Leases”). During the second quarter of 2022, the Company exercised its early termination right to reduce the SLO Leases term to 180 days. This early termination resulted in a reduction in lease liability and ROU assets. The ROU asset was reduced to $nil. Due to differences in carrying value between the lease asset and liability, a gain on lease termination of $4.9 million has been recorded for the year ended December 31, 2022, which is included in Other income (expense), net, in the Consolidated Statements of Operations. The remaining liability for the SLO Leases expired in the fourth quarter of 2022. The Company has liabilities for real estate leases and other financing agreements in which the lessor is Clear Heights Properties where Dominic Sergi, MVS shareholder, is Chief Executive Officer. The liabilities were incurred by entering into operating leases, finance leases and other financing transactions with terms that will expire in 2030. During the years ended December 31, 2022 and 2021 , the Company received tenant improvement allowance reimbursements of $1.4 million and $nil , res pectively. The Company expects to receive further reimbursements of $0.8 million within the next twelve months. Below is a summary of the expense resulting from the related party lease liabilities for the years ended December 31, 2022 and 2021: Year Ended ($ in thousands) Classification 2022 2021 Operating Leases Lessor has minority interest in SLO Rent expense $ 513 $ 1,563 Lessor has minority interest in MedMar Rent expense 288 238 Lessor is an MVS shareholder Rent expense 1,187 1,168 Finance Leases Lessor has minority interest in MedMar Depreciation expense $ 306 $ 277 Lessor has minority interest in MedMar Interest expense 270 310 Lessor is an MVS shareholder Depreciation expense 81 74 Lessor is an MVS shareholder Interest expense 76 88 Additionally, below is a summary of the ROU assets and lease liabilities attributable to related party leases as of December 31, 2022 and 2021: As of December 31, 2022 As of December 31, 2021 ($ in thousands) ROU Asset Lease Liability ROU Asset Lease Liability Operating Leases Lessor has minority interest in SLO $ — $ — $ 6,996 $ 11,938 Lessor has minority interest in MedMar 1,415 1,456 1,525 1,549 Lessor is an MVS shareholder 5,849 5,907 6,314 4,867 Finance Leases Lessor has minority interest in MedMar $ 2,034 $ 2,452 $ 2,137 $ 2,457 Lessor is an MVS shareholder 596 555 616 1,063 During both the years ended December 31, 2022 and 2021, the Company recorded interest expense on finance liabilities of $0.3 million. As of December 31, 2022 and 2021, the Company had finance liabilities totaling $1.5 million. The incremental borrowing rate for these liabilities is 17.2%. All finance liabilities outstanding are due to an entity controlled by an MVS shareholder.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Text Block [Abstract]
Commitments and Contingencies	NOTE 15. COMMITMENTS AND CONTINGENCIES (a) Claims and Litigation From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2022, there were no pending or threatened lawsuits, except as disclosed below, that could reasonably be expected to have a material effect on the results of the Company’s results of operations, financial positions or cash flows. There are also no proceedings in which any of the Company’s directors, officers, or affiliates are an adverse party or has a material interest adverse to the Company’s interest. During the year ended December 31, 2020, a former executive of the Company commenced proceedings against the Company. On January 29, 2021, the Company commenced an action in the Supreme Court of British Columbia against various parties, including this former executive and a special purpose acquisition entity. On February 1, 2021, a binding settlement was reached, and the terms were memorialized in an agreement as of March 1, 2021. The agreed-upon terms included a payment of 1.3 million SVS to the counterparty relating to certain equity awards previously held by the counterparty in exchange for a number of covenants including non-solicitation, non-hire, certain provisions surrounding voting rights and limitations on future sales of Company shares. As contemplated by the settlement, the Company discontinued the action on February 4, 2021, and a mutual release of claims resulted. At December 31, 2020, the Company had recorded an estimated liability, based on certain assumptions impacting the value of the settlement and benefits to the Company, of $13.6 million for this settlement within Accounts payable and other accrued expenses, in accordance with ASC 450. The payment of 1.3 million SVS was made during the first quarter of 2021. The settlement and payment resulted in an increase to share capital of $15.8 million, a non-solicitation and cooperation agreement intangible asset of $3.0 million to be amortized over two years, and litigation accrual adjustment of $0.8 million in Selling, general and administrative expense to adjust the settlement expense from $13.6 million to $12.8 million. The fair value of the non-solicitation and cooperation agreement intangible asset was estimated using the with-or-without method. The with-and-without method estimates the value of an intangible asset by quantifying the loss of economic profits under a hypothetical condition where only the subject intangible does not exist and needs to be re-created. Projected revenues, operating expenses and cash flows are calculated in each “with” and “without” scenario and the difference in the cash flow is discounted to present value. (b) Contingencies The Company’s operations are subject to a variety of federal, state and local regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on the Company’s operations, suspension or revocation of permits or licenses, or other disciplinary actions (collectively, “Disciplinary Actions”) that could adversely affect the Company’s financial position and results of operations. While management believes that the Company is in substantial compliance with state and local regulations as of December 31, 2022 and through the date of filing of these financial statements, these regulations continue to evolve and are subject to differing interpretations and enforcement. As a result, the Company may be subject to Disciplinary Actions in the future. (c) Commitments As of December 31, 2022, the Company had total commitments of $19.0 million related to material construction projects. During the first quarter of 2022, pursuant to the Illinois Cannabis Regulation and Tax Act, the Company issued an additional $0.2 million in loans to an Illinois company which has secured Craft Grower Licenses to operate in the state and $1.0 million in loans to groups that have been identified by the state of Illinois as having the opportunity to receive Conditional Adult Use Dispensing Organization Licenses. These loans are discussed in Note 16. These loans fully satisfy the Company’s funding requirements under Illinois Cannabis Regulation and Tax Act; however, the Company may elect to fund similar loans in the future. The Company has employment agreements with key management personnel which include severance in the event of termination totaling approximately $4.6 million with additional equity and/or benefit compensation.

Financial Instruments And Finan

Financial Instruments And Financial Risk Management	12 Months Ended
	Dec. 31, 2022
Financial Instruments [Abstract]
Financial Instruments And Financial Risk Management	NOTE 16. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT Financial Instruments The Company’s financial instruments are held at amortized cost (adjusted for impairments or ECLs, as applicable) or fair value. The carrying values of financial instruments held at amortized cost approximate their fair values as of December 31, 2022 and 2021 due to their nature and relatively short maturity date. Financial assets and liabilities with embedded derivative features are carried at fair value. Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three levels of hierarchy are: • Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; • Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and • Level 3 – Inputs for the asset or liability that are not based on observable market data. There have been no transfers into or out of level 3 during the years ended December 31, 2022 and 2021. The following tables summarize the Company’s financial instruments as of December 31, 2022 and 2021: December 31, 2022 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 119,341 $ — $ — $ — $ 119,341 Restricted cash 1 2,169 — — — 2,169 Security deposits 2 4,367 — — — 4,367 Accounts receivable, net 56,492 — — — 56,492 Loans receivable, short-term 447 — — — 447 Loans receivable, long-term 823 — — — 823 Investments — 136 432 660 1,228 Financial Liabilities: Accounts payable $ 28,093 $ — $ — $ — $ 28,093 Accrued liabilities 65,161 — — — 65,161 Short-term borrowings 18,812 — — — 18,812 Current portion of lease liabilities 26,124 — — — 26,124 Deferred consideration and other payables, short-term 6 7 — 47,821 47,834 Lease liabilities 156,180 — — — 156,180 Deferred consideration, long-term — — — 7,770 7,770 Long-term notes payable and loans payable 469,055 — — — 469,055 Other long-term liabilities 7,000 — — — 7,000 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. December 31, 2021 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 223,543 $ — $ — $ — $ 223,543 Restricted cash 1 2,559 — — — 2,559 Security deposits 2 3,941 — — — 3,941 Accounts receivable, net 43,379 — — — 43,379 Loans receivable, short-term 747 — — 565 1,312 Loans receivable, long-term 505 — — — 505 Investments — 4,710 542 660 5,912 Financial Liabilities: Accounts payable $ 32,278 $ — $ — $ — $ 32,278 Accrued liabilities 95,442 — — — 95,442 Short-term borrowings 19,928 — — — 19,928 Current portion of lease liabilities 20,792 — — — 20,792 Deferred consideration, contingent consideration and other payables, short-term 5 12 — 71,816 71,833 Derivative liabilities, short-term — — — 1,172 1,172 Lease liabilities 118,936 — — — 118,936 Deferred consideration, long-term — — — 17,651 17,651 Long-Term Notes Payable and Loans Payable 465,079 — — — 465,079 Other long-term liabilities 7,001 — — — 7,001 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. The following table presents a rollforward of the balance sheet amounts measured at fair value on a recurring basis and classified as Level 3. The classification of an item as Level 3 is based on inputs for assets or liabilities that are not based on observable market data. December 31, 2022 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Investments Deferred consideration and other payables, short-term Derivative liabilities, short-term Deferred consideration, long-term Balance as of December 31, 2021 $ 565 $ 660 $ 71,816 $ 1,172 $ 17,651 Change in fair value recorded in Interest expense, net — — 900 — (881) Change in fair value recorded in Other income, net — — 5,647 (1,172) — Payments (1,837) — (39,542) — — Change in fair value recorded in Selling, general and administrative 1,272 — — — — Other 1 — — 9,000 — (9,000) Balance as of December 31, 2022 $ — $ 660 $ 47,821 $ — $ 7,770 1 Other relates to reclassifications from long-term to short-term due to the projected dispensary opening dates. December 31, 2021 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Loans receivable, long- term Investments Deferred consideration and other payables, short-term Derivative liabilities, short-term Derivative liabilities, long-term Deferred consideration and contingent, long-term Balance as of December 31, 2020 $1,517 $20,019 $119 $19,093 $— $17,505 $7,247 Additions — — 593 69,099 — — 9,026 Change in fair value recorded in Interest expense, net — — — 196 27 (223) 1,378 Change in fair value recorded in Other income, net — — — (14,743) (11,897) (4,231) — Payments (400) — — (1,829) — — — Settlement — (20,019) (52) — — (9) — Change in fair value recorded in Selling, general and administrative (552) — — — — — — Other 1 — — — — 13,042 (13,042) — Balance as of December 31, 2021 $565 $— $660 $71,816 $1,172 $— $17,651 1 Other relates to reclassifications from long-term to short-term due to the projected dispensary opening dates. (a) Loans receivable, short-term The following is a summary of Loans receivable, short-term balances and valuation classifications (discussed further below) as of December 31, 2022 and 2021: ($ in thousands) Valuation December 31, 2022 December 31, 2021 Short-term loans receivable - Lighthouse Fair value $ — $ 565 Short-term loans receivable - Other, net of ECL Amortized cost 447 — Interest receivable Amortized cost — 747 Total Loans receivable, short-term $ 447 $ 1,312 (i) Lighthouse Loan On August 12, 2019, the Company issued a secured convertible promissory note that is convertible, at the Company’s discretion, into additional membership units approximating 1% ownership of the parent company of Lighthouse. The loan was amended in March 2021 to extend the maturity date from February 2021 to February 2022. During the first quarter of 2022, the Company received payment for the outstanding balance and accrued interest. (ii) Other Loans In connection with the acquisition of Origin House, the Company assum ed a long-term loan receivable with a balance o f $0.4 million as of December 31, 2021. The entire balance was reclassified to loans receivable, short-term as of December 31, 2022 as payment is expected during 2023. (b) Loans receivable, long-term ($ in thousands) Valuation December 31, 2022 December 31, 2021 Long-term loans receivable - Illinois Incubator, net of ECL Amortized cost $ 823 $ 100 Long-term loans receivable - Other, net of ECL Amortized cost — 405 Total Loans receivable, long-term $ 823 $ 505 (i) Illinois Incubator Loans Pursuant to the Illinois Cannabis Regulation and Tax Act, the Company has issued $0.3 million in loans to an Illinois company which has secured a Craft Grower License to operate in the state and $1.0 million in loans to groups that have been identified by the state of Illinois as having the opportunity to receive Conditional Adult Use Dispensing Organization Licenses. One (1) $0.1 million loan related to the Craft Grower License, was fully funded on July 20, 2021 and matures on July 20, 2026. The remaining loans of $1.2 million were fully funded on March 21, 2022 and matures on July 20, 2027. The loans are measured at amortized cost and bear no interest. (ii) Other Loans In connection with the acquisition of Origin House, the Company assum ed a loan receivable with a balance o f $0.4 million as of December 31, 2021, which was reclassified to loans receivable, short-term as of December 31, 2022 as discussed above. (c) Share Purchase Warrants As of December 31, 2022, all share purchase warrants have expired, leaving none outstanding. At December 31, 2021, the Company had 9.8 million warrants outstanding, of which 4.2 million warrants were classified as current liabilities. 3.7 million of these liability-classified warrants were from issuances to underwriters associated with the September 2019 financing. In the second quarter of 2022, the Company reduced the fair value of the liability-classified warrants to $nil, resulting in a mark-to-market gain of $1.2 million for the year ended December 31, 2022. The gain was driven by changes in the Company’s share price, volatility and the remaining expected life of the warrants. During the third quarter of 2022, all liability-classified warrants expired. For the year ended December 31, 2021, the Company recorded a mark-to-market gain of $16.7 million due to changes in the Company’s share prices, volatility and remaining expected life; additionally, the Company recorded a $0.3 million unrealized loss on foreign exchange. All warrants classified as derivative liabilities are measured at fair value. As of December 31, 2021, the fair value of liability-classified warrants was determined using the Black-Scholes option-pricing model utilizing the following assumptions: 2021 Risk-free annual interest rate 0.15% Expected annual dividend yield 0.0% Expected stock price volatility 47.3% Expected life of stock warrants < 1 year Forfeiture rate 0% Share price at period end $6.62 Strike price at period end $9.86 Volatility was calculated by using the Company’s historical share volatility. Prior to 2021, volatility was calculated by using the average historical volatility of comparable companies from a representative peer group of publicly traded companies. The change in volatility rate was made because the Company now has a reasonable observable history of volatility to use a company-specific rate, whereas in the past it did not. The impact of the change in volatility rates resu lted i n a one-time gain of $5.2 million , which is incl uded in Other income (expense), net on the Consolidated Statements of Operations for the year ended December 31, 2021. An increase in volatility would result in an increase in fair value at grant date. The expected life in years represents the period of time before warrants expire. The risk-free rate is based on U.S. treasury bills with a remaining term equal to the expected life of the options. Financial Risk Management The Company is exposed in varying degrees to a variety of financial instrument-related risks. The Board of Directors and Company management mitigate these risks by assessing, monitoring and approving the Company’s risk management processes: (a) Credit and Banking Risk Credit risk is the risk of a potential loss to the Company if a customer or a third-party to a financial instrument fails to meet its contractual obligations. The maximum credit exposure as of December 31, 2022 and 2021 is the carrying amount of cash, accounts receivable and loans receivable. The Company does not have significant credit risk with respect to its growth in its key retail markets, as payment is typically due upon transferring the goods to the customer at our dispensaries, which currently accept only cash and debit cards. Additionally, the Company does not have significant credit risk with respect to its loan counterparties as the interest rate on our Senior Loan is not variable and therefore, is not materially impacted by interest rate increases enacted by the Federal Reserve. Although all deposited cash is placed with U.S. financial institutions in good standing with regulatory authorities, changes in U.S. federal banking laws related to the deposit and holding of funds derived from activities related to the cannabis industry have passed the U.S. House of Representatives but were not voted on within the U.S. Senate, and would need to be reintroduced by the new Congress. Given that current U.S. federal law provides that the production and possession of cannabis is illegal, there is a strong argument that banks cannot accept or deposit funds from businesses involved with the cannabis industry, leading to an increased risk of legal actions against the Company and forfeitures of the Company’s assets. The Company’s aging of Accounts receivables as of December 31, 2022 and 2021 was as follows: ($ in thousands) 2022 2021 0 to 60 days $ 49,303 $ 37,750 61 to 120 days 6,118 4,309 120 days + 3,698 3,540 Total accounts receivable, gross 59,119 45,599 Allowance for doubtful accounts 2,627 2,220 Total accounts receivable, net $ 56,492 $ 43,379 For the years ended December 31, 2022 and 2021, the Company recorded bad debt expense of $0.4 million and $1.0 million, respectively, to account for ECL and recorded an additional $1.9 million and $0.3 million, respectively, in bad debt related to invoice write-offs. (b) Asset Forfeiture Risk Because the cannabis industry remains illegal under U.S. federal law, any property owned by participants in the cannabis industry which are either used in the course of conducting such business, or are the proceeds of such business, could be subject to seizure by law enforcement and subsequent civil asset forfeiture. Even if the owner of the property was never charged with a crime, the property in question could still be seized and subject to an administrative proceeding by which, with minimal due process, it could be subject to forfeiture. (c) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company primarily manages liquidity risk through the management of its capital structure by ensuring that it will have sufficient liquidity to settle obligations and liabilities when due. As of December 31, 2022, the Company had working capital (defined as current assets less restricted cash, less current liabilities) of $43.0 million. The Company expects to continue to raise capital to fund operations and the expansion of its business. In addition to the commitments outlined in Note 15, the Company has the following contractual obligations as of December 31, 2022: ($ in thousands) < 1 Year 1 to 3 Years 3 to 5 Years Total Accounts payable & Accrued liabilities $ 93,254 $ — $ — $ 93,254 Deferred consideration, contingent consideration and other payables, short-term 47,834 — — 47,834 Deferred consideration, long-term — 7,770 — 7,770 Long-term notes payable and loans payable and Short-term borrowings 18,812 — 469,055 487,867 Other long-term liabilities 7,000 7,000 Total obligations as of December 31, 2022 $ 159,900 $ 7,770 $ 476,055 $ 643,725 (d) Market Risk (i) Currency Risk The operating results and balance sheet of the Company are reported in USD. As of December 31, 2022 and 2021, the Company’s financial assets and liabilities are primarily in USD. However, from time to time some of the Company’s financial transactions are denominated in currencies other than USD. The results of the Company’s operations are subject to currency transaction and translation risks. The Company recorded a $0.9 million gain in foreign currency exchanges during the year ended December 31, 2022 and a $1.2 million loss in foreign currency exchanges during the year ended December 31, 2021. See Note 13 for additional details. As of December 31, 2022 and 2021, the Company had no hedging agreements in place with respect to foreign exchange rates. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks at this time. (ii) Interest Rate Risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. An increase or decrease in the Company’s incremental borrowing rate would result in an associated increase or decrease in Deferred consideration, contingent consideration and other payables and Interest expense, net. The Company’s Senior Loan accrues interest at a rate of 9.5%, per annum and has an effective interest rate of 11.0%. (iii) Price Risk Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company is subject to price risk related to derivative liabilities and contingent consideration that are valued based on the Company’s own stock price. An increase or decrease in stock price would result in an associated increase or decrease to Deferred consideration, contingent consideration and other payables, short-term and Derivative liabilities, short-term with a corresponding change to Other income, net. (iv) Tax Risk Tax risk is the risk of changes in the tax environment that would have a material adverse effect on the Company’s business, results of operations and financial condition. Currently, state-licensed marijuana businesses are assessed a comparatively high effective federal tax rate due to IRC Section 280E, which bars businesses from deducting all expenses except their cost of goods sold when calculating federal tax liability. Any increase in tax levies resulting from additional tax measures may have a further adverse effect on the operations of the Company, while any decrease in such tax levies will be beneficial to future operations. See Note 20 for the Company’s disclosure of uncertain tax positions. (v) Regulatory Risk Regulatory risk pertains to the risk that the Company’s business objectives are contingent, in part, upon the compliance of regulatory requirements. Due to the nature of the industry, the Company recognizes that regulatory requirements are more stringent and punitive in nature. Any delays in obtaining, or failure to obtain regulatory approvals can significantly delay operational and product development and can have a material adverse effect on the Company’s business, results of operation and financial condition. The Company is cognizant of the advent of regulatory changes occurring in the cannabis industry on the city, state and national levels. Although the regulatory outlook on the cannabis industry has been moving in a positive trend, any unforeseen regulatory changes could have a material adverse impact on the goals and operation of the Company's business. (vi) Novel Coronavirus ( “ COVID-19 ”) Risk COVID-19 was declared a pandemic by the World Health Organization on March 12, 2020. During the fourth quarter of 2020, the first vaccine utilized to prevent coronavirus infection was approved by the U.S. Food and Drug Administration. As of December 31, 2022, the vaccine is widely available, however, there remains significant economic uncertainty and consequently, it is difficult to reliably measure the potential impact of this uncertainty on the Company’s future financial results. (vii) Inflation Risk The Company has experienced increased inflationary pressures, including increased cultivation costs, distribution costs and operating expenses, which adversely has impacted our operating results. The Company expects these inflationary pressures to continue in 2023. The Company maintains strategies to mitigate the impact of higher raw material, energy and commodity costs, which include cost reduction, sourcing and other actions, which may help to offset a portion of the adverse impact.

Variable Interest Entities

Variable Interest Entities	12 Months Ended
	Dec. 31, 2022
Variable Interest Entities [Abstract]
Variable Interest Entities	NOTE 17. VARIABLE INTEREST ENTITIES The following table presents the summarized financial information about the Company’s consolidated VIEs which are included in the Consolidated Balance Sheets as of December 31, 2022 and 2021. All of these entities were determined to be VIEs as the Company possesses the power to direct activities through written agreements and is subject to the risk and rewards as a primary beneficiary: December 31, 2022 December 31, 2021 ($ in thousands) Cresco Labs Michigan, LLC Cresco Labs Michigan, LLC Current assets $ 17,506 $ 9,850 Non-current assets $ 63,212 $ 63,320 Current liabilities $ (3,158) $ (9,476) Non-current liabilities $ (108,113) $ (86,124) Deficit attributable to Cresco Labs Inc. $ (30,553) $ (22,430) The following table presents the summarized financial information about the Company’s consolidated VIEs which are included in the Consolidated Statements of Operations for the years ended December 31, 2022 and 2021: December 31, 2022 December 31, 2021 ($ in thousands) Cresco Labs Michigan, LLC Cresco Labs Michigan, LLC Revenue $ 12,659 $ 4,031 Net income (loss) attributable to Cresco Labs Inc. $ (8,617) $ (9,120) Net income (loss) $ (8,617) $ (9,120)

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2022
Disclosure of operating segments [abstract]
Segment Information	NOTE 18. SEGMENT INFORMATION The Company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis. The Chief Executive Officer, the Chief Financial Officer, the Chief Operating Officer and the Chief Commercial Officer of the Company have been identified as the Chief Operating Decision Makers (“CODM”) and manage the Company’s operations as a whole. For the purpose of evaluating financial performance and allocating resources, the CODM review certain financial information presented on a consolidated basis accompanied by information by customer and geographic region. For the years ended December 31, 2022 and 2021, the Company generate d 100.0% and 99.6%, respectively,

Provision For Income Taxes And

Provision For Income Taxes And Deferred Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Provision For Income Taxes And Deferred Income Taxes	NOTE 20. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES As the Company operates in the cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal income tax purposes as well as state income tax purposes for all states except California, Maryland, Michigan and Massachusetts. Under IRC Section 280E, the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, certain states do not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its income tax returns in these states. The Company intends to be treated as a U.S. corporation for U.S. federal income tax purposes under IRC Section 7874 and is subject to U.S. federal income tax on its worldwide income. However, for Canadian tax purposes the Company, regardless of any application of IRC Section 7874, is treated as a Canadian resident company, as defined in the Income Tax Act (Canada), for Canadian income tax purposes. As a result, the Company will be subject to taxation both in Canada and the U.S. Provision for income taxes consists of the following for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Current Federal $ 69,240 $ 51,815 State 24,341 23,337 Foreign — — Total current $ 93,581 $ 75,152 Deferred Federal $ (8,332) $ (29,445) State (9,858) (14,043) Foreign 1,190 5,759 Total deferred $ (17,000) $ (37,729) Change in valuation allowance $ 12,357 $ 2,684 Total $ 88,938 $ 40,107 As of December 31, 2022 and 2021, the components of deferred tax assets and liabilities were as follows: ($ in thousands) 2022 2021 Deferred tax assets Share-based compensation $ 1,381 $ 1,029 Financing fees 1,291 2,542 Net operating losses 43,629 36,096 Inventory 662 239 Lease liabilities 28,362 26,761 Other 386 730 Total deferred tax assets $ 75,711 $ 67,397 Deferred tax liabilities ROU assets $ (9,560) $ (7,824) Property, plant and equipment (12,393) (11,885) Intangible assets (84,099) (93,761) Other (1,329) (1,948) Total deferred tax liabilities $ (107,381) $ (115,418) Valuation allowance $ (43,442) $ (31,085) Net deferred tax liabilities $ (75,112) $ (79,105) As of December 31, 2022, the Company had the following loss carryforwards: • $63.5 million of non-capital Canadian losses which expire from 2038-2042, which are fully offset by valuation allowance. • $52.2 million of U.S. federal net operating losses which have an indefinite carryforward period, a portion of which are not recorded as the Company does not consider these to be more-likely-than-not to be realized. $45.7 million of U.S. federal net operating loss carryforwards are offset by valuation allowance. • $184.3 million of state net operating losses, which expire in 2038-2042, a portion of which are not recorded as the Company does not consider these to be more-likely-than-not to be realized. $180.8 million of state net of state net operating loss carryforwards are offset by valuation allowance. As of December 31, 2021, the Company had $66.1 million of non-capital Canadian losses, fully offset by valuation allowance; $30.8 million of U.S. federal net operating losses which have an indefinite carryforward period, $0.4 million offset by valuation allowance; $138.3 million of state net operating losses, which expire from 2038-2041, $128.0 million offset by valuation allowance. A valuation allowance to reflect management’s estimate of the temporary deductible differences that may expire prior to their utilization has been recorded at December 31, 2022 and 2021. During 2021 and 2022, the Company maintained a full valuation allowance against its net Canadian deferred tax assets, as losses are generated in Canada with no projection of future taxable income. As of December 31, 2022, the Company recorded a full valuation allowance against its net deferred tax assets at entities operating in California. In 2022, the Company reduced its tax asset related to the step-up in basis from shareholder redemptions under the tax receivable agreement for Cresco Labs LLC by $1.2 million. The Company also recognized in equity a reduction to the tax receivable agreement liability of $0.6 million related to estimated payables to certain shareholders. In 2022, the Company recorded measurement period adjustments of $0.4 million to the deferred tax liabilities recorded through goodwill related to the acquisition of Bluma, Cultivate and Laurel Harvest. The reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows: ($ in thousands) 2022 2021 Expected income tax expense at statutory tax rate $ (26,650) $ (53,912) Tax rate differences (2,296) (1,109) Pass through and non-controlling entities (2,183) (7,373) State tax expense, net 6,782 8,697 IRC Section 280E disallowance 50,521 47,100 Changes in value of deferred consideration 699 (10,103) Loss on debt modification — 7,554 Uncertain tax treatment (including penalties and interest) 13,245 (4,749) Share-based compensation 2,097 3,941 Goodwill impairment 25,334 45,314 Accrued current tax penalties and interest 4,155 563 Change in valuation allowance 12,357 2,684 Change in state tax rates 4,520 622 Other 357 876 Income tax expense $ 88,938 $ 40,107 Effective tax rate (70.1 %) (15.6 %) During 2022, the Company adopted a tax position whereby certain expenses incurred at dispensary locations are treated as inventoriable costs for tax purposes, reducing the impact of IRC Section 280E on the 2021 tax returns and in the current period. The Company has determined that the tax benefit associated with this position does not meet the more likely than not criteria under ASC 740-10 due to the evolving interpretations of IRC Section 280E. As a result, the Company has recorded a reserve of $12.7 million for unrecognized tax benefits and accrued $0.5 million of penalties and interest related to unrecognized tax benefits as of December 31, 2022. The Company records unrecognized tax benefits as liabilities in accordance with ASC 740 and adjusts these liabilities when judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. It is possible that additional tax distribution liabilities may become due to certain non-controlling interest members as a result of unrecognized tax benefits. While the probable amount of any future tax distribution liability cannot reasonably be estimated, the maximum future tax distribution liability associated with these unrecognized tax benefits is estimated to be $5.6 million. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: ($ in thousands) 2022 2021 Balance at January 1 $ — $ 4,749 Additions based on tax positions related to the current year 7,380 — Additions for tax positions of prior years 5,366 — Reductions for tax positions of prior years — (4,749) Balance at the end of the year $ 12,746 $ — The Company is currently under examination by U.S. federal, state and Canadian tax authorities. As of December 31, 2022, no additional liabilities are anticipated as a result of these examinations. With few exceptions, the Company is generally not subject to examination by tax authorities for years before 2019.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	NOTE 21. SUBSEQUENT EVENTS The Company has evaluated subsequent events through March 21, 2023, which is the date on which these financial statements were issued. On February 27, 2023, the Company announced it has mutually agreed with Columbia Care Inc. to extend the outside date to complete the proposed acquisition by Cresco of Columbia Care from March 31, 2023 to June 30, 2023. The extension will allow the Companies additional time to finalize divestiture agreements and obtain the regulatory approvals required to close.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies [Abstract]
Basis of Preparation	Basis of PreparationThe accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Basis of Measurement	Basis of MeasurementThe accompanying consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain equity method investments as well as certain loans receivable, investments, derivative instruments and contingent considerations, which are recorded at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets acquired and the contractual obligation for liabilities incurred.
Functional and Presentation Currency	Functional and Presentation Currency The Company’s functional currency and that of the majority of its subsidiaries is the United States (“U.S.”) dollar. The Company’s reporting currency is the U.S. dollar (“USD”). All references to “C$” refer to Canadian dollars. Foreign currency denominated assets and liabilities are re-measured into the functional currency using period-end exchange rates. Gains and losses from foreign currency transactions are included in Other income, net in the Consolidated Statements of Operations. Assets and liabilities of foreign operations having a functional currency other than USD (e.g., C$) are translated at the rate of exchange prevailing at the reporting date; revenues and expenses are translated at the monthly average rate of exchange during the period. Gains or losses on translation of foreign subsidiaries and net investments in foreign operations are included in Foreign currency translation differences, net of tax in the Consolidated Statements of Comprehensive Loss and Accumulated other comprehensive loss on the Consolidated Balance Sheets.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries with intercompany balances and transactions eliminated upon consolidation. Subsidiaries are those entities over which the Company has the power over the investee, is exposed, or has rights, to variable involvement with the investee; and has the ability to use its power to affect its returns. The following are Cresco Labs’ wholly-owned or controlled entities as of December 31, 2022: Entity Location Purpose Percentage Cresco Labs Inc. British Columbia, Canada Parent Company Cali-AntiFragile Corp. California Holding Company 100% Alta Supply Inc. California Distribution 100% Kaya Management Inc. California Production 100% River Distributing Co., LLC California Distribution 100% FloraCal California Cultivation 100% Cub City, LLC California Cultivation 100% CRHC Holdings Corp. Ontario, Canada Holding Company 100% Laurel Harvest Labs, LLC Pennsylvania Cultivation and Dispensary Facility 100% JDRC Mount Joy, LLC Illinois Holding Company 100% JDRC Scranton, LLC Illinois Holding Company 100% Bluma Wellness Inc. British Columbia, Canada Holding Company 100% CannCure Investments Inc. Ontario, Canada Holding Company 100% Cannabis Cures Investments, LLC Florida Holding Company 100% 3 Boys Farm, LLC (One Plant Florida) Florida Cultivation, Production and Dispensary Facility 100% Farm to Fresh Holdings, LLC Florida Holding Company 100% Cresco U.S. Corp. Illinois Manager of Cresco Labs, LLC 100% Entity Location Purpose Percentage MedMar Inc. Illinois Holding Company 100% MedMar Lakeview, LLC Illinois Dispensary 88% MedMar Rockford, LLC Illinois Dispensary 75% Gloucester Street Capital, LLC New York Holding Company 100% Valley Agriceuticals, LLC New York Operating Entity 100% JDRC Ellenville, LLC Illinois Holding Company 100% CMA Holdings, LLC Illinois Holding Company 100% BL Real Estate, LLC Massachusetts Holding Company 100% Cultivate Licensing LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Worcester, Inc Massachusetts Dispensary 100% Cultivate Leicester, Inc. Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Framingham, Inc. Massachusetts Dispensary 100% Cultivate Burncoat, Inc. Massachusetts Holding Company 100% Cultivate Cultivation, LLC Massachusetts Cultivation and Production Entity 100% Good News Holdings, LLC Illinois Holding Company 100% Wonder Holdings, LLC Illinois Holding Company 100% JDRC Seed, LLC Illinois Holding Company 100% CP Pennsylvania Holdings, LLC Illinois Holding Company 100% Bay, LLC Pennsylvania Dispensary 100% Bay Asset Management, LLC Pennsylvania Holding Company 100% Ridgeback, LLC Colorado Holding Company 100% Cresco Labs, LLC Illinois Operating Entity 58% Cresco Labs Notes Issuer, LLC Illinois Holding Company Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 99% Wellbeings, LLC Delaware CBD Wellness Product Development 100% Cresco Labs SLO, LLC California Holding Company 100% SLO Cultivation Inc. California Cultivation and Production Facility 80% Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100% Cresco Labs PA, LLC Illinois Holding Company 100% Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100% JDC Newark, LLC Ohio Holding Company 100% Verdant Creations Newark, LLC Ohio Dispensary 100% JDC Marion, LLC Ohio Holding Company 100% Verdant Creations Marion, LLC Ohio Dispensary 100% JDC Chillicothe, LLC Ohio Holding Company 100% Verdant Creations Chillicothe, LLC Ohio Dispensary 100% JDC Columbus, LLC Ohio Holding Company 100% Care Med Associates, LLC Ohio Dispensary 100% Cresco Labs Arizona, LLC Arizona Holding Company 100% Arizona Facilities Supply, LLC Arizona Cultivation, Production and Dispensary Facility 100% AFS Maryland, LLC Maryland Production Facility 100% Cresco Labs Tinad, LLC Illinois Holding Company 100% PDI Medical III, LLC Illinois Dispensary 100% Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100% Phoenix Farms of Illinois, LLC Illinois Dispensary 100% JDC Elmwood, LLC Illinois Holding Company 100% FloraMedex, LLC Illinois Dispensary 100% Cresco Edibles, LLC Illinois Holding Company 100% TSC Cresco, LLC Illinois Licensing 75% Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85% (a) Cresco Labs Michigan, LLC is 85% owned by related parties within management of the Company. Cresco U.S. Corp., which is wholly owned by the Company, is the sole manager of Cresco Labs, LLC; Cresco Labs, LLC is the sole owner and manager of Cresco Labs Notes Issuer, LLC. Therefore, the Company controls Cresco Labs Notes Issuer, LLC and has consolidated its results into the consolidated financial statements. Non-controlling interests (“NCI”) represent ownership interests in consolidated subsidiaries by parties that are not shareholders of the Company. They are shown as a component of total equity in the Consolidated Balance Sheets, and the share of income attributable to NCI is shown as Net income attributable to non-controlling interests, net of tax in the Consolidated Statements of Operations and in the Consolidated Statements of Comprehensive Loss. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.
Cash and Cash Equivalents	Cash and Cash EquivalentsCash and cash equivalents include cash deposits in financial institutions, other deposits that are readily convertible into cash and cash on hand at retail locations. The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents and mainly consist of certificates of deposits.
Restricted Cash	Restricted CashRestricted cash represents amounts held in escrow related to investments, acquisitions and building improvements.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded net of allowance for doubtful accounts. The Company estimates the allowance for doubtful accounts based on contractual payment terms, actual payment history of its customers, current economic conditions and individual customer circumstances. Accounts receivable are evaluated quarterly and an allowance is recorded as needed. When a receivable is uncollectible, it is written off against the provision. Subsequent recoveries of amounts previously written off are credited to the Consolidated Statements of Operations . See Note 16 for further discussion.
Inventory	Inventory Inventory is primarily composed of raw materials (cannabis and non-cannabis), work-in-process and finished goods. Inventory is recorded at the lower of cost or net realizable value, with cost determined using the weighted average cost method. For manufactured inventory, costs incurred during the growing and production of cannabis and cannabis-based products are capitalized, net of yield adjustments, as incurred to the extent that costs are less than net realizable value. These costs include, but are not limited to, materials, labor, overhead costs, cannabis taxes and depreciation expense on equipment involved in manufacturing, packaging, labeling, inspection and testing. Costs related to purchased finished goods are recorded at cost, including freight. The Company reviews inventory for obsolete, redundant and slow-moving goods and any such inventory is written down to net realizable value.
Property and Equipment	Property and EquipmentProperty and equipment is stated at cost, net of accumulated depreciation. Land is recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The Company evaluates the recoverability of property, plant and equipment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. In those cases, the assets are assessed for impairment based on the estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying value of an asset exceeds its estimated future undiscounted cash flows, the Company will determine the fair value of the assets within the asset group and record an impairment loss calculated as the excess in carrying value over fair value. Equipment is derecognized upon disposal or when no future economic benefits are expected from its use. Leasehold improvements are amortized over the lesser of the life of the lease or estimated useful life of the improvement. Any gain or loss arising from derecognition or impairment of the asset (calculated as the difference between the net disposal proceeds and the carrying value of the asset) is included in the accompanying Consolidated Statements of Operations. The Company assesses property and equipment for indicators of impairment throughout the reporting period. See Note 4 for additional details. Category Estimated Leasehold Improvements 1 - 15 years Machinery and Equipment 5 - 15 years Furniture and Fixtures 3 - 8 years Vehicles 5 years Website and Software 3 - 7 years Computer Equipment 3 - 7 years Buildings and Building Improvements 5 - 39 years Repairs and maintenance that do not improve efficiency or extend economic life are charged to expense as incurred.
Intangible Assets	Intangible Assets Intangible assets are recorded at cost, less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date or date of consolidation/control. Amortization of definite-lived intangible assets is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. Costs incurred during the year to renew or extend the term of a recognized intangible asset are included within additions and are amortized on a straight-line basis over the useful lives of the permit or license renewal period. See Note 7 for additional details. Intangible assets are amortized over the following terms: Category Estimated Customer Relationships 7 - 19 years Non-Compete Agreements 4 - 5 years Trade Names 10 years Permit Application Fees 1 - 2 years Non-Solicitation Agreements 1 - 2 years The estimated useful lives and residual values are reviewed at each year end and any changes in estimates are accounted for prospectively. Intangible assets that have an indefinite useful life are not subject to amortization. The Company’s indefinite-lived intangible assets consist of licenses which represent the future benefits associated with the Company’s cultivation, processing and dispensary licenses. Absent such license intangibles, the Company cannot continue as a going concern and as such, there is no foreseeable limit to the period over which these assets are expected to generate future cash inflows to the Company. Definite-lived intangible assets are tested for impairment when there is an indication of impairment. Indefinite-lived intangible assets are tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment.
Equity Method Investments	Equity Method Investments The Company determines how to account for investments based on the level of control or significant influence it has over the investee. If the Company determines it has control, then the investee is consolidated. Investees in which the Company has significant influence, but no control, are considered equity method investments. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but without control or joint control over those policies. Investments in equity method investments are accounted for using the equity method of accounting. Interests in equity method investments accounted for using the equity method are initially recognized at cost. The carrying value is then adjusted for the Company’s share of comprehensive loss, additional contributions to the investee and additional distributions from the investee. The carrying value of equity method investments is assessed for impairment at each balance sheet date. The Company’s investments in equity-accounted investees are classified within Investments in the Consolidated Balance Sheets. Investments in which the Company does not have significant influence or control are first recognized at cost. At each reporting period, the investment balances are adjusted to fair value, with changes in value recognized through profit and loss. See Note 6 for additional information.
Goodwill	Goodwill Goodwill represents the excess of the purchase price paid for the acquisition of a business over the fair value of the net assets acquired. Goodwill is allocated to the reporting unit or reporting units, which are expected to benefit from the synergies of the combination. Goodwill is not subject to amortization and is tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment may have occurred. For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to reporting units or groups of reporting units representing the lowest level at which the assets generate cash inflow and outflow independent of other assets. An impaired asset is written down to its estimated fair value based on the most recent information available. The Company assesses the fair values of its reporting units using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows. The income approach requires management to estimate a number of factors for each reporting unit, including projected future operating results, economic projections, anticipated future cash flows, discount rates, and the allocation of shared or corporate costs. The impairment review, which is performed October 1 of each year, begins with a qualitative assessment of all reporting units. If the Company determines, based on weighting of all available evidence, that a reporting unit’s carrying value may exceed its fair value at the testing date, the Company performs a quantitative impairment assessment. If the carrying value of these intangible assets or the reporting unit exceeds the fair values, the Company would record an impairment charge based on the excess of the carrying value over the fair value. See Note 7 for additional details. As of December 31, 2022,
Income Taxes	Income TaxesTax expense recognized in profit or loss is comprised of the sum of current and deferred taxes not recognized in other comprehensive loss or directly in equity. (i) Current Tax Current tax assets and/or liabilities are comprised of claims from, or obligations to, fiscal authorities relating to the current or prior reporting periods that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. (ii) Deferred Tax Deferred taxes are calculated using the asset and liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realization, provided they are enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are always provided for in full. The measurement of deferred tax assets is reduced through a valuation allowance, if necessary, by the amount of any tax benefits that, based on available evidence, are more likely than not expected to be unrealized. Deferred tax assets and liabilities are offset only when the Company has a right and intention to offset current tax assets and liabilities from the same taxation authority. Changes in deferred tax assets or liabilities are recognized as a component of tax income or expense in profit or loss, except where they relate to items that are recognized in other comprehensive loss or directly in equity, in which case the related deferred tax is also recognized in other comprehensive loss or equity, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company accounts for assets and liabilities measured at fair value on a recurring basis in accordance with Accounting Standards Codification (“ASC”) 820 Fair Value Measurements . Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the inputs to the fair value measurements. The three levels of the hierarchy are: – Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; – Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; – Level 3 – Inputs for the asset or liability that are not based on observable market data. See Note 16 for additional details.
Loans Receivable	Loans Receivable The Company may provide financing to various related and non-related businesses within the cannabis industry. These loans are classified as held for investment and accounted for as financial instruments in accordance with ASC 310 Receivables . In certain instances, the Company has elected the fair value option in accordance with ASC 825 Financial Instruments ; in these instances, such instruments are labeled as measured at fair value. At each reporting date, the Company applies its judgment to evaluate the
Leases	Leases The Company has entered into leases primarily for its corporate office, cultivation facilities, processing facilities and dispensaries. At inception of a contract, the Company determines whether the contract includes a lease. A contract contains a lease if it includes enforceable rights and obligations under which the right to control the use of an identified asset is conveyed for a period of time in exchange for consideration. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the commencement date – the date when the asset is available for use by the lessee. The Company assesses at lease commencement whether it is reasonably certain to exercise extension or termination options. The Company reassesses its lease portfolio to determine whether it is reasonably certain to exercise the options if there is a significant event or significant change in circumstances within its control. The extension options which are considered reasonably certain to be exercised are mainly those for which operational decisions have been made that make the lease assets vital to the continued relevant business activities. Liabilities arising from a lease are initially measured at the present value of the lease payments not yet paid, using the Company’s incremental borrowing rate. Lease liabilities include the value of the following payments: (i) Fixed payments, including in-substance fixed payments, less any lease incentives receivable; (ii) The exercise price of a purchase option if the Company is reasonably certain to exercise that option; and (iii) Penalties for early termination of the lease, if the lease term reflects the Company exercising an option to terminate the lease. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is decreased by cash paid net of interest expense incurred. The lease liability is remeasured when there is a change in future lease payments, or if the Company changes its assessment of whether it will exercise an extension, purchase or termination option. ROU assets are measured at cost and are comprised of the following: (i) The amount of the initial measurement of lease liability; (ii) Lease payments made at or before the commencement date less any lease incentives received; (iii) Any initial direct costs; and (iv) An estimate of costs of dismantling and removing the underlying asset, restoring the site on which it is located or the underlying asset, if applicable. The ROU asset is depreciated on a straight-line basis from the commencement date to the end of the lease term. A fixed amount of rent expense is recognized on a straight-line basis over the lease term for operating leases. For finance leases, depreciation expense on the ROU asset and interest expense on the lease liability are recognized over the lease term. The value of the ROU asset is periodically reduced by impairment losses, if any and adjusted for certain revaluations of the lease liability. In accordance with the guidance in ASC 842 Leases , the Company has elected not to recognize ROU assets and lease liabilities where the total lease term is less than or equal to twelve months. The payments for such leases are recognized as rent expense within Selling, general and administrative expenses or Cost of goods sold in the Consolidated Statements of Operations on a straight-line basis over the lease term. See Note 5 for additional information on leases.
Revenue Recognition	Revenue Recognition Revenue is recognized by the Company in accordance with ASC 606 Revenue from Contracts with Customers . Through application of ASC 606, the Company recognizes revenue to depict the transfer of promised goods to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. In order to recognize revenue under ASC 606, the Company applies the following five (5) steps: • Identify a customer along with a corresponding contract; • Identify the performance obligation(s) in the contract to transfer goods to a customer; • Determine the transaction price the Company expects to be entitled to in exchange for transferring promised goods to a customer; • Allocate the transaction price to the performance obligation(s) in the contract; and • Recognize revenue when or as the Company satisfies the performance obligation(s). Revenue consists of wholesale and retail sales of cannabis and other cannabis-derived and related products. Wholesale and retail sales are both generally recognized at a point in time when control over the goods has been transferred to the customer and is recorded net of sales discounts. For retail sales, payment is typically due upon transferring the goods to the customer. For wholesale sales, payment is typically due upon transferring the goods to the customer or within a specified time period permitted under agreed-upon payment terms. Revenue is recognized upon the satisfaction of the performance obligation. The Company satisfies its performance obligation and transfers control upon delivery and acceptance by the customer. For some of its locations, the Company has customer loyalty programs where retail customers accumulate points based on their level of spending and use these points for discounts on cannabis and cannabis related products. These points are recorded as a contract liability until customers redeem their points for discounts. In addition, the Company records a performance obligation as a reduction of revenue based on the estimated probability of point redemption, which is calculated based on a standalone selling price and using historical redemption rates. Upon redemption, the loyalty program obligation is relieved and the offset is recorded as revenue. In the event of a product recall, the expected value method is utilized to estimate the financial impact and a reduction of revenue is recorded. See Note 12 for additional information on revenue and loyalty programs.
Advertising Costs	Advertising CostsAdvertising costs are expensed as incurred and are included in Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations and totaled $8.1 million and $12.3 million for the years ended December 31, 2022 and 2021, respectively.
Excise Tax	Excise TaxThe Company recognizes excise tax and community benefit fees as Cost of goods sold or Selling, general and administrative expense based on whether the tax is generated on production of cannabis or as part of selling costs, respectively.
Share-Based Compensation	Share-Based CompensationThe Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. For awards with performance conditions, compensation expense is recognized over the service period of awards and adjusted for the probability of achievement of performance-based goals. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share-based payments granted to non-employees, the compensation expense is measured at the fair value of the equity instrument on the grant date. For awards where the holder has the election of settling their award in either cash or equity, the fair value of share-based compensation is recorded as a liability and remeasured at the end of each reporting period until the corresponding awards are settled. See Note 9 for additional information on share-based compensation.
Earnings (Loss) Per Share	Earnings (Loss) Per Share Earnings (loss) per share (“EPS”) is calculated by dividing the net earnings or loss attributable to shareholders by the weighted average shares outstanding during the period. The Company presents basic and diluted EPS in the Consolidated Statements of Operations. Basic EPS is calculated by dividing the profit or loss attributable to shareholders by the weighted average number of shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares outstanding for the effects of all dilutive potential shares, which are comprised of redeemable Cresco Labs, LLC shares (“Redeemable Units”); options, warrants and restricted stock units (“RSUs”) issued. Shares with anti-dilutive impacts are excluded from the calculation. The number of shares included with respect to Redeemable Units, options, warrants and RSUs is computed using the treasury stock method. As of December 31, 2022, all warrants that had not previously been exercised have expired. Potentially dilutive shares as of December 31, 2022 and 2021, which were excluded from the calculation of diluted EPS for the periods presented consisted of the following: (in thousands) 2022 2021 Redeemable Units 107,443 115,136 Options 25,528 23,609 Warrants — 9,842 RSUs 4,182 999 Total potentially dilutive shares 137,153 149,586
Variable Interest Entities	Variable Interest Entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under ASC 810 Consolidations , where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the financial results of the entity. See Note 17 for additional information on VIEs.
Business Combinations and Assets Held for Sale	Business Combinations and Assets Held for Sale A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for by applying the acquisition method. The total consideration transferred in a business combination is the sum of the fair values of assets transferred, liabilities assumed, equity interests and other consideration issued by the acquirer in exchange for control of the acquiree. The acquisition date is the date on which the Company obtains control of the acquiree. The identifiable assets acquired, and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where ASC 805 Business Combinations provides exceptions to recording the amounts at fair value. Preliminary balances recorded are subject to change during the measurement period which will conclude at the earlier of the date the Company receives the information it was seeking about facts and circumstances that existed as of the acquisition date, learns that more information is not obtainable, or one year following the acquisition date. Acquisition costs of the acquirer are expensed to profit or loss; acquisition costs of the acquiree paid by the acquirer may comprise a portion of consideration transferred. Non-controlling interest in the acquiree, if any, is recognized at fair value. The Company classifies an asset or disposal group as held for sale in accordance with ASC 360 Property, Plant and Equipment, when the following criteria are met: • management, having the authority to approve the action, commits to a plan to sell the asset (disposal group); • the asset (disposal group) is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets (disposal groups); • an active program to locate a buyer and other actions required to complete the plan to sell the asset (disposal group) have been initiated; • the sale of the asset (disposal group) is probable, and transfer of the asset (disposal group) is expected to qualify for recognition as a completed sale, within one year; • the asset (disposal group) is being actively marketed for sale at a price that is reasonable in relation to its current fair value; • actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.
Critical Accounting Estimates, Judgments, and Assumptions	Critical Accounting Estimates, Judgments and Assumptions The preparation of the Company’s consolidated financial statements under GAAP requires management to make estimates, judgments and assumptions about the carrying amounts of certain assets and liabilities. Estimates and related assumptions are based on historical experience and other relevant factors. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis for reasonableness and relevancy. Where revisions are required, they are recognized in the period in which the estimate is revised for the current as well as future periods that are affected. Estimates, judgments and assumptions that have the most significant effect on the amounts recognized in the accompanying consolidated financial statements are described below. (i) Expected Credit Loss ( “ ECL ”) on Loans receivable The Company calculates ECLs in accordance with ASC 326 Financial Instruments - Credit Losses using the Current ECL methodology. The Company develops a provision matrix and measures the expected credit losses based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors. In developing a provision matrix, the Company (1) determines the appropriate groupings of receivables into categories of shared credit risk characteristics, (2) determines historical loss rates, (3) considers forward-looking macro-economic factors and adjusts historical loss rates to reflect relevant future economic conditions, (4) calculates expected credit losses and (5) concludes on the accounting implications. The inputs and models used for calculating expected credit losses may not always capture all characteristics of the market at the date of the financial statements. To reflect this, temporary, qualitative adjustments may be made using expert credit judgment. The allowance the Company records, if any, is the sum of these probability-weighted outcomes. (ii) Inventory In calculating final inventory values, management compares the inventory cost to estimated net realizable value. The net realizable value of inventories represents the estimated selling price of inventory in the ordinary course of business, less all estimated costs of completion and costs necessary to complete the sale. The determination of net realizable value requires significant judgment including consideration of factors such as shrinkage, the aging of and future demand for inventory and the future selling price the Company expects to realize by selling the inventory. Reserves for excess and obsolete inventory are based upon quantities on hand, projected volumes from demand forecasts and net realizable value. The estimates are judgmental in nature and are made at a point in time, using available information, expected business plans and expected market conditions. As a result, the actual amount received on sale could differ from estimates. Periodic reviews are performed on the inventory balance and the impact of changes in inventory reserves is recorded in Cost of goods sold. See Note 3 for additional information. (iii) Estimated Useful Lives, Depreciation of Property and Equipment and Amortization of Intangible Assets Depreciation of property and equipment and amortization of definite-lived intangible assets are recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. Estimating useful lives of property and equipment and definite-lived intangible assets requires careful judgement. Inappropriate estimations could result in impairment losses recognized in later periods. (iv) Property and Equipment Impairment The Company evaluates the carrying value of long-lived assets throughout the reporting period, whenever there is indication that a long-lived asset is impaired. Such indicators include evidence of physical damage, indicators that the economic performance of the asset is worse than expected, or that the decline in asset value is more than the passage of time or normal use, or significant changes occur with an adverse effect on the Company’s business. If any such indication exists, the Company estimates the recoverable amount of the asset. An asset is impaired when its carrying amount exceeds its recoverable amount. The Company measures impairment based on the amount by which the carrying value exceeds the estimated fair value of the long-lived asset. The fair value is determined primarily by using the projected future cash flows. Losses on long-lived assets to be disposed of are determined in a similar manner, except that the fair values are reduced based on an estimate of the cost to dispose or abandon. Both property and equipment and intangible assets are reviewed for impairment periodically. The impairment review is performed October 1 of each year. (v) Goodwill and Indefinite-Lived Intangible Asset Impairment Goodwill and indefinite-lived intangible assets are tested for impairment annually during the fourth quarter and whenever events or changes in circumstances indicate that the carrying amount of these assets has been impaired. In order to determine if the value of these assets might be impaired, the reporting unit to which the assets have been allocated must be valued using present value techniques. When applying this valuation technique, the Company relies on a number of factors, including historical results, business plans, forecasts, market data and discount rates. An estimated fair value is determined using the present value of estimated future cash flows under this methodology, and any excess of recorded goodwill over estimated fair value is written off through impairment expense. Changes in the conditions for these judgments and estimates can significantly affect the assessed value of goodwill and indefinite-lived intangibles. Management has determined the Company’s reporting units that hold such goodwill and indefinite-lived intangible assets to be Arizona, California, Florida, Illinois, Maryland, Massachusetts, New York, Ohio and Pennsylvania . See Note 7 for additional details. (vi) Business Combinations and Asset Acquisitions Determination of an acquisition as a business combination or an asset acquisition depends on whether the assets acquired constitute a business. The classification can have a significant impact on the accounting on and subsequent to the acquisition date. a. Business Combinations In determining the fair value of all identifiable assets, liabilities, contingent liabilities and non-controlling interests acquired, the most significant estimates relate to contingent consideration and intangible assets. Management exercises judgment in estimating the probability and timing of when contingent payments are expected to be made and at what amounts, which is used as the basis for estimating fair value. For any intangible asset identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. The valuations are linked closely to the assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. b. Asset Acquisitions Acquisitions that do not meet the definition of a business combination are accounted for as an asset acquisition. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values. Goodwill is not recorded as a result of an asset acquisition. (vii) Share-Based Compensation In determining the fair value of share-based awards for the purpose of calculating compensation expense, key estimates such as the rate of forfeiture of awards granted, the expected life of options, the volatility of the Company’s stock price and the risk-free interest rate are used. For awards with performance conditions, additional estimates for the probability of achievement of performance-based goals are also necessary. (viii) Income Tax Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities, and it is possible that there could be non-income-based tax or other liabilities (including distribution liabilities to non-controlling interest holders which are based on income taxes) that result from these audits. Where the final outcome of these tax‑related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. Any impact to non-income-based taxes and other liabilities are evaluated in accordance with ASC 450 Contingencies . See section (xi) Contingencies for additional information. Uncertain tax positions are recognized and measured using a two-step process: (1) determine whether a benefit may be recognized and (2) measure the amount of the benefit. Tax benefits from uncertain tax positions may be recognized only if it is more likely than not that the tax position is sustainable based on its technical merits. Uncertain tax positions are evaluated at the individual tax position level. The tax benefit is measured by using a cumulative probability model: the largest amount of tax benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions are recognized within Income tax payable in the Consolidated Balance Sheets. (ix) Measurement of ROU Assets and Sale and Leaseback Accounting Assets and liabilities arising from a lease are initially measured at the present value of the lease payments not yet paid, discounted using the Company’s incremental borrowing rate. The Company applies ASC 842 when accounting for lease transactions. Significant estimates and judgments are involved in determining the implicit interest rate. A sale and leaseback transaction involves the transfer of an asset to another entity and the leaseback of the same asset. The Company applies ASC 606 and ASC 842 when accounting for sale and leaseback transactions. Significant estimates and judgments applied include determination of the fair value of the underlying asset, transfer of control and determination of the implicit interest rate. The Company recognizes gains or losses related to the transfer of rights of the asset to the buyer-lessor and measures the ROU asset arising from the leaseback at the retained portion of the previous carrying amount. In cases where the transaction does not qualify for sale and leaseback accounting treatment, the asset is not derecognized and no gain or loss is recorded. The transaction is treated as a financing transaction. See Note 5 for additional information. (x) Fair Value Measurements Fair value is defined as a price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on a specified date. The Company estimates fair value of financial instruments in accordance ASC 820, using quoted market prices whenever available and utilizing standard pricing models in situations where quoted market prices are not available. See Note 16 for additional information on the inputs utilized in the determination of fair values, including fair value hierarchy considerations. (xi) Contingencies The Company is subject to lawsuits, investigations and other claims related to employment, commercial, regulatory and other matters that arise out of operations in the normal course of business. At each reporting period, the Company reviews the status of each significant matter and assesses the potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable, and the amount can be reliably estimated, such amount is recognized in other accrued expenses. Contingent liabilities are measured at management’s best estimate of the expenditure required to settle the obligation at the end of the reporting period and are discounted to present value where the effect is material.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2020-06 simplifies and adds disclosure requirements for the accounting and measurement of convertible instruments and the settlement assessment for contracts in an entity’s own equity. The amendments in this update are effective for public business entities that meet the definition of a Securities and Exchange Commission (“SEC”) filer for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. In May 2021, FASB issued ASU No. 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The adoption of this guidance has not had a material impact on the Company’s consolidated financial statements. In October 2021, FASB issued ASU No. 2021-08 Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . ASU 2021-08 primarily addresses the accounting for contract assets and contract liabilities from revenue contracts with customers in a business combination. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The Company has elected to early adopt this guidance; the adoption did not have a material impact on the Company’s consolidated financial statements.
Recently Issued Accounting Standards	Recently Issued Accounting StandardsThe Company reviews recently issued accounting standards on a quarterly and annual basis and has determined there are no standards yet to be adopted which are relevant to the business for disclosure.
Reclassifications	ReclassificationsCertain amounts in the prior period have been reclassified to conform with the report classifications of the current period, including the reclassification of Prepaid expenses, previously included in Other current assets on the Consolidated Balance Sheets. The reclassification had no effect on previously reported total current assets or cash flow from operating activities.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies [Abstract]
Summary of Significant Investments in Subsidiaries	The following are Cresco Labs’ wholly-owned or controlled entities as of December 31, 2022: Entity Location Purpose Percentage Cresco Labs Inc. British Columbia, Canada Parent Company Cali-AntiFragile Corp. California Holding Company 100% Alta Supply Inc. California Distribution 100% Kaya Management Inc. California Production 100% River Distributing Co., LLC California Distribution 100% FloraCal California Cultivation 100% Cub City, LLC California Cultivation 100% CRHC Holdings Corp. Ontario, Canada Holding Company 100% Laurel Harvest Labs, LLC Pennsylvania Cultivation and Dispensary Facility 100% JDRC Mount Joy, LLC Illinois Holding Company 100% JDRC Scranton, LLC Illinois Holding Company 100% Bluma Wellness Inc. British Columbia, Canada Holding Company 100% CannCure Investments Inc. Ontario, Canada Holding Company 100% Cannabis Cures Investments, LLC Florida Holding Company 100% 3 Boys Farm, LLC (One Plant Florida) Florida Cultivation, Production and Dispensary Facility 100% Farm to Fresh Holdings, LLC Florida Holding Company 100% Cresco U.S. Corp. Illinois Manager of Cresco Labs, LLC 100% Entity Location Purpose Percentage MedMar Inc. Illinois Holding Company 100% MedMar Lakeview, LLC Illinois Dispensary 88% MedMar Rockford, LLC Illinois Dispensary 75% Gloucester Street Capital, LLC New York Holding Company 100% Valley Agriceuticals, LLC New York Operating Entity 100% JDRC Ellenville, LLC Illinois Holding Company 100% CMA Holdings, LLC Illinois Holding Company 100% BL Real Estate, LLC Massachusetts Holding Company 100% Cultivate Licensing LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Worcester, Inc Massachusetts Dispensary 100% Cultivate Leicester, Inc. Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Framingham, Inc. Massachusetts Dispensary 100% Cultivate Burncoat, Inc. Massachusetts Holding Company 100% Cultivate Cultivation, LLC Massachusetts Cultivation and Production Entity 100% Good News Holdings, LLC Illinois Holding Company 100% Wonder Holdings, LLC Illinois Holding Company 100% JDRC Seed, LLC Illinois Holding Company 100% CP Pennsylvania Holdings, LLC Illinois Holding Company 100% Bay, LLC Pennsylvania Dispensary 100% Bay Asset Management, LLC Pennsylvania Holding Company 100% Ridgeback, LLC Colorado Holding Company 100% Cresco Labs, LLC Illinois Operating Entity 58% Cresco Labs Notes Issuer, LLC Illinois Holding Company Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 99% Wellbeings, LLC Delaware CBD Wellness Product Development 100% Cresco Labs SLO, LLC California Holding Company 100% SLO Cultivation Inc. California Cultivation and Production Facility 80% Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100% Cresco Labs PA, LLC Illinois Holding Company 100% Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100% JDC Newark, LLC Ohio Holding Company 100% Verdant Creations Newark, LLC Ohio Dispensary 100% JDC Marion, LLC Ohio Holding Company 100% Verdant Creations Marion, LLC Ohio Dispensary 100% JDC Chillicothe, LLC Ohio Holding Company 100% Verdant Creations Chillicothe, LLC Ohio Dispensary 100% JDC Columbus, LLC Ohio Holding Company 100% Care Med Associates, LLC Ohio Dispensary 100% Cresco Labs Arizona, LLC Arizona Holding Company 100% Arizona Facilities Supply, LLC Arizona Cultivation, Production and Dispensary Facility 100% AFS Maryland, LLC Maryland Production Facility 100% Cresco Labs Tinad, LLC Illinois Holding Company 100% PDI Medical III, LLC Illinois Dispensary 100% Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100% Phoenix Farms of Illinois, LLC Illinois Dispensary 100% JDC Elmwood, LLC Illinois Holding Company 100% FloraMedex, LLC Illinois Dispensary 100% Cresco Edibles, LLC Illinois Holding Company 100% TSC Cresco, LLC Illinois Licensing 75% Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85% (a) Cresco Labs Michigan, LLC is 85% owned by related parties within management of the Company.
Summary of Property and Equipment	Category Estimated Leasehold Improvements 1 - 15 years Machinery and Equipment 5 - 15 years Furniture and Fixtures 3 - 8 years Vehicles 5 years Website and Software 3 - 7 years Computer Equipment 3 - 7 years Buildings and Building Improvements 5 - 39 years As of December 31, 2022 and 2021, Property and equipment consisted of the following: ($ in thousands) Land and Buildings Machinery and Equipment Furniture and Fixtures Leasehold Improvements Website, Computer Equipment and Software Vehicles Construction In Progress Total Cost Balance as of January 1, 2021 $ 96,526 $ 23,206 $ 17,636 $ 88,369 $ 5,772 $ 1,946 $ 19,197 $ 252,652 Additions 7,873 5,772 4,484 12,339 1,650 921 63,413 96,452 Transfers 4,021 4,923 3,560 39,494 580 65 (52,646) (3) Disposals — (130) (407) (811) (23) (30) — (1,401) Additions from acquisition 39,106 5,279 834 12,448 111 377 12,839 70,994 Effect of foreign exchange and other adjustments (642) (82) 120 939 58 (21) 44 416 As of December 31, 2021 $ 146,884 $ 38,968 $ 26,227 $ 152,778 $ 8,148 $ 3,258 $ 42,847 $ 419,110 Additions 29,826 2,112 1,416 5,691 296 134 45,056 84,531 Transfers 360 3,489 2,645 19,310 1,863 146 (27,813) — Disposals — (1,096) (312) (3,658) (70) (19) (4,583) (9,738) Sale related to sale and leaseback transaction (2,305) (3,333) (2,188) (29,857) — — — (37,683) Measurement period adjustments 1,829 (210) 929 (1,348) — — — 1,200 Effect of foreign exchange and other adjustments — (2) 7 (36) (5) 33 — (3) As of December 31, 2022 $ 176,594 $ 39,928 $ 28,724 $ 142,880 $ 10,232 $ 3,552 $ 55,507 $ 457,417 Accumulated depreciation Balance as of January 1, 2021 $ (2,033) $ (3,235) $ (3,199) $ (12,882) $ (2,006) $ (493) $ — $ (23,848) Depreciation (5,465) (3,603) (4,387) (10,358) (1,882) (588) — (26,283) Disposals — 74 140 297 13 19 — 543 Adjustments — (57) (133) (206) (52) 18 — (430) As of December 31, 2021 $ (7,498) $ (6,821) $ (7,579) $ (23,149) $ (3,927) $ (1,044) $ — $ (50,018) Depreciation (6,469) (6,288) (6,345) (18,293) (2,460) (667) — (40,522) Disposals — 69 24 5,098 — 1 — 5,192 Sale related to sale and leaseback transaction 36 736 950 6,262 — — — 7,984 Adjustments — (275) (2) 1 5 (60) — (331) As of December 31, 2022 $ (13,931) $ (12,579) $ (12,952) $ (30,081) $ (6,382) $ (1,770) $ — $ (77,695) Net book value As of December 31, 2021 $ 139,386 $ 32,147 $ 18,648 $ 129,629 $ 4,221 $ 2,214 $ 42,847 $ 369,092 As of December 31, 2022 $ 162,663 $ 27,349 $ 15,772 $ 112,799 $ 3,850 $ 1,782 $ 55,507 $ 379,722
Summary of Intangible Assets	Intangible assets are amortized over the following terms: Category Estimated Customer Relationships 7 - 19 years Non-Compete Agreements 4 - 5 years Trade Names 10 years Permit Application Fees 1 - 2 years Non-Solicitation Agreements 1 - 2 years
Schedule Of Potential Dilutive Shares Excluded From Computation Of Diluted Earnings Per Share	Potentially dilutive shares as of December 31, 2022 and 2021, which were excluded from the calculation of diluted EPS for the periods presented consisted of the following: (in thousands) 2022 2021 Redeemable Units 107,443 115,136 Options 25,528 23,609 Warrants — 9,842 RSUs 4,182 999 Total potentially dilutive shares 137,153 149,586

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory [Abstract]
Summary of Inventory	Inventory as of December 31, 2022 and 2021, consisted of the following: ($ in thousands) 2022 2021 Raw materials $ 36,233 $ 38,618 Raw materials - non-cannabis 26,709 22,260 Work-in-process 41,164 26,561 Finished goods 30,502 49,204 Total Inventory $ 134,608 $ 136,643

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, plant and equipment [abstract]
Summary of Property and Equipment	Category Estimated Leasehold Improvements 1 - 15 years Machinery and Equipment 5 - 15 years Furniture and Fixtures 3 - 8 years Vehicles 5 years Website and Software 3 - 7 years Computer Equipment 3 - 7 years Buildings and Building Improvements 5 - 39 years As of December 31, 2022 and 2021, Property and equipment consisted of the following: ($ in thousands) Land and Buildings Machinery and Equipment Furniture and Fixtures Leasehold Improvements Website, Computer Equipment and Software Vehicles Construction In Progress Total Cost Balance as of January 1, 2021 $ 96,526 $ 23,206 $ 17,636 $ 88,369 $ 5,772 $ 1,946 $ 19,197 $ 252,652 Additions 7,873 5,772 4,484 12,339 1,650 921 63,413 96,452 Transfers 4,021 4,923 3,560 39,494 580 65 (52,646) (3) Disposals — (130) (407) (811) (23) (30) — (1,401) Additions from acquisition 39,106 5,279 834 12,448 111 377 12,839 70,994 Effect of foreign exchange and other adjustments (642) (82) 120 939 58 (21) 44 416 As of December 31, 2021 $ 146,884 $ 38,968 $ 26,227 $ 152,778 $ 8,148 $ 3,258 $ 42,847 $ 419,110 Additions 29,826 2,112 1,416 5,691 296 134 45,056 84,531 Transfers 360 3,489 2,645 19,310 1,863 146 (27,813) — Disposals — (1,096) (312) (3,658) (70) (19) (4,583) (9,738) Sale related to sale and leaseback transaction (2,305) (3,333) (2,188) (29,857) — — — (37,683) Measurement period adjustments 1,829 (210) 929 (1,348) — — — 1,200 Effect of foreign exchange and other adjustments — (2) 7 (36) (5) 33 — (3) As of December 31, 2022 $ 176,594 $ 39,928 $ 28,724 $ 142,880 $ 10,232 $ 3,552 $ 55,507 $ 457,417 Accumulated depreciation Balance as of January 1, 2021 $ (2,033) $ (3,235) $ (3,199) $ (12,882) $ (2,006) $ (493) $ — $ (23,848) Depreciation (5,465) (3,603) (4,387) (10,358) (1,882) (588) — (26,283) Disposals — 74 140 297 13 19 — 543 Adjustments — (57) (133) (206) (52) 18 — (430) As of December 31, 2021 $ (7,498) $ (6,821) $ (7,579) $ (23,149) $ (3,927) $ (1,044) $ — $ (50,018) Depreciation (6,469) (6,288) (6,345) (18,293) (2,460) (667) — (40,522) Disposals — 69 24 5,098 — 1 — 5,192 Sale related to sale and leaseback transaction 36 736 950 6,262 — — — 7,984 Adjustments — (275) (2) 1 5 (60) — (331) As of December 31, 2022 $ (13,931) $ (12,579) $ (12,952) $ (30,081) $ (6,382) $ (1,770) $ — $ (77,695) Net book value As of December 31, 2021 $ 139,386 $ 32,147 $ 18,648 $ 129,629 $ 4,221 $ 2,214 $ 42,847 $ 369,092 As of December 31, 2022 $ 162,663 $ 27,349 $ 15,772 $ 112,799 $ 3,850 $ 1,782 $ 55,507 $ 379,722

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Lease liabilities [abstract]
Summary of Maturities of Lease Liabilities	As of December 31, 2022, maturities of lease liabilities were as follows: ($ in thousands) Total Operating Leases Finance 2023 $ 33,027 $ 27,595 $ 5,432 2024 33,465 27,857 5,608 2025 34,289 28,531 5,758 2026 34,715 28,816 5,899 2027 34,949 28,948 6,001 Thereafter 212,253 185,139 27,114 Total lease payments $ 382,698 $ 326,886 $ 55,812 Less: imputed interest (194,752) (169,170) (25,582) Less: tenant improvement allowance (5,642) (4,997) (645) Present value of lease liabilities 182,304 152,719 29,585 Less: current lease liabilities (26,124) (21,850) (4,274) Present value of long-term lease liabilities $ 156,180 $ 130,869 $ 25,311
Summary of Maturities of Financial Liabilities	As of December 31, 2022, maturities of financing liabilities were as follows: ($ in thousands) Financing Liabilities 2023 $ 13,204 2024 $ 13,535 2025 $ 13,875 2026 $ 14,223 2027 $ 14,580 Thereafter $ 111,880 Total financing payments $ 181,297 Less: interest $ (84,207) Less: tenant improvement allowance $ (173) Present value of financing liabilities $ 96,917 Less: short-term financing liabilities $ (9,312) Present value of long-term financing liabilities $ 87,605
Summary of Contractual Receipts for Lease Contract Due	Other information related to leases as of and for the years ended December 31, 2022 and 2021 was as follows: 2022 2021 ($ in thousands) Operating Leases Finance Leases Operating Leases Finance Leases Right-of-use assets $ 106,127 $ 22,137 $ 62,329 $ 25,688 Lease liabilities (current) $ 21,850 $ 4,274 $ 16,348 $ 4,444 Lease liabilities (non-current) $ 130,869 $ 25,311 $ 92,919 $ 26,017 Weighted average remaining lease term 1 11.9 10.4 4.7 11.2 Weighted average discount rate 14.5 % 13.6 % 13.5 % 13.8 % 1 Note that Weighted average remaining lease term does not include extensions which we are not reasonably certain to enter into.
Summary of Lease Cost	Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2022 and 2021 are as follows: ($ in thousands) 2022 2021 Interest paid on finance leases $ 3,877 $ 4,742

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Investment property [abstract]
Summary of Investments at Fair Value	The following is a summary of the investments held at fair value as of December 31, 2022 and 2021: ($ in thousands) 2022 2021 420 Capital $ 68 $ 68 Lighthouse 339 542 Two Roots Brewing Co. 93 — Old Pal 592 592 IMC 136 4,710 Total Investments $ 1,228 $ 5,912

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible assets and goodwill [abstract]
Detailed information of Intangible assets and Goodwill	As of December 31, 2022 and 2021, Intangible assets and Goodwill consisted of the following: ($ in thousands) Customer Relation-ships Trade Names Permit Application Costs Licenses Other Intangibles (a) Goodwill Total Cost Balance at January 1, 2021 $ 70,529 $ 39,700 $ 8,752 $ 89,347 $ 6,390 $ 450,569 $ 665,287 Additions — — 3,169 — 3,002 — 6,171 Additions from acquisitions 24,250 1,400 — 317,200 1,151 212,140 556,141 Impairment (62,900) (39,000) — — (3,783) (215,551) (321,234) Measurement period adjustments — — — (2,240) — (391) (2,631) Disposals — — — — (476) — (476) Balance at December 31, 2021 $ 31,879 $ 2,100 $ 11,921 $ 404,307 $ 6,284 $ 446,767 $ 903,258 Additions — — 3,106 — — — 3,106 Impairment — — — (21,800) — (117,024) (138,824) Measurement period adjustments — — — (1,000) — 812 (188) Balance at December 31, 2022 $ 31,879 $ 2,100 $ 15,027 $ 381,507 $ 6,284 $ 330,555 $ 767,352 Accumulated amortization Balance at January 1, 2021 $ (5,129) $ (3,970) $ (7,118) $ — $ (2,960) $ — $ (19,177) Amortization 932 3,275 (3,330) — (642) — 235 Disposals — — — — 95 — 95 Balance at December 31, 2021 (4,197) (695) (10,448) — (3,507) — $ (18,847) Amortization (3,930) (915) (3,449) — (2,066) — (10,360) Disposals — — — — — — — Balance at December 31, 2022 $ (8,127) $ (1,610) $ (13,897) $ — $ (5,573) $ — $ (29,207) Net book value December 31, 2021 $ 27,682 $ 1,405 $ 1,473 $ 404,307 $ 2,777 $ 446,767 $ 884,411 December 31, 2022 $ 23,752 $ 490 $ 1,130 $ 381,507 $ 711 $ 330,555 $ 738,145 (a) Other Intangibles includes non-compete agreements, non-solicitation agreements and related amortization.
Disclosure of estimated amortization expense of intangible assets other than goodwill explanatory	The following table outlines the estimated annual amortization expense related to intangible assets as of December 31, 2022: ($ in thousands) Estimated Amortization 2023 $ 5,776 2024 4,282 2025 4,093 2026 3,968 2027 3,271 Thereafter 4,693 Total estimated amortization $ 26,083

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2022
Share Capital [Abstract]
Summary of Issued And Outstanding Shares	As of December 31, 2022 and 2021, issued and outstanding shares and units consisted of the following: (in thousands) Redeemable Subordinate Proportionate Voting Shares (PVS)** Super Voting Shares (MVS) Special Subordinate Voting Shares (SSVS)*** Beginning balance, January 1, 2021 126,338 194,231 29,311 500 1 Options and warrants exercised — 3,030 — — — RSU issued — 351 — — — Issuance of shares related to acquisitions — 35,425 — — — Issuance of shares related to distribution agreements — (249) — — — Cresco LLC redemption (16,897) 16,897 — — — PVS converted to SVS — 8,644 (8,644) — — Issuances related to employee taxes on certain share-based payment arrangements — 173 — — — Share issuances — 11,469 — — — Ending balance, December 31, 2021 109,441 269,971 20,667 500 1 Options and warrants exercised — 1,279 — — — RSUs issued — 337 — — — Issuance of shares related to acquisitions — 5,339 — — — Cresco LLC redemption (3,335) 3,335 — — — PVS converted to SVS — 585 (585) — — Issuances related to employee taxes on certain share-based payment arrangements — 148 — — — Ending balance, December 31, 2022 106,106 280,994 20,082 500 1 *SVS includes shares pending issuance or cancellation **PVS presented on an “as-converted” basis to SVS (1-to-200) ***SSVS presented on an “as-converted” basis to SVS (1-to-0.00001)
Summary of Company Issued Shares In Conjunction With Acquisitions	During the years ended December 31, 2022 and 2021, the Company issued shares in conjunction with certain acquisitions* as follows: (in thousands) Acquisition date SVS shares issued Replacement shares issued Equity-based consideration Year Ended December 31, 2022: Cultivate - Contingent Consideration September 02, 2021 5,340 — $ 34,708 Year Ended December 31, 2021: Verdant February 16, 2021 127 — $ 2,004 Bluma April 14, 2021 15,061 814 193,310 Cultivate September 02, 2021 4,818 — 46,643 Cure Penn November 24, 2021 6,167 — 54,240 Laurel Harvest December 09, 2021 8,354 — 65,844 *Verdant Creations, LLC (“Verdant”); Bluma Wellness, Inc. (“Bluma”); Cultivate Licensing, LLC (“Cultivate”); Bay, LLC (“Cure Penn”) and Laurel Harvest, LLC (“Laurel Harvest”)
Summary Of Warrants Outstanding	A summary of the status of the warrants outstanding is as follows: Number of warrants* Weighted average exercise price Balance as of January 1, 2021 6,183 $ 7.80 Bluma replacement warrants 4,665 11.64 Exercised (721) 6.15 Forfeited (285) 11.64 Balance as of December 31, 2021 9,842 $ 9.63 Exercised (12) 4.24 Forfeited (9,830) 9.54 Balance as of December 31, 2022 — $ — *PVS presented on an “as-converted” basis to SVS (1-to-200)
Summary of Noncontrolling Interest And Intercompany Eliminations	As of and for the year ended December 31, 2022, non-controlling interest included the following amounts before intercompany eliminations: ($ in thousands) TSC Cresco, LLC MedMar MedMar Cresco SLO Cultivation Other entities including Cresco Labs LLC 1,3 Eliminations Total Non-current assets $ 4,813 $ 31,151 $ 22,700 $ 16,736 $ 5,376 $ 1,176,870 $ — $ 1,257,646 Current assets 69,844 142,723 232,194 70,693 92,594 88,545 (370,547) 326,046 Non-current liabilities — (10,889) (3,850) (12,515) (2,728) (685,161) — (715,143) Current liabilities (56,341) (127,329) (164,550) (64,479) (126,575) (123,889) 382,297 (280,866) Net assets $ 18,316 $ 35,656 $ 86,494 $ 10,435 $ (31,333) $ 456,365 $ 11,750 $ 587,683 Net assets attributable to NCI $ 4,190 $ 3,979 $ 7,468 $ (32) $ (12,434) $ (42,527) $ — $ (39,356) — Revenue $ 35,302 $ 53,259 $ 88,645 $ 17,834 $ 6,484 $ 670,060 $ (28,903) $ 842,681 Gross profit 23,387 35,485 62,503 1,338 (13,652) 294,993 2,959 407,013 Net income (loss) $ 19,290 $ 13,322 $ 43,500 $ (4,933) $ (16,458) $ (270,564) $ — $ (215,843) Net income (loss) allocated to NCI $ 4,822 $ 1,652 $ 10,875 $ (49) $ (3,292) $ (17,804) $ — $ (3,796) NCI percentage at December 31, 2022 25.0 % 1 12.4 % 2 25.0 % 2 1.0 % 1 20.0 % 1 42.0 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 42.0% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments As of and for the year ended December 31, 2021, Non-controlling interest included the following amounts before intercompany eliminations: ($ in thousands) TSC Cresco, LLC MedMar MedMar Cresco SLO Cultivation Inc. Other entities including Cresco Labs LLC 1,3 Eliminations Total Non-current assets $ 5,208 $ 33,698 $ 22,934 $ 16,093 $ 23,422 $ 1,257,353 $ — $ 1,358,708 Current assets 54,506 95,522 154,929 64,897 97,276 250,029 (295,404) 421,755 Non-current liabilities — (11,213) (3,443) (12,286) (14,071) (653,320) — (694,333) Current liabilities (49,726) (92,049) (124,597) (73,441) (147,993) (107,143) 306,555 (288,394) Net assets $ 9,988 $ 25,958 $ 49,823 $ (4,737) $ (41,366) $ 746,919 $ 11,151 $ 797,736 Net assets attributable to NCI $ 2,850 $ 3,910 $ 6,123 $ 18 $ (9,143) $ 38,424 $ — $ 42,182 Revenue $ 21,549 $ 48,435 $ 84,932 $ 22,661 $ 21,011 $ 663,602 $ (40,508) $ 821,682 Gross profit 13,592 32,020 47,922 10,650 (6,250) 320,419 (12,006) 406,347 Net income (loss) $ 12,387 $ 12,043 $ 30,666 $ (4,627) $ (19,247) $ (328,056) $ — $ (296,834) Net income (loss) allocated to NCI $ 3,097 $ 1,493 $ 7,666 $ (46) $ (3,849) $ 14,402 $ — $ 22,763 NCI percentage at December 31, 2021 25.0 % 1 12.4 % 2 25.0 % 2 1.0 % 1 20.0 % 1 43.3 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 43.3% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangements [Abstract]
Summary of the status of the stock options outstanding	A summary of the status of the options outstanding consisted of the following: (Shares in thousands) Number of stock options outstanding Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value Outstanding – December 31, 2021 23,610 $ 5.54 7.70 $ 53,455 Granted 7,649 3.77 Exercised (1,631) 1.51 Forfeited (4,100) 7.27 Outstanding - December 31, 2022 25,528 $ 5.00 7.54 $ 921 Exercisable - December 31, 2022 14,027 $ 4.32 6.42 $ 921
Summary of weighted average grant date fair value and intrinsic value of options exercised	The following table summarizes the weighted average grant date fair value and total intrinsic value of options exercised for the years ended December 31, 2022 and 2021: (In thousands, except per share data) 2022 2021 Weighted average grant date fair value (per share) of stock option units granted $2.59 $7.39 Intrinsic value of stock option units exercised, using market price at exercise date $5,106 $21,131
Summary of fair value of stock options granted under the plan	The fair value of stock options granted under the Plan during the years ended December 31, 2022 and 2021, was determined using the Black-Scholes option-pricing model with the following range of assumptions at the time of the grant: 2022 2021 Risk-free annual interest rate 1.4% to 3.0% 0.4% to 1.2% Expected annual dividend yield 0% 0% Expected stock price volatility 74.9% to 80.4% 67.0% to 82.2% Expected life of stock options 5.5 to 7.0 years 5.0 to 7.0 years Forfeiture rate 7.2% to 28.0% 7.5% to 24.9% Fair value at grant date $1.23 to $4.90 $4.47 to $8.78 Stock price at grant date $1.81 to $6.91 $6.62 to $13.10 Exercise price range $1.81 to $6.91 $6.62 to $13.10
Summary of outstanding restricted stock units	A summary of outstanding RSUs is provided below: (Shares in thousands) Number of RSUs outstanding Weighted average fair value Weighted average remaining contractual life (years) Aggregate intrinsic value Outstanding – December 31, 2021 1,093 $ 8.83 3.50 $ 9,657 Granted 4,438 5.36 Vested and settled (452) 5.31 Forfeited (821) 6.46 Outstanding - December 31, 2022 4,258 $ 5.71 4.00 $ 24,330
Summary of total fair value of restricted stock units vested	The following table summarizes the total fair value of RSUs vested for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Total fair value of RSUs vested, using market price at vest date $ 2,396 $ 4,783
Summary of shares movement	A summary of the share movement is provided below: (In thousands, except per share data) Shares issued Fair value Compensation expense Bluma replacement shares 814 $ 12.17 $ 239 Subscription award 62 $ 11.25 $ 694
Summary of expense from share-based payment transactions with employees	The following table sets forth the classification of stock-based compensation expense related to options awards for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Cost of goods sold $ 1,984 $ 2,958 Selling, general and administrative expense 11,749 17,743 Total compensation expense for option awards $ 13,733 $ 20,701 The following table sets forth the classification of stock-based compensation expense related to RSU awards for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Cost of goods sold $ 2,097 $ 579 Selling, general and administrative expense 7,914 3,985 Total compensation expense for RSU awards $ 10,011 $ 4,563

Acquisitions and Dispositions (

Acquisitions and Dispositions (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations And Discontinued Operations [Abstract]
Summary of significant business combinations	The table below summarizes significant business combinations completed during the year ended December 31, 2021. There were no completed business combinations during the year ended December 31, 2022. ($ in thousands) Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total Total consideration Common shares issued $ 2,000 $ 183,262 $ 46,643 $ 52,610 $ 65,844 $ 350,359 Cash 1,500 — — 33,304 20,480 55,284 Cashless exercise option on loan 10,000 — — — — 10,000 Settlement of leases 90 — — — — 90 Loan settlement 11,414 21,226 1,852 — 3,339 37,831 Warrants issued — 18,415 — — — 18,415 Replacement RSU awards — 10,048 — — — 10,048 Payment of acquisition-related transaction costs on behalf of the acquiree — 3,373 1,001 3,135 331 7,840 Payment of 3rd-party debt on behalf of the acquiree — — 20,125 — — 20,125 Deferred consideration — 1,806 — — 46,677 48,483 Contingent consideration — — 29,642 — — 29,642 Total consideration $ 25,004 $ 238,130 $ 99,263 $ 89,049 $ 136,671 $ 588,117 Net identifiable assets (liabilities) acquired Cash $ 1,360 $ 1,623 $ 2,938 $ 751 $ 937 $ 7,609 Accounts receivable — — 6,494 33 — 6,527 Inventory 1,519 19,244 24,862 2,963 506 49,094 Loans receivable, short-term — 1,600 — — — 1,600 Other current assets 76 1,205 662 134 36 2,113 Property & equipment 996 26,152 30,128 1,845 11,873 70,994 Right-of-use assets 127 13,709 1,304 1,834 859 17,833 Other non-current assets 47 — — — — 47 Customer relationships 1,370 6,700 13,600 2,320 260 24,250 License 16,320 117,000 12,000 70,950 98,690 314,960 Trade name — — 1,400 — — 1,400 Non-compete agreements — — 800 270 80 1,150 Investments — 693 — — — 693 Total identifiable assets acquired $ 21,815 $ 187,926 $ 94,188 $ 81,100 $ 113,241 $ 498,270 Short-term liabilities (1,601) (3,733) (14,585) (1,186) (151) (21,256) Lease liability (127) (13,685) (1,304) (1,834) (859) (17,809) Contract liability-loyalty program — (456) — (355) — (811) Deferred tax liability (3,968) (36,940) (10,597) — (30,753) (82,258) Total identifiable liabilities acquired (5,696) (54,814) (26,486) (3,375) (31,763) (122,134) Net identifiable assets acquired $ 16,119 $ 133,112 $ 67,702 $ 77,725 $ 81,478 $ 376,136 Purchase price allocation Net identifiable assets acquired 16,119 133,112 67,702 77,725 81,478 376,136 Goodwill 8,885 105,018 31,561 11,324 55,193 211,981 Total consideration $ 25,004 $ 238,130 $ 99,263 $ 89,049 $ 136,671 $ 588,117 (i) Verdant On February 16, 2021, the Company completed the acquisition of 100% of the membership interests of Verdant dispensaries in Cincinnati, Chillicothe, Newark and Marion, Ohio. As a result of this acquisition, the Company holds additional licenses to distribute medical cannabis in the state of Ohio, bringing the Company’s dispensary presence in Ohio to five (5), the maximum allowed by the state, as of the date of acquisition. As of December 31, 2021, the Company had recorded estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets acquired and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2021, the Company recorded measurement period adjustments (“MPAs”) related to changes in the valuation of certain intangible assets, lease settlements and deferred taxes, which resulted in a net reduction in goodwill of $0.2 million. The measurement period expired on February 16, 2022, with no further measurement period adjustments recorded during the year ended December 31, 2022. Consideration for the acquisition included 0.1 million SVS issued as of the acquisition date. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (ii) Bluma On April 14, 2021, the Company completed the acquisition of 100% of the membership interests of Bluma, a vertically integrated operator in Florida. As a result of this acquisition, the Company now holds a license to cultivate, process, transport and dispense medical cannabis in the state of Florida, bringing the Company’s dispensary presence in Florida to eight (8), as of the acquisition date. As of December 31, 2021, the Company had recorded preliminary estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets acquired and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2021, the Company recorded MPAs related to RSU awards, short-term loans receivable, inventory and deferred taxes, which resulted in a net increase in goodwill of $0.5 million. During the year ended December 31, 2022, the Company recorded MPAs related to deferred taxes and income taxes payable, which resulted in a net increase in goodwill of $1.8 million. As the measurement period ended April 14, 2022, no amounts are subject to additional adjustments as of December 31, 2022. Consideration for the acquisition included 15.1 million SVS issued as of the acquisition date. The Company recorded transaction costs of $1.5 million in connection with the Bluma acquisition as Selling, general and administrative expenses in the Consolidated Statements of Operations for the year ended December 31, 2021. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (iii) Cultivate On September 2, 2021, the Company completed the acquisition of 100% of the membership interests of Cultivate. As a result of this acquisition, the Company holds additional licenses to cultivate, process, transport and dispense medical and adult-use cannabis in the state of Massachusetts, bringing the Company’s dispensary presence in Massachusetts to four (4), as of the date of acquisition. As of December 31, 2021, the Company had recorded preliminary estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets acquired and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2021, the Company recorded MPAs related to property and equipment, short-term liabilities and deferred taxes, which resulted in a net reduction in goodwill of $0.7 million. During the year ended December 31, 2022, the Company recorded MPAs related to property and equipment, deferred consideration, licenses and deferred taxes, which resulted in a net increase in goodwill of $0.4 million. As the measurement period ended September 2, 2022, no amounts are subject to additional adjustments as of December 31, 2022. Consideration for the acquisiti on included 4.8 million SVS issued as of the acquisition date. The Company recorded transaction costs of $1.6 million in connection with the Cultivate acquisition as Selling, general and administrative expenses in the Consolidated Statements of Operations for the year ended December 31, 2021. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (iv) Cure Penn On November 24, 2021, the Company announced that it had completed the acquisition of 100% of the membership interests of Cure Penn. As a result of this acquisition, the Company holds additional licenses to dispense medical cannabis in the state of Pennsylvania, bringing the Company’s dispensary presence in Pennsylvania to eight (8) as of the date of acquisition. As of December 31, 2021, the Company had recorded preliminary estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2022, the Company recorded an MPA related to a working capital adjustment, which resulted in a net increase in goodwill of $0.1 million. As the measurement period ended November 25, 2022, no amounts are subject to additional adjustments as of December 31, 2022. Consideration for the acquisition included 6.2 million SVS issued as of the acquisition date. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (v) Laurel Harvest On December 9, 2021, the Company announced that it had completed the acquisition of 100% of the membership interests of Laurel Harvest. As a result of this acquisition, the Company holds additional licenses to cultivate, process, transport and dispense medical cannabis in the state of Pennsylvania, bringing the Company’s dispensary presence in Pennsylvania to nine (9) as of the date of acquisition. As of December 31, 2021, the Company had recorded preliminary estimates of the fair value of assets acquired and liabilities assumed. Any changes to the preliminary estimates of the fair value of the assets and liabilities assumed were recorded as adjustments to those assets and liabilities and residual amounts were allocated to goodwill. During the year ended December 31, 2022, the Company recorded MPAs related to deferred taxes, income taxes payable and a working capital adjustment, which resulted in a net reduction in goodwill of $1.5 million. As the measurement period ended December 10, 2022, no amounts are subject to additional adjustments as of December 31, 2022. Consideration for the acquisition included 8.4 million SVS issued as of the acquisition date. The Company recorded transaction costs of $1.1 million in connection with the Laurel Harvest acquisition as Selling, general and administrative expenses in the Consolidated Statements of Operations for the year ended December 31, 2021. See sections (vi) and (vii) below for Year-of-Acquisition Contributed Revenue and Net Income (Loss) and Unaudited Pro Forma Information, respectively. (vi) Year-of-Acquisition Contributed Revenue and Net Income (Loss) The unaudited table below summarizes contributed Revenue and Net income (loss) for the year ended December 31, 2021: ($ in thousands) Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total Contributed revenue $ 26,547 $ 26,642 $ 29,279 $ 2,966 $ 328 $ 85,762 Net income (loss) 5,352 (8,382) 14,944 (50) (136) $ 11,728 (vii) Unaudited Pro Forma Information - Significant 2021 Acquisitions The following unaudited pro forma financial information reflects the combined results of operations of Cresco Labs Inc. and the pre-acquisition results of entities acquired by Cresco Labs Inc. during the year ended December 31, 2021, as though the acquisitions occurred as of January 1, 2020: For the year ended December 31, 2021 Cresco Labs Inc. Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total ($ in thousands) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) Pro forma revenue $ 821,682 $ 2,677 $ 7,906 $ 39,033 $ 29,281 $ 1,966 $ 902,545 Pro forma net income: Pre-acquisition net income (846) (13,784) 4,550 8,161 (2,121) Pro forma adjustments: (a) Transaction costs 399 1,461 1,555 439 1,081 (b) Post-acquisition share-based compensation — 2,440 — — — (c) Intangible amortization (150) (599) (860) (355) (68) Total pro forma adjustments $ 250 $ 3,302 $ 695 $ 84 $ 1,013 Total pro forma net income $ (296,834) $ (596) $ (10,482) $ 5,245 $ 8,245 $ (1,109) $ (295,531) (a) includes removal of transaction costs as they will be reflected as of the beginning of the earliest period presented (January 1, 2020). These costs were included as Selling, general and administrative expenses in the Consolidated Statements of Operations. (b) includes removal of post-acquisition share-based compensation expense related to warrants issued, replacement shares and replacement RSU awards recorded related to the Bluma acquisition. These costs were included as Selling, general and administrative expenses in the Consolidated Statements of Operations. (c) includes estimated amortization expense on intangible assets acquired. These costs were recorded in Cost of goods sold and Selling, general and administrative expenses in the Consolidated Statements of Operations. For the year ended December 31, 2020 Cresco Labs Inc. Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total ($ in thousands) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) Pro forma revenue $ 476,251 $ 15,195 $ 12,338 $ 22,965 $ 29,119 $ 1 $ 555,869 Pro forma net income: Pre-acquisition net income (1,982) (25,998) 772 8,384 (650) Pro forma adjustments: (a) Transaction costs (399) (1,461) (1,555) (439) (1,081) (b) Post-acquisition share-based compensation — (2,440) — — — (c) Intangible amortization (171) (853) (3,483) (387) (73) Total pro forma adjustments $ (571) $ (4,754) $ (5,037) $ (826) $ (1,153) Total pro forma net income $ (92,771) $ (2,553) $ (30,752) $ (4,266) $ 7,558 $ (1,803) $ (124,587) (a) includes transaction costs related to acquisitions (reflected as of January 1, 2020). (b) includes post-acquisition share-based compensation expense related to warrants issued, replacement shares and replacement RSU awards recorded related to the Bluma acquisition. (c) includes estimated amortization expense on intangible assets acquired.
Summary of contributed revenue and net income (loss)	The unaudited table below summarizes contributed Revenue and Net income (loss) for the year ended December 31, 2021: ($ in thousands) Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total Contributed revenue $ 26,547 $ 26,642 $ 29,279 $ 2,966 $ 328 $ 85,762 Net income (loss) 5,352 (8,382) 14,944 (50) (136) $ 11,728
Summary of pro forma information	The following unaudited pro forma financial information reflects the combined results of operations of Cresco Labs Inc. and the pre-acquisition results of entities acquired by Cresco Labs Inc. during the year ended December 31, 2021, as though the acquisitions occurred as of January 1, 2020: For the year ended December 31, 2021 Cresco Labs Inc. Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total ($ in thousands) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) Pro forma revenue $ 821,682 $ 2,677 $ 7,906 $ 39,033 $ 29,281 $ 1,966 $ 902,545 Pro forma net income: Pre-acquisition net income (846) (13,784) 4,550 8,161 (2,121) Pro forma adjustments: (a) Transaction costs 399 1,461 1,555 439 1,081 (b) Post-acquisition share-based compensation — 2,440 — — — (c) Intangible amortization (150) (599) (860) (355) (68) Total pro forma adjustments $ 250 $ 3,302 $ 695 $ 84 $ 1,013 Total pro forma net income $ (296,834) $ (596) $ (10,482) $ 5,245 $ 8,245 $ (1,109) $ (295,531) (a) includes removal of transaction costs as they will be reflected as of the beginning of the earliest period presented (January 1, 2020). These costs were included as Selling, general and administrative expenses in the Consolidated Statements of Operations. (b) includes removal of post-acquisition share-based compensation expense related to warrants issued, replacement shares and replacement RSU awards recorded related to the Bluma acquisition. These costs were included as Selling, general and administrative expenses in the Consolidated Statements of Operations. (c) includes estimated amortization expense on intangible assets acquired. These costs were recorded in Cost of goods sold and Selling, general and administrative expenses in the Consolidated Statements of Operations. For the year ended December 31, 2020 Cresco Labs Inc. Verdant (i) Bluma (ii) Cultivate (iii) Cure Penn (iv) Laurel Harvest (v) Total ($ in thousands) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) Pro forma revenue $ 476,251 $ 15,195 $ 12,338 $ 22,965 $ 29,119 $ 1 $ 555,869 Pro forma net income: Pre-acquisition net income (1,982) (25,998) 772 8,384 (650) Pro forma adjustments: (a) Transaction costs (399) (1,461) (1,555) (439) (1,081) (b) Post-acquisition share-based compensation — (2,440) — — — (c) Intangible amortization (171) (853) (3,483) (387) (73) Total pro forma adjustments $ (571) $ (4,754) $ (5,037) $ (826) $ (1,153) Total pro forma net income $ (92,771) $ (2,553) $ (30,752) $ (4,266) $ 7,558 $ (1,803) $ (124,587) (a) includes transaction costs related to acquisitions (reflected as of January 1, 2020). (b) includes post-acquisition share-based compensation expense related to warrants issued, replacement shares and replacement RSU awards recorded related to the Bluma acquisition. (c) includes estimated amortization expense on intangible assets acquired.
Summary of deferred consideration and contingent consideration classified as short term	The following is a summary of Deferred and contingent consideration balances as of December 31, 2022 and 2021, which are classified as short-term: ($ in thousands) 2022 2021 Cultivate contingent consideration, short-term $ — $ 33,969 Laurel Harvest deferred consideration, short-term 47,821 37,847 Total Deferred and contingent consideration, short-term $ 47,821 $ 71,816
Summary of long-term deferred consideration	The following is a summary of Deferred consideration as of December 31, 2022 and 2021, which is classified as long-term: ($ in thousands) 2022 2021 Valley Agriceuticals, LLC (“Valley Ag”) operating cash flows deferred consideration $ 7,770 $ 8,577 Laurel Harvest deferred consideration — 9,074 Total Deferred consideration, long-term $ 7,770 $ 17,651

Long-term Notes and Loans Pay_2

Long-term Notes and Loans Payable, Net - (Tables)	12 Months Ended
	Dec. 31, 2022
Borrowings [abstract]
Summary of Loans Payable Balances is Follows	The following table represents the Company’s Long-term notes and loans payable, net balances as of December 31, 2022 and 2021: ($ in thousands) 2022 2021 Senior Loan $ 400,000 $ 400,000 Interest payable 9,500 9,711 Financing liability 96,917 97,797 Total borrowings and interest payable $ 506,417 $ 507,508 Less: Unamortized debt issuance costs (18,550) (22,501) Less: Short-term borrowings and interest payable (9,500) (9,711) Less: Current portion of financing liability (9,312) (10,217) Total Long-term notes and loans payable, net $ 469,055 $ 465,079

Revenues and Loyalty Programs (

Revenues and Loyalty Programs (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue [abstract]
Summary of Disaggregated Revenue by Source	The following table represents the Company’s disaggregated revenue by source, due to the Company’s contracts with its customers, for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Wholesale $ 367,222 $ 414,908 Dispensary 475,459 406,774 Total Revenues $ 842,681 $ 821,682

Other Income , Net (Tables)

Other Income , Net (Tables)	12 Months Ended
	Dec. 31, 2022
Other Operating Income (Expense) [Abstract]
Summary of Other Income (Expense), Net	For the years ended December 31, 2022 and 2021, Other income, net consisted of the following: ($ in thousands) 2022 2021 Unrealized gain on derivative liabilities - warrants $ 1,184 $ 16,669 (Loss) gain on derivative instruments (5,698) 23,909 Gain (loss) on provision - loan receivable 572 (753) Unrealized loss on investments held at fair value (4,609) (7,135) Loss on debt extinguishment — (17,987) Gain (loss) on conversion of investment 22 (880) Gain (loss) on disposition of assets 14,711 (6) Gain (loss) on foreign currency 931 (1,228) Gain (loss) on lease termination 4,876 (43) Other income, net 3,238 485 Total Other income, net $ 15,227 $ 13,031

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Related party transactions [abstract]
Summary of Expense Resulting from the Related Party Transactions	Below is a summary of the expense resulting from the related party lease liabilities for the years ended December 31, 2022 and 2021: Year Ended ($ in thousands) Classification 2022 2021 Operating Leases Lessor has minority interest in SLO Rent expense $ 513 $ 1,563 Lessor has minority interest in MedMar Rent expense 288 238 Lessor is an MVS shareholder Rent expense 1,187 1,168 Finance Leases Lessor has minority interest in MedMar Depreciation expense $ 306 $ 277 Lessor has minority interest in MedMar Interest expense 270 310 Lessor is an MVS shareholder Depreciation expense 81 74 Lessor is an MVS shareholder Interest expense 76 88
Summary of ROU Assets and Lease Liabilities Attributable to Related Party Transactions	Additionally, below is a summary of the ROU assets and lease liabilities attributable to related party leases as of December 31, 2022 and 2021: As of December 31, 2022 As of December 31, 2021 ($ in thousands) ROU Asset Lease Liability ROU Asset Lease Liability Operating Leases Lessor has minority interest in SLO $ — $ — $ 6,996 $ 11,938 Lessor has minority interest in MedMar 1,415 1,456 1,525 1,549 Lessor is an MVS shareholder 5,849 5,907 6,314 4,867 Finance Leases Lessor has minority interest in MedMar $ 2,034 $ 2,452 $ 2,137 $ 2,457 Lessor is an MVS shareholder 596 555 616 1,063

Financial Instruments And Fin_2

Financial Instruments And Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Instruments [Abstract]
Financial assets measured at fair value	The following tables summarize the Company’s financial instruments as of December 31, 2022 and 2021: December 31, 2022 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 119,341 $ — $ — $ — $ 119,341 Restricted cash 1 2,169 — — — 2,169 Security deposits 2 4,367 — — — 4,367 Accounts receivable, net 56,492 — — — 56,492 Loans receivable, short-term 447 — — — 447 Loans receivable, long-term 823 — — — 823 Investments — 136 432 660 1,228 Financial Liabilities: Accounts payable $ 28,093 $ — $ — $ — $ 28,093 Accrued liabilities 65,161 — — — 65,161 Short-term borrowings 18,812 — — — 18,812 Current portion of lease liabilities 26,124 — — — 26,124 Deferred consideration and other payables, short-term 6 7 — 47,821 47,834 Lease liabilities 156,180 — — — 156,180 Deferred consideration, long-term — — — 7,770 7,770 Long-term notes payable and loans payable 469,055 — — — 469,055 Other long-term liabilities 7,000 — — — 7,000 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. December 31, 2021 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 223,543 $ — $ — $ — $ 223,543 Restricted cash 1 2,559 — — — 2,559 Security deposits 2 3,941 — — — 3,941 Accounts receivable, net 43,379 — — — 43,379 Loans receivable, short-term 747 — — 565 1,312 Loans receivable, long-term 505 — — — 505 Investments — 4,710 542 660 5,912 Financial Liabilities: Accounts payable $ 32,278 $ — $ — $ — $ 32,278 Accrued liabilities 95,442 — — — 95,442 Short-term borrowings 19,928 — — — 19,928 Current portion of lease liabilities 20,792 — — — 20,792 Deferred consideration, contingent consideration and other payables, short-term 5 12 — 71,816 71,833 Derivative liabilities, short-term — — — 1,172 1,172 Lease liabilities 118,936 — — — 118,936 Deferred consideration, long-term — — — 17,651 17,651 Long-Term Notes Payable and Loans Payable 465,079 — — — 465,079 Other long-term liabilities 7,001 — — — 7,001 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. The following table presents a rollforward of the balance sheet amounts measured at fair value on a recurring basis and classified as Level 3. The classification of an item as Level 3 is based on inputs for assets or liabilities that are not based on observable market data. December 31, 2022 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Investments Deferred consideration and other payables, short-term Derivative liabilities, short-term Deferred consideration, long-term Balance as of December 31, 2021 $ 565 $ 660 $ 71,816 $ 1,172 $ 17,651 Change in fair value recorded in Interest expense, net — — 900 — (881) Change in fair value recorded in Other income, net — — 5,647 (1,172) — Payments (1,837) — (39,542) — — Change in fair value recorded in Selling, general and administrative 1,272 — — — — Other 1 — — 9,000 — (9,000) Balance as of December 31, 2022 $ — $ 660 $ 47,821 $ — $ 7,770 1 Other relates to reclassifications from long-term to short-term due to the projected dispensary opening dates. December 31, 2021 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Loans receivable, long- term Investments Deferred consideration and other payables, short-term Derivative liabilities, short-term Derivative liabilities, long-term Deferred consideration and contingent, long-term Balance as of December 31, 2020 $1,517 $20,019 $119 $19,093 $— $17,505 $7,247 Additions — — 593 69,099 — — 9,026 Change in fair value recorded in Interest expense, net — — — 196 27 (223) 1,378 Change in fair value recorded in Other income, net — — — (14,743) (11,897) (4,231) — Payments (400) — — (1,829) — — — Settlement — (20,019) (52) — — (9) — Change in fair value recorded in Selling, general and administrative (552) — — — — — — Other 1 — — — — 13,042 (13,042) — Balance as of December 31, 2021 $565 $— $660 $71,816 $1,172 $— $17,651 1 Other relates to reclassifications from long-term to short-term due to the projected dispensary opening dates. The following is a summary of Loans receivable, short-term balances and valuation classifications (discussed further below) as of December 31, 2022 and 2021: ($ in thousands) Valuation December 31, 2022 December 31, 2021 Short-term loans receivable - Lighthouse Fair value $ — $ 565 Short-term loans receivable - Other, net of ECL Amortized cost 447 — Interest receivable Amortized cost — 747 Total Loans receivable, short-term $ 447 $ 1,312 ($ in thousands) Valuation December 31, 2022 December 31, 2021 Long-term loans receivable - Illinois Incubator, net of ECL Amortized cost $ 823 $ 100 Long-term loans receivable - Other, net of ECL Amortized cost — 405 Total Loans receivable, long-term $ 823 $ 505
Financial liabilities measured at fair value	The following tables summarize the Company’s financial instruments as of December 31, 2022 and 2021: December 31, 2022 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 119,341 $ — $ — $ — $ 119,341 Restricted cash 1 2,169 — — — 2,169 Security deposits 2 4,367 — — — 4,367 Accounts receivable, net 56,492 — — — 56,492 Loans receivable, short-term 447 — — — 447 Loans receivable, long-term 823 — — — 823 Investments — 136 432 660 1,228 Financial Liabilities: Accounts payable $ 28,093 $ — $ — $ — $ 28,093 Accrued liabilities 65,161 — — — 65,161 Short-term borrowings 18,812 — — — 18,812 Current portion of lease liabilities 26,124 — — — 26,124 Deferred consideration and other payables, short-term 6 7 — 47,821 47,834 Lease liabilities 156,180 — — — 156,180 Deferred consideration, long-term — — — 7,770 7,770 Long-term notes payable and loans payable 469,055 — — — 469,055 Other long-term liabilities 7,000 — — — 7,000 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. December 31, 2021 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 223,543 $ — $ — $ — $ 223,543 Restricted cash 1 2,559 — — — 2,559 Security deposits 2 3,941 — — — 3,941 Accounts receivable, net 43,379 — — — 43,379 Loans receivable, short-term 747 — — 565 1,312 Loans receivable, long-term 505 — — — 505 Investments — 4,710 542 660 5,912 Financial Liabilities: Accounts payable $ 32,278 $ — $ — $ — $ 32,278 Accrued liabilities 95,442 — — — 95,442 Short-term borrowings 19,928 — — — 19,928 Current portion of lease liabilities 20,792 — — — 20,792 Deferred consideration, contingent consideration and other payables, short-term 5 12 — 71,816 71,833 Derivative liabilities, short-term — — — 1,172 1,172 Lease liabilities 118,936 — — — 118,936 Deferred consideration, long-term — — — 17,651 17,651 Long-Term Notes Payable and Loans Payable 465,079 — — — 465,079 Other long-term liabilities 7,001 — — — 7,001 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. The following table presents a rollforward of the balance sheet amounts measured at fair value on a recurring basis and classified as Level 3. The classification of an item as Level 3 is based on inputs for assets or liabilities that are not based on observable market data. December 31, 2022 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Investments Deferred consideration and other payables, short-term Derivative liabilities, short-term Deferred consideration, long-term Balance as of December 31, 2021 $ 565 $ 660 $ 71,816 $ 1,172 $ 17,651 Change in fair value recorded in Interest expense, net — — 900 — (881) Change in fair value recorded in Other income, net — — 5,647 (1,172) — Payments (1,837) — (39,542) — — Change in fair value recorded in Selling, general and administrative 1,272 — — — — Other 1 — — 9,000 — (9,000) Balance as of December 31, 2022 $ — $ 660 $ 47,821 $ — $ 7,770 1 Other relates to reclassifications from long-term to short-term due to the projected dispensary opening dates. December 31, 2021 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Loans receivable, long- term Investments Deferred consideration and other payables, short-term Derivative liabilities, short-term Derivative liabilities, long-term Deferred consideration and contingent, long-term Balance as of December 31, 2020 $1,517 $20,019 $119 $19,093 $— $17,505 $7,247 Additions — — 593 69,099 — — 9,026 Change in fair value recorded in Interest expense, net — — — 196 27 (223) 1,378 Change in fair value recorded in Other income, net — — — (14,743) (11,897) (4,231) — Payments (400) — — (1,829) — — — Settlement — (20,019) (52) — — (9) — Change in fair value recorded in Selling, general and administrative (552) — — — — — — Other 1 — — — — 13,042 (13,042) — Balance as of December 31, 2021 $565 $— $660 $71,816 $1,172 $— $17,651 1 Other relates to reclassifications from long-term to short-term due to the projected dispensary opening dates.
Disclosure of Liability-Classified Warrants Fair Value Assumptions	As of December 31, 2021, the fair value of liability-classified warrants was determined using the Black-Scholes option-pricing model utilizing the following assumptions: 2021 Risk-free annual interest rate 0.15% Expected annual dividend yield 0.0% Expected stock price volatility 47.3% Expected life of stock warrants < 1 year Forfeiture rate 0% Share price at period end $6.62 Strike price at period end $9.86
Summary of Aging Accounts Receivables	The Company’s aging of Accounts receivables as of December 31, 2022 and 2021 was as follows: ($ in thousands) 2022 2021 0 to 60 days $ 49,303 $ 37,750 61 to 120 days 6,118 4,309 120 days + 3,698 3,540 Total accounts receivable, gross 59,119 45,599 Allowance for doubtful accounts 2,627 2,220 Total accounts receivable, net $ 56,492 $ 43,379
Summary of Contractual Obligations	In addition to the commitments outlined in Note 15, the Company has the following contractual obligations as of December 31, 2022: ($ in thousands) < 1 Year 1 to 3 Years 3 to 5 Years Total Accounts payable & Accrued liabilities $ 93,254 $ — $ — $ 93,254 Deferred consideration, contingent consideration and other payables, short-term 47,834 — — 47,834 Deferred consideration, long-term — 7,770 — 7,770 Long-term notes payable and loans payable and Short-term borrowings 18,812 — 469,055 487,867 Other long-term liabilities 7,000 7,000 Total obligations as of December 31, 2022 $ 159,900 $ 7,770 $ 476,055 $ 643,725

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	12 Months Ended
	Dec. 31, 2022
Variable Interest Entities [Abstract]
Summary of Assets Liabilities and Networth of Variable Interest Entities	The following table presents the summarized financial information about the Company’s consolidated VIEs which are included in the Consolidated Balance Sheets as of December 31, 2022 and 2021. All of these entities were determined to be VIEs as the Company possesses the power to direct activities through written agreements and is subject to the risk and rewards as a primary beneficiary: December 31, 2022 December 31, 2021 ($ in thousands) Cresco Labs Michigan, LLC Cresco Labs Michigan, LLC Current assets $ 17,506 $ 9,850 Non-current assets $ 63,212 $ 63,320 Current liabilities $ (3,158) $ (9,476) Non-current liabilities $ (108,113) $ (86,124) Deficit attributable to Cresco Labs Inc. $ (30,553) $ (22,430)
Summary of Income Expenses and Net Income Loss of Variable Interest Entities	The following table presents the summarized financial information about the Company’s consolidated VIEs which are included in the Consolidated Statements of Operations for the years ended December 31, 2022 and 2021: December 31, 2022 December 31, 2021 ($ in thousands) Cresco Labs Michigan, LLC Cresco Labs Michigan, LLC Revenue $ 12,659 $ 4,031 Net income (loss) attributable to Cresco Labs Inc. $ (8,617) $ (9,120) Net income (loss) $ (8,617) $ (9,120)

Interest Expense, Net (Tables)

Interest Expense, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Interest Income (Expense) [Abstract]
Summary of Interest expense, net	Interest expense, net consisted of the following for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Interest expense – leases $ (3,952) $ (4,053) Interest expense – notes and loans payable (38,528) (29,661) Accretion of debt discount and amortization of deferred financing fees (3,951) (5,153) Interest expense – financing activities and sale and leasebacks (11,887) (11,586) Other interest expense (198) (1,696) Interest income 679 938 Total Interest expense, net $ (57,837) $ (51,211)

Provision For Income Taxes An_2

Provision For Income Taxes And Deferred Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Summary of provision for income taxes	Provision for income taxes consists of the following for the years ended December 31, 2022 and 2021: ($ in thousands) 2022 2021 Current Federal $ 69,240 $ 51,815 State 24,341 23,337 Foreign — — Total current $ 93,581 $ 75,152 Deferred Federal $ (8,332) $ (29,445) State (9,858) (14,043) Foreign 1,190 5,759 Total deferred $ (17,000) $ (37,729) Change in valuation allowance $ 12,357 $ 2,684 Total $ 88,938 $ 40,107
Summary of components of deferred tax assets and liabilities	As of December 31, 2022 and 2021, the components of deferred tax assets and liabilities were as follows: ($ in thousands) 2022 2021 Deferred tax assets Share-based compensation $ 1,381 $ 1,029 Financing fees 1,291 2,542 Net operating losses 43,629 36,096 Inventory 662 239 Lease liabilities 28,362 26,761 Other 386 730 Total deferred tax assets $ 75,711 $ 67,397 Deferred tax liabilities ROU assets $ (9,560) $ (7,824) Property, plant and equipment (12,393) (11,885) Intangible assets (84,099) (93,761) Other (1,329) (1,948) Total deferred tax liabilities $ (107,381) $ (115,418) Valuation allowance $ (43,442) $ (31,085) Net deferred tax liabilities $ (75,112) $ (79,105)
Summary of reconciliation between the effective tax rate	The reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows: ($ in thousands) 2022 2021 Expected income tax expense at statutory tax rate $ (26,650) $ (53,912) Tax rate differences (2,296) (1,109) Pass through and non-controlling entities (2,183) (7,373) State tax expense, net 6,782 8,697 IRC Section 280E disallowance 50,521 47,100 Changes in value of deferred consideration 699 (10,103) Loss on debt modification — 7,554 Uncertain tax treatment (including penalties and interest) 13,245 (4,749) Share-based compensation 2,097 3,941 Goodwill impairment 25,334 45,314 Accrued current tax penalties and interest 4,155 563 Change in valuation allowance 12,357 2,684 Change in state tax rates 4,520 622 Other 357 876 Income tax expense $ 88,938 $ 40,107 Effective tax rate (70.1 %) (15.6 %)
Summary of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: ($ in thousands) 2022 2021 Balance at January 1 $ — $ 4,749 Additions based on tax positions related to the current year 7,380 — Additions for tax positions of prior years 5,366 — Reductions for tax positions of prior years — (4,749) Balance at the end of the year $ 12,746 $ —

Nature of Operations - Addition

Nature of Operations - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022	Nov. 30, 2018
Nature Of Operations [Abstract]
Date of incorporation	Jul. 06, 1990
Share consolidation ratio		812.63

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Significant Investments in Subsidiaries (Detail)	12 Months Ended
	Dec. 31, 2022
Cali-AntiFragile Corp.
Disclosure of subsidiaries [line items]
Location	California
Purpose	Holding Company
Percentage Held	100%
Alta Supply Inc.
Disclosure of subsidiaries [line items]
Location	California
Purpose	Distribution
Percentage Held	100%
Kaya Management Inc.
Disclosure of subsidiaries [line items]
Location	California
Purpose	Production
Percentage Held	100%
River Distributing Co., LLC
Disclosure of subsidiaries [line items]
Location	California
Purpose	Distribution
Percentage Held	100%
FloraCal
Disclosure of subsidiaries [line items]
Location	California
Purpose	Cultivation
Percentage Held	100%
Cub City, LLC
Disclosure of subsidiaries [line items]
Location	California
Purpose	Cultivation
Percentage Held	100%
CRHC Holdings Corp.
Disclosure of subsidiaries [line items]
Location	Ontario, Canada
Purpose	Holding Company
Percentage Held	100%
Laurel Harvest Labs, LLC
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Cultivation and Dispensary Facility
Percentage Held	100%
JDRC Mount Joy, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
JDRC Scranton, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Bluma Wellness Inc.
Disclosure of subsidiaries [line items]
Location	British Columbia, Canada
Purpose	Holding Company
Percentage Held	100%
CannCure Investments Inc.
Disclosure of subsidiaries [line items]
Location	Ontario, Canada
Purpose	Holding Company
Percentage Held	100%
Cannabis Cures Investments, LLC
Disclosure of subsidiaries [line items]
Location	Florida
Purpose	Holding Company
Percentage Held	100%
3 Boys Farm, LLC (One Plant Florida)
Disclosure of subsidiaries [line items]
Location	Florida
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Farm to Fresh Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Florida
Purpose	Holding Company
Percentage Held	100%
Cresco U.S. Corp.
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Manager of Cresco Labs, LLC
Percentage Held	100%
MedMar Inc.
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
MedMar Lakeview, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	88%
MedMar Rockford, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	75%
Gloucester Street Capital, LLC
Disclosure of subsidiaries [line items]
Location	New York
Purpose	Holding Company
Percentage Held	100%
Valley Agriceuticals, LLC
Disclosure of subsidiaries [line items]
Location	New York
Purpose	Operating Entity
Percentage Held	100%
JDRC Ellenville, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
CMA Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
BL Real Estate, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
Cultivate Licensing LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Cultivate Worcester, Inc
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Dispensary
Percentage Held	100%
Cultivate Leicester, Inc.
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Cultivate Framingham, Inc.
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Dispensary
Percentage Held	100%
Cultivate Burncoat, Inc.
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
Cultivate Cultivation, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Cultivation and Production Entity
Percentage Held	100%
Good News Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Wonder Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
JDRC Seed, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
CP Pennsylvania Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Bay, LLC
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Dispensary
Percentage Held	100%
Bay Asset Management, LLC
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Holding Company
Percentage Held	100%
Ridgeback, LLC
Disclosure of subsidiaries [line items]
Location	Colorado
Purpose	Holding Company
Percentage Held	100%
Cresco Labs, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Operating Entity
Percentage Held	58%
Cresco Labs Notes Issuer, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held
Cresco Labs Ohio, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	99%
Wellbeings, LLC
Disclosure of subsidiaries [line items]
Location	Delaware
Purpose	CBD Wellness Product Development
Percentage Held	100%
Cresco Labs SLO, LLC
Disclosure of subsidiaries [line items]
Location	California
Purpose	Holding Company
Percentage Held	100%
SLO Cultivation Inc.
Disclosure of subsidiaries [line items]
Location	California
Purpose	Cultivation and Production Facility
Percentage Held	80%
Cresco Labs Joliet, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Cultivation and Production Facility
Percentage Held	100%
Cresco Labs Kankakee, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Cultivation and Production Facility
Percentage Held	100%
Cresco Labs Logan, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Cultivation and Production Facility
Percentage Held	100%
Cresco Labs PA, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Cresco Yeltrah, LLC
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
JDC Newark, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
Verdant Creations Newark, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Dispensary
Percentage Held	100%
JDC Marion, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
Verdant Creations Marion, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Dispensary
Percentage Held	100%
JDC Chillicothe, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
Verdant Creations Chillicothe, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Dispensary
Percentage Held	100%
JDC Columbus, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
Care Med Associates, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Dispensary
Percentage Held	100%
Cresco Labs Arizona, LLC
Disclosure of subsidiaries [line items]
Location	Arizona
Purpose	Holding Company
Percentage Held	100%
Arizona Facilities Supply, LLC
Disclosure of subsidiaries [line items]
Location	Arizona
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
AFS Maryland, LLC
Disclosure of subsidiaries [line items]
Location	Maryland
Purpose	Production Facility
Percentage Held	100%
Cresco Labs Tinad, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
PDI Medical III, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	100%
Cresco Labs Phoenix Farms, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Phoenix Farms of Illinois, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	100%
JDC Elmwood, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
FloraMedex, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	100%
Cresco Edibles, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
TSC Cresco, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Licensing
Percentage Held	75%
Cresco HHH, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Cresco Labs Michigan, LLC
Disclosure of subsidiaries [line items]
Location	Michigan
Purpose	Cultivation and Production Facility
Percentage Held	85%
Cresco Labs Michigan LLC | Within the Management of the Company
Disclosure of subsidiaries [line items]
Percentage Held	85%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Useful Lives of Property And Equipment (Detail)	12 Months Ended
	Dec. 31, 2022
Leasehold Improvements | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	15 years
Leasehold Improvements | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	1 year
Machinery and Equipment | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	15 years
Machinery and Equipment | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	5 years
Furniture and Fixtures | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	8 years
Furniture and Fixtures | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	3 years
Vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	5 years
Website and Software | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	7 years
Website and Software | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	3 years
Computer Equipment | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	7 years
Computer Equipment | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	3 years
Buildings and Building Improvements | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	39 years
Buildings and Building Improvements | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Life	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Useful Lives of Finite Lived Intangible Assets Other Than Goodwill (Detail)	12 Months Ended
	Dec. 31, 2022
Customer Relationships | Top of range
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	19 years
Customer Relationships | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	7 years
Non-Compete Agreements | Top of range
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	5 years
Non-Compete Agreements | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	4 years
Trade Names
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	10 years
Permit Application Fees | Top of range
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	2 years
Permit Application Fees | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	1 year
Non-Solicitation Agreements | Top of range
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	2 years
Non-Solicitation Agreements | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Estimated Useful Life	1 year

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Advertising costs	$ 8.1	$ 12.3

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Potential Dilutive Shares Excluded Computation of Diluted Earnings Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [line items]
Total potentially dilutive shares	137,153,000	149,586,000
Redeemable Units
Earnings per share [line items]
Total potentially dilutive shares	107,443,000	115,136,000
Options
Earnings per share [line items]
Total potentially dilutive shares	25,528,000	23,609,000
Warrants
Earnings per share [line items]
Total potentially dilutive shares	0	9,842,000
RSUs
Earnings per share [line items]
Total potentially dilutive shares	4,182,000	999,000

Inventory - Summary of Inventor

Inventory - Summary of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Detailed Information About Inventories [Line Items]
Work-in-process	$ 41,164	$ 26,561
Finished goods	30,502	49,204
Total Inventory	134,608	136,643
Cannabis
Disclosure of Detailed Information About Inventories [Line Items]
Raw materials	36,233	38,618
Non Cannabis
Disclosure of Detailed Information About Inventories [Line Items]
Raw materials	$ 26,709	$ 22,260

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Inventory [Abstract]
Write-downs (reversals of write-downs) of inventories	$ 7.4	$ 2.7

Property And Equipment - Summar

Property And Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	$ 369,092
Depreciation	(41,100)	$ (26,300)
Ending balance	379,722	369,092
Gross carrying amount
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	419,110	252,652
Additions	84,531	96,452
Transfers	0	(3)
Disposals	(9,738)	(1,401)
Additions from acquisition		70,994
Effect of foreign exchange and other adjustments	(3)	416
Sale related to sale and leaseback transaction	(37,683)
Measurement period adjustments	1,200
Ending balance	457,417	419,110
Accumulated depreciation and amortisation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(50,018)	(23,848)
Disposals	5,192	543
Effect of foreign exchange and other adjustments	(331)	(430)
Sale related to sale and leaseback transaction	7,984
Depreciation	(40,522)	(26,283)
Ending balance	(77,695)	(50,018)
Land and Buildings
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	139,386
Ending balance	162,663	139,386
Land and Buildings | Gross carrying amount
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	146,884	96,526
Additions	29,826	7,873
Transfers	360	4,021
Disposals	0	0
Additions from acquisition		39,106
Effect of foreign exchange and other adjustments	0	(642)
Sale related to sale and leaseback transaction	(2,305)
Measurement period adjustments	1,829
Ending balance	176,594	146,884
Land and Buildings | Accumulated depreciation and amortisation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(7,498)	(2,033)
Disposals	0	0
Effect of foreign exchange and other adjustments	0	0
Sale related to sale and leaseback transaction	36
Depreciation	(6,469)	(5,465)
Ending balance	(13,931)	(7,498)
Machinery and Equipment
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	32,147
Ending balance	27,349	32,147
Machinery and Equipment | Gross carrying amount
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	38,968	23,206
Additions	2,112	5,772
Transfers	3,489	4,923
Disposals	(1,096)	(130)
Additions from acquisition		5,279
Effect of foreign exchange and other adjustments	(2)	(82)
Sale related to sale and leaseback transaction	(3,333)
Measurement period adjustments	(210)
Ending balance	39,928	38,968
Machinery and Equipment | Accumulated depreciation and amortisation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(6,821)	(3,235)
Disposals	69	74
Effect of foreign exchange and other adjustments	(275)	(57)
Sale related to sale and leaseback transaction	736
Depreciation	(6,288)	(3,603)
Ending balance	(12,579)	(6,821)
Furniture and Fixtures
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	18,648
Ending balance	15,772	18,648
Furniture and Fixtures | Gross carrying amount
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	26,227	17,636
Additions	1,416	4,484
Transfers	2,645	3,560
Disposals	(312)	(407)
Additions from acquisition		834
Effect of foreign exchange and other adjustments	7	120
Sale related to sale and leaseback transaction	(2,188)
Measurement period adjustments	929
Ending balance	28,724	26,227
Furniture and Fixtures | Accumulated depreciation and amortisation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(7,579)	(3,199)
Disposals	24	140
Effect of foreign exchange and other adjustments	(2)	(133)
Sale related to sale and leaseback transaction	950
Depreciation	(6,345)	(4,387)
Ending balance	(12,952)	(7,579)
Leasehold Improvements
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	129,629
Ending balance	112,799	129,629
Leasehold Improvements | Gross carrying amount
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	152,778	88,369
Additions	5,691	12,339
Transfers	19,310	39,494
Disposals	(3,658)	(811)
Additions from acquisition		12,448
Effect of foreign exchange and other adjustments	(36)	939
Sale related to sale and leaseback transaction	(29,857)
Measurement period adjustments	(1,348)
Ending balance	142,880	152,778
Leasehold Improvements | Accumulated depreciation and amortisation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(23,149)	(12,882)
Disposals	5,098	297
Effect of foreign exchange and other adjustments	1	(206)
Sale related to sale and leaseback transaction	6,262
Depreciation	(18,293)	(10,358)
Ending balance	(30,081)	(23,149)
Website, Computer Equipment and Software
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	4,221
Ending balance	3,850	4,221
Website, Computer Equipment and Software | Gross carrying amount
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	8,148	5,772
Additions	296	1,650
Transfers	1,863	580
Disposals	(70)	(23)
Additions from acquisition		111
Effect of foreign exchange and other adjustments	(5)	58
Sale related to sale and leaseback transaction	0
Measurement period adjustments	0
Ending balance	10,232	8,148
Website, Computer Equipment and Software | Accumulated depreciation and amortisation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(3,927)	(2,006)
Disposals	0	13
Effect of foreign exchange and other adjustments	5	(52)
Sale related to sale and leaseback transaction	0
Depreciation	(2,460)	(1,882)
Ending balance	(6,382)	(3,927)
Vehicles
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	2,214
Ending balance	1,782	2,214
Vehicles | Gross carrying amount
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	3,258	1,946
Additions	134	921
Transfers	146	65
Disposals	(19)	(30)
Additions from acquisition		377
Effect of foreign exchange and other adjustments	33	(21)
Sale related to sale and leaseback transaction	0
Measurement period adjustments	0
Ending balance	3,552	3,258
Vehicles | Accumulated depreciation and amortisation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(1,044)	(493)
Disposals	1	19
Effect of foreign exchange and other adjustments	(60)	18
Sale related to sale and leaseback transaction	0
Depreciation	(667)	(588)
Ending balance	(1,770)	(1,044)
Construction In Progress
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	42,847
Ending balance	55,507	42,847
Construction In Progress | Gross carrying amount
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	42,847	19,197
Additions	45,056	63,413
Transfers	(27,813)	(52,646)
Disposals	(4,583)	0
Additions from acquisition		12,839
Effect of foreign exchange and other adjustments	0	44
Sale related to sale and leaseback transaction	0
Measurement period adjustments	0
Ending balance	55,507	42,847
Construction In Progress | Accumulated depreciation and amortisation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	0	0
Disposals	0	0
Effect of foreign exchange and other adjustments	0	0
Sale related to sale and leaseback transaction	0
Depreciation	0	0
Ending balance	$ 0	$ 0

Property And Equipment - Additi

Property And Equipment - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 01, 2022	Jul. 31, 2022	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment			$ 379,722,000		$ 379,722,000	$ 369,092,000
Depreciation, property, plant and equipment					41,100,000	26,300,000
Impairment losses related to property and equipment					0	0
Selling, general and administrative expense
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					11,300,000	6,500,000
Cost of Sales and Ending Inventory
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					29,800,000	19,800,000
Accumulated depreciation and amortisation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment			(77,695,000)		(77,695,000)	(50,018,000)	$ (23,848,000)
Depreciation, property, plant and equipment					40,522,000	26,283,000
Brookville, Pennsylvania Facility
Disclosure of detailed information about property, plant and equipment [line items]
Gains on disposals of non-current assets	$ 14,700,000
Proceeds from sales of property, plant and equipment	43,700,000
Construction In Progress, Materials Not Used
Disclosure of detailed information about property, plant and equipment [line items]
Non-current assets or disposal groups classified as held for sale			900,000	$ 2,400,000	900,000
Gains (losses) arising from sale of property, plant and equipment		$ (1,500,000)	600,000
Proceeds from sale of property, plant and equipment		$ 900,000
Proceeds from sales of property, plant and equipment			300,000
Leasehold Improvements
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment			112,799,000		112,799,000	129,629,000
Leasehold Improvements | Accumulated depreciation and amortisation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment			(30,081,000)		(30,081,000)	(23,149,000)	(12,882,000)
Depreciation, property, plant and equipment					18,293,000	10,358,000
Leasehold Improvements | Cultivation Facility And Production Facility, California
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment				0
Depreciation, property, plant and equipment				$ 2,700,000
Other property, plant and equipment | Cultivation Facility And Production Facility, California
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					500,000
Land and Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment			162,663,000		162,663,000	139,386,000
Land and Buildings | Accumulated depreciation and amortisation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment			$ (13,931,000)		(13,931,000)	(7,498,000)	$ (2,033,000)
Depreciation, property, plant and equipment					6,469,000	5,465,000
Land and Buildings | Brookville, Pennsylvania Facility
Disclosure of detailed information about property, plant and equipment [line items]
Non-current assets or disposal groups classified as held for sale or as held for distribution to owners	29,700,000
Gains on disposals of non-current assets	$ 14,700,000
Construction In Progress, Abandoned Project | Accumulated depreciation and amortisation
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					600,000
Ending Inventories
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					10,900,000	9,100,000
Ending Inventories | Selling, general and administrative expense
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					28,000,000	14,300,000
Ending Inventories | Selling, general and administrative expense | Previously stated
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					$ 9,100,000	$ 3,600,000

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Sep. 01, 2022	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Leases [Line Items]
Right-of-use assets			$ 128,264	$ 88,017
Interest expense on finance liabilities			3,952	4,053
Depreciation capitalised related to leases			2,800	2,600
Rental expense			17,100	17,700
Reimbursements of tenant improvement allowance, finance and operating lease			3,600	28,600
Reimbursements of tenant improvement allowance, other financing transactions			600	7,500
Reimbursements of tenant improvement allowance in future periods, finance and operating lease			5,600
Reimbursements of tenant improvement allowance in future periods, other financing transactions			800
Depreciation related to leases			100
Lease liabilities			182,304
Long-term financing liabilities			87,605	87,600
Interest payable			12,900	12,600
Interest expense – financing activities and sale and leasebacks			11,887	11,586
California Reporting Unit
Disclosure of Leases [Line Items]
Impairment of right-of-use assets			1,000
Arizona Reporting Unit
Disclosure of Leases [Line Items]
Impairment of right-of-use assets			800
Cultivation Facility And Production Facility, California
Disclosure of Leases [Line Items]
Right-of-use assets		$ 0
Gain (loss) on termination of lease		$ 4,900
Brookville, Pennsylvania Facility
Disclosure of Leases [Line Items]
Lease term (in years) (less than for bottom of range)	10 years
Right-of-use assets	$ 29,700
Proceeds from sales of property, plant and equipment	43,700
Gains on disposals of non-current assets	14,700
Lease liabilities	$ 29,700
Selling, general and administrative expense
Disclosure of Leases [Line Items]
Depreciation capitalised related to leases			2,500	2,300
Rental expense			9,900	6,500
Short term lease rent expenses			600	2,100
Cost of Sales and Ending Inventory
Disclosure of Leases [Line Items]
Depreciation capitalised related to leases			300
Cost of goods sold
Disclosure of Leases [Line Items]
Depreciation related to leases			300	400
Cost of goods sold | Previously stated
Disclosure of Leases [Line Items]
Depreciation related to leases			$ 100	$ 200
Bottom of range
Disclosure of Leases [Line Items]
Lease term (in years) (less than for bottom of range)			1 year
Lease renewal term (in years) (less than for bottom of range)			1 year
Lease exercise renewal options term (in years) (less than for bottom of range)			1 year
Top of range
Disclosure of Leases [Line Items]
Lease term (in years) (less than for bottom of range)			20 years
Lease renewal term (in years) (less than for bottom of range)			25 years
Lease exercise renewal options term (in years) (less than for bottom of range)			10 years

Leases - Summary of Maturities

Leases - Summary of Maturities of Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	$ 382,698
Less: imputed interest	(194,752)
Less: tenant improvement allowance	(5,642)
Present value of lease liabilities	182,304
Less: current lease liabilities	(26,124)	$ (20,792)
Lease liabilities	156,180	118,936
Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	326,886
Less: imputed interest	(169,170)
Less: tenant improvement allowance	(4,997)
Present value of lease liabilities	152,719
Less: current lease liabilities	(21,850)	(16,348)
Lease liabilities	130,869	92,919
Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	55,812
Less: imputed interest	(25,582)
Less: tenant improvement allowance	(645)
Present value of lease liabilities	29,585
Less: current lease liabilities	(4,274)	(4,444)
Lease liabilities	25,311	$ 26,017
2023
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	33,027
2023 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	27,595
2023 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	5,432
2024
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	33,465
2024 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	27,857
2024 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	5,608
2025
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	34,289
2025 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	28,531
2025 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	5,758
2026
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	34,715
2026 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	28,816
2026 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	5,899
2027
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	34,949
2027 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	28,948
2027 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	6,001
Thereafter
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	212,253
Thereafter | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	185,139
Thereafter | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Undiscounted lease payments to be paid	$ 27,114

Leases - Summary of Maturitie_2

Leases - Summary of Maturities of Financing Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	$ 181,297
Less: interest	(84,207)
Less: tenant improvement allowance	(173)
Present value of financing liabilities	96,917
Less: short-term financing liabilities	(9,312)	$ (10,217)
Long-term financing liabilities	87,605	$ 87,600
2023
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	13,204
2024
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	13,535
2025
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	13,875
2026
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	14,223
2027
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	14,580
Thereafter
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	$ 111,880

Leases - Summary of Lease Cost

Leases - Summary of Lease Cost (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lease Cost [Line Items]
Right-of-use assets	$ 128,264,000	$ 88,017,000
Lease liabilities (current)	26,124,000	20,792,000
Lease liabilities (non-current)	156,180,000	118,936,000
Interest paid on finance leases	3,877,000	4,742,000
Operating Leases
Lease Cost [Line Items]
Right-of-use assets	106,127,000	62,329,000
Lease liabilities (current)	21,850,000	16,348,000
Lease liabilities (non-current)	$ 130,869,000	$ 92,919,000
Weighted average remaining lease term	11 years 10 months 24 days	4 years 8 months 12 days
Weighted average discount rate	0.145	0.135
Finance Leases
Lease Cost [Line Items]
Right-of-use assets	$ 22,137,000	$ 25,688,000
Lease liabilities (current)	4,274,000	4,444,000
Lease liabilities (non-current)	$ 25,311,000	$ 26,017,000
Weighted average remaining lease term	10 years 4 months 24 days	11 years 2 months 12 days
Weighted average discount rate	0.136	0.138

Investments - Additional Inform

Investments - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) entity	Dec. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jan. 08, 2020 USD ($)
Disclosure Of Significant Investments [Line Items]
Number of entities where investments are held | entity	5
Two Roots Brewing Co.
Disclosure Of Significant Investments [Line Items]
Ownership interest (in percent)	0.80%
Other operating income expense
Disclosure Of Significant Investments [Line Items]
Gain on ownership conversion			$ 9.3
Trichome Financial Corp
Disclosure Of Significant Investments [Line Items]
Investments at fair value and equity				$ 4.3
Market risk
Disclosure Of Significant Investments [Line Items]
Mark to market loss of investments held	$ (4.6)	$ (7.3)

Investments - Summary of Invest

Investments - Summary of Investments at Fair Value (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	$ 1,228	$ 5,912
420 Capital
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	68	68
Lighthouse
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	339	542
Two Roots Brewing Co.
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	93	0
Old Pal
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	592	592
IMC
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	$ 136	$ 4,710

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Detailed Information of Intangible assets and Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Disposals		$ (476)
Intangible assets and goodwill, net	$ 738,145	884,411
Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill, net	23,752	27,682
Trade Names
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill, net	490	1,405
Permit Application Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill, net	1,130	1,473
Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill, net	381,507	404,307
Other Intangibles
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill, net	711	2,777
Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill, net	330,555	446,767
Gross carrying amount
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	903,258	665,287
Additions	3,106	6,171
Additions from acquisitions		556,141
Impairment	(138,824)	(321,234)
Measurement period adjustments	(188)	(2,631)
Disposals		(476)
Ending balance	767,352	903,258
Gross carrying amount | Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	31,879	70,529
Additions	0	0
Additions from acquisitions		24,250
Impairment	0	(62,900)
Measurement period adjustments	0	0
Disposals		0
Ending balance	31,879	31,879
Gross carrying amount | Trade Names
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	2,100	39,700
Additions	0	0
Additions from acquisitions		1,400
Impairment	0	(39,000)
Measurement period adjustments	0	0
Disposals		0
Ending balance	2,100	2,100
Gross carrying amount | Permit Application Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	11,921	8,752
Additions	3,106	3,169
Additions from acquisitions		0
Impairment	0	0
Measurement period adjustments	0	0
Disposals		0
Ending balance	15,027	11,921
Gross carrying amount | Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	404,307	89,347
Additions	0	0
Additions from acquisitions		317,200
Impairment	(21,800)	0
Measurement period adjustments	(1,000)	(2,240)
Disposals		0
Ending balance	381,507	404,307
Gross carrying amount | Other Intangibles
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	6,284	6,390
Additions	0	3,002
Additions from acquisitions		1,151
Impairment	0	(3,783)
Measurement period adjustments	0	0
Ending balance	6,284	6,284
Gross carrying amount | Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	446,767	450,569
Additions	0	0
Additions from acquisitions		212,140
Impairment	(117,024)	(215,551)
Measurement period adjustments	812	(391)
Disposals		0
Ending balance	330,555	446,767
Accumulated depreciation and amortisation
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	(18,847)	(19,177)
Disposals	0	95
Amortization	(10,360)	235
Ending balance	(29,207)	(18,847)
Accumulated depreciation and amortisation | Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	(4,197)	(5,129)
Disposals	0	0
Amortization	(3,930)	932
Ending balance	(8,127)	(4,197)
Accumulated depreciation and amortisation | Trade Names
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	(695)	(3,970)
Disposals	0	0
Amortization	(915)	3,275
Ending balance	(1,610)	(695)
Accumulated depreciation and amortisation | Permit Application Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	(10,448)	(7,118)
Disposals	0	0
Amortization	(3,449)	(3,330)
Ending balance	(13,897)	(10,448)
Accumulated depreciation and amortisation | Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	0	0
Disposals	0	0
Amortization	0	0
Ending balance	0	0
Accumulated depreciation and amortisation | Other Intangibles
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	(3,507)	(2,960)
Disposals	0	95
Amortization	(2,066)	(642)
Ending balance	(5,573)	(3,507)
Accumulated depreciation and amortisation | Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [abstract]
Opening balance	0	0
Disposals	0	0
Amortization	0	0
Ending balance	$ 0	$ 0

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Amortisation expense	$ 10,400,000	$ 15,300,000
Intangible assets, net	$ 407,590,000	437,644,000
Growth rate used to extrapolate cash flow projections (in percent)	3%
Ending inventory	$ 1,600,000	1,100,000
Bottom of range
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Discount rate applied to cash flow projections (in percent)	12.50%
Top of range
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Discount rate applied to cash flow projections (in percent)	17.50%
California Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment loss recognised in profit or loss, goodwill	$ 89,500,000	215,600,000
Arizona Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment loss recognised in profit or loss, goodwill	10,100,000
Maryland Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment loss recognised in profit or loss, goodwill	900,000
Massachusetts Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment charge	21,800,000
Impairment loss recognised in profit or loss, goodwill	16,500,000
Selling, general and administrative expense
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Amortisation expense	6,900,000	12,800,000
Cost of Sales and Ending Inventory
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Amortisation expense	3,500,000	2,500,000
Cost of goods sold
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Amortisation expense	2,900,000	2,400,000
Amortization capitalized to inventory in prior years	1,100,000	1,000,000
Gross carrying amount
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Additions from acquisitions		556,141,000
Gross carrying amount | Customer Relationships
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Additions from acquisitions		24,250,000
Gross carrying amount | Trade Names
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Additions from acquisitions		1,400,000
Gross carrying amount | Licenses
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Additions from acquisitions	$ 0	317,200,000
Accumulated depreciation and amortisation | Trade Names And Customer Relationship Intangibles
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment charge		15,700,000
Carrying Amount Subject To Impairment | Customer Relationships
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Intangible assets, net		57,100,000
Carrying Amount Subject To Impairment | Trade Names
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Intangible assets, net		32,200,000
Carrying Amount Subject To Impairment | Market-Related Intangibles
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Intangible assets, net		$ 800,000

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Summary Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill Explanatory (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	$ 26,083
2023
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	5,776
2024
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	4,282
2025
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	4,093
2026
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	3,968
2027
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	3,271
Thereafter
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	$ 4,693

Share Capital - Additional Info

Share Capital - Additional Information (Details)		1 Months Ended					3 Months Ended	12 Months Ended
		Apr. 30, 2021 USD ($)	Feb. 28, 2021 shares	Jan. 31, 2021 CAD ($) shares	Jan. 31, 2021 USD ($) shares	Dec. 31, 2019 CAD ($)	Jun. 30, 2021 USD ($) shares	Dec. 31, 2022 USD ($) vote shares	Dec. 31, 2021 USD ($) shares
Share Capital [Line Items]
Warrant exercises into share capital								$ 100,000	$ 5,100,000
Redeemable units, redeemed during period (in shares) | shares								3,300,000	16,900,000
Decrease in noncontrolling interest (in percent)								1.30%	6.70%
2022 and 2021 Unit and Other Minority Holders
Share Capital [Line Items]
Accrued dividends recognised as distributions to unit holders								$ 4,900,000	$ 36,400,000
Dividends recognised as distributions to owners								$ 83,600,000
2021 and 2020 Unit and Other Minority Interest Holders
Share Capital [Line Items]
Required tax distribution amounts									73,600,000
Bluma Wellness Inc.
Share Capital [Line Items]
Increase (decrease) in equity									$ 2,900,000
Number of warrants, Issued | shares									200,000
Value of warrants issued during period									$ 2,200,000
Cresco Warrants | Bluma Wellness Inc.
Share Capital [Line Items]
Number of warrants, Issued | shares							4,700,000
Value of warrants issued during period							$ 18,400,000
Former Executive
Share Capital [Line Items]
Shares issued during period for renewal of distribution agreement (in shares) | shares			1,300,000
Subordinate Voting Shares (SVS)
Share Capital [Line Items]
Number of shares issued | shares								281,147,586	270,033,270
Voting rights | vote								1
Subordinate Voting Shares (SVS) | Canacord Genuity Corp.
Share Capital [Line Items]
Proceeds from issue of ordinary shares		$ 100,000,000
Number of shares issued during period (in shares) | shares								0	0
Subordinate Voting Shares (SVS) | ATM Offering | Canacord Genuity Corp.
Share Capital [Line Items]
Proceeds from issue of ordinary shares						$ 55,000,000
Subordinate Voting Shares (SVS) | Private Placement
Share Capital [Line Items]
Proceeds from issue of ordinary shares					$ 120,700,000
Number of shares issued during period (in shares) | shares				9,900,000	9,900,000
Shares issued during period (in dollars per share)				$ 16,000	$ 12,670
Commission and other fees					3,400,000
Increase (decrease) in equity					$ 124,100,000
Proportionate Voting Shares (PVS)
Share Capital [Line Items]
Number of shares issued | shares	[1]							20,082,384	20,667,206
Voting rights | vote								1
Voting rights conversion | vote								200
Description of stock conversion ratio								0.005
Super Voting Shares (MVS)
Share Capital [Line Items]
Number of shares issued | shares								500,000	500,000
Voting rights | vote								2,000
Special Subordinate Voting Shares (SSVS)
Share Capital [Line Items]
Number of shares issued | shares	[2]							639	639
Voting rights | vote								0.00001
Description of stock conversion ratio								100,000
[1] 1 Proportionate Voting Shares (“PVS”) presented on an “as-converted” basis to Subordinate Voting Shares (“SVS”) (1-to-200) 2 Special Subordinate Voting Shares (“SSVS”) presented on an “as-converted” basis to SVS (1-to-0.00001)

Share Capital - Summary of Issu

Share Capital - Summary of Issued And Outstanding Shares (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Redeemable Units
Disclosure of classes of share capital [line items]
Beginning balance	109,441	126,338
Ending balance	106,106	109,441
Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Beginning balance	269,971	194,231
Ending balance	280,994	269,971
Proportionate Voting Shares (PVS)
Disclosure of classes of share capital [line items]
Beginning balance	20,667	29,311
Ending balance	20,082	20,667
Super Voting Shares (MVS)
Disclosure of classes of share capital [line items]
Beginning balance	500	500
Ending balance	500	500
Special Subordinate Voting Shares (SSVS)
Disclosure of classes of share capital [line items]
Beginning balance	1	1
Ending balance	1	1
Options and warrants exercised | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	1,279	3,030
RSU issued | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	337	351
Issuance of shares related to acquisitions | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	5,339	35,425
Issuance of shares related to distribution agreements | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding		(249)
Cresco LLC redemption | Redeemable Units
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	(3,335)	(16,897)
Cresco LLC redemption | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	3,335	16,897
PVS converted to SVS | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	585	8,644
PVS converted to SVS | Proportionate Voting Shares (PVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	(585)	(8,644)
Issuances related to employee taxes on certain share-based payment arrangements | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	148	173
Share issuances | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding		11,469

Share Capital - Summary Of Comp

Share Capital - Summary Of Company Issued Shares In Conjunction Acquisitions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Shares Issued During Acquisition [Line Items]
Equity-based consideration		$ 350,359
Cultivate - Contingent Consideration
Disclosure Of Shares Issued During Acquisition [Line Items]
Acquisition date	Sep. 02, 2021
SVS shares issued	5,340,000
Replacement shares issued	0
Equity-based consideration	$ 34,708
Verdant
Disclosure Of Shares Issued During Acquisition [Line Items]
Acquisition date		Feb. 16, 2021
SVS shares issued		127,000
Replacement shares issued		0
Equity-based consideration		$ 2,004
Bluma
Disclosure Of Shares Issued During Acquisition [Line Items]
Acquisition date		Apr. 14, 2021
SVS shares issued		15,061,000
Replacement shares issued		814,000
Equity-based consideration		$ 193,310
Cultivate
Disclosure Of Shares Issued During Acquisition [Line Items]
Acquisition date		Sep. 02, 2021
SVS shares issued		4,818,000
Replacement shares issued		0
Equity-based consideration		$ 46,643
Cure Penn
Disclosure Of Shares Issued During Acquisition [Line Items]
Acquisition date		Nov. 24, 2021
SVS shares issued		6,167,000
Replacement shares issued		0
Equity-based consideration		$ 54,240
Laurel Harvest
Disclosure Of Shares Issued During Acquisition [Line Items]
Acquisition date		Dec. 09, 2021
SVS shares issued		8,354,000
Replacement shares issued		0
Equity-based consideration		$ 65,844

Share Capital - Summary Of Warr

Share Capital - Summary Of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Detailed Information About Warrants Outstanding [Line Items]
Number of warrants, beginning balance (in shares)	9,842,000	6,183,000
Number of warrants, exercised (in shares)	(12,000)	(721,000)
Number of warrants, forfeited (in shares)	(9,830,000)	(285,000)
Number of warrants, ending balance (in shares)	0	9,842,000
Weighted average exercise price, beginning balance (in dollars per share)	$ 9.63	$ 7.80
Weighted average exercise price, exercised (in dollars per share)	4.24	6.15
Weighted average exercise price, forfeited (in dollars per share)	$ 9.54	11.64
Weighted average exercise price, ending balance (in dollars per share)		$ 9.63
Bluma
Disclosure of Detailed Information About Warrants Outstanding [Line Items]
Number of warrants, Bluma replacement warrants (in shares)		4,665,000
Weighted average exercise price, Bluma replacement warrants (in dollars per share)		$ 11.64

Share Capital - Summary Of Chan

Share Capital - Summary Of Changes In Ownership And Noncontrolling Interests (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	$ 1,257,646	$ 1,358,708
Current assets	326,046	421,755
Non-current liabilities	(715,143)	(694,333)
Current liabilities	(280,866)	(288,394)
Net assets	587,683	797,736
Revenue	842,681	821,682
Gross profit	407,013	406,347
Net income (loss)	(215,843)	(296,834)
Net income (loss) allocated to NCI	(3,796)	22,763
Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	(39,356)	42,182
Net income (loss)	(3,796)	22,763
Reportable Legal Entity | TSC Cresco, LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	4,813	5,208
Current assets	69,844	54,506
Non-current liabilities	0	0
Current liabilities	(56,341)	(49,726)
Net assets	18,316	9,988
Revenue	35,302	21,549
Gross profit	23,387	13,592
Net income (loss)	19,290	12,387
Net income (loss) allocated to NCI	$ 4,822	$ 3,097
NCI percentage	25%	25%
Reportable Legal Entity | TSC Cresco, LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ 4,190	$ 2,850
Reportable Legal Entity | MedMar  Inc. (Lakeview)
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	31,151	33,698
Current assets	142,723	95,522
Non-current liabilities	(10,889)	(11,213)
Current liabilities	(127,329)	(92,049)
Net assets	35,656	25,958
Revenue	53,259	48,435
Gross profit	35,485	32,020
Net income (loss)	13,322	12,043
Net income (loss) allocated to NCI	$ 1,652	$ 1,493
NCI percentage	12.40%	12.40%
Reportable Legal Entity | MedMar  Inc. (Lakeview) | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ 3,979	$ 3,910
Reportable Legal Entity | MedMar  Inc. (Rockford)
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	22,700	22,934
Current assets	232,194	154,929
Non-current liabilities	(3,850)	(3,443)
Current liabilities	(164,550)	(124,597)
Net assets	86,494	49,823
Revenue	88,645	84,932
Gross profit	62,503	47,922
Net income (loss)	43,500	30,666
Net income (loss) allocated to NCI	$ 10,875	$ 7,666
NCI percentage	25%	25%
Reportable Legal Entity | MedMar  Inc. (Rockford) | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ 7,468	$ 6,123
Reportable Legal Entity | Cresco Labs Ohio, LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	16,736	16,093
Current assets	70,693	64,897
Non-current liabilities	(12,515)	(12,286)
Current liabilities	(64,479)	(73,441)
Net assets	10,435	(4,737)
Revenue	17,834	22,661
Gross profit	1,338	10,650
Net income (loss)	(4,933)	(4,627)
Net income (loss) allocated to NCI	$ (49)	$ (46)
NCI percentage	1%	1%
Reportable Legal Entity | Cresco Labs Ohio, LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ (32)	$ 18
Reportable Legal Entity | SLO Cultivation Inc.
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	5,376	23,422
Current assets	92,594	97,276
Non-current liabilities	(2,728)	(14,071)
Current liabilities	(126,575)	(147,993)
Net assets	(31,333)	(41,366)
Revenue	6,484	21,011
Gross profit	(13,652)	(6,250)
Net income (loss)	(16,458)	(19,247)
Net income (loss) allocated to NCI	$ (3,292)	$ (3,849)
NCI percentage	20%	20%
Reportable Legal Entity | SLO Cultivation Inc. | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ (12,434)	$ (9,143)
Reportable Legal Entity | Other entities including Cresco Labs LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	1,176,870	1,257,353
Current assets	88,545	250,029
Non-current liabilities	(685,161)	(653,320)
Current liabilities	(123,889)	(107,143)
Net assets	456,365	746,919
Revenue	670,060	663,602
Gross profit	294,993	320,419
Net income (loss)	(270,564)	(328,056)
Net income (loss) allocated to NCI	$ (17,804)	$ 14,402
NCI percentage	42%	43.30%
Reportable Legal Entity | Other entities including Cresco Labs LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ (42,527)	$ 38,424
Consolidation Elimination
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	0	0
Current assets	(370,547)	(295,404)
Non-current liabilities	0	0
Current liabilities	382,297	306,555
Net assets	11,750	11,151
Revenue	(28,903)	(40,508)
Gross profit	2,959	(12,006)
Net income (loss)	0	0
Net income (loss) allocated to NCI	0	0
Consolidation Elimination | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ 0	$ 0

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Gross proceeds from exercise of options		$ 2,900	$ 3,700
Weighted average exercise price of stock options exercised (in dollars per share)		$ 1.51
Compensation expense		$ 10,011	4,563
Unrecognized compensation expense		$ 17,400
Unrecognized compensation expense of option awards, period of recognition		4 years
Compensation expense capitalized to inventory		$ 1,200	200
Cost of goods sold
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense		3,600	2,500
Deferred Share Awards
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense		13,733	20,701
RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense		10,000	4,600
Unrecognized compensation expense		$ 8,900
Unrecognized compensation expense of other equity awards, period of recognition		4 years
Capitalized compensation expense		$ 1,700	$ 1,200
Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period (in years)		4 years
Number of shares issued under the plan not exceed the percentage of issued and outstanding shares		10%
Weighted average
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price of stock options exercised (in dollars per share)		$ 4.64	$ 10.13
Bluma | RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Post acquisition compensation expense	$ 2,100

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Status of the Stock Options Outstanding (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) shares $ / shares	Dec. 31, 2021 USD ($) shares $ / shares
Share-Based Payment Arrangements [Abstract]
Number of stock options outstanding, beginning balance (in shares) | shares	23,610,000
Number of stock options granted (in shares) | shares	7,649,000
Number of stock options exercised (in shares) | shares	(1,631,000)
Number of stock options forfeited (in shares) | shares	(4,100,000)
Number of stock options outstanding, ending balance (in shares) | shares	25,528,000	23,610,000
Number of stock options exercisable (in shares) | shares	14,027,000
Weighted average exercise price of stock options outstanding, beginning balance (in dollars per share) | $ / shares	$ 5.54
Weighted average exercise price of stock options granted (in dollars per share) | $ / shares	3.77
Weighted average exercise price of stock options exercised (in dollars per share) | $ / shares	1.51
Weighted average exercise price of stock options forfeited (in dollars per share) | $ / shares	7.27
Weighted average exercise price of stock options outstanding, ending balance (in dollars per share) | $ / shares	5	$ 5.54
Weighted average exercise price of stock options exercisable (in dollars per share) | $ / shares	$ 4.32
Weighted average remaining contractual life of outstanding share options	7 years 6 months 14 days	7 years 8 months 12 days
Weighted average remaining contractual life of exercisable stock options	6 years 5 months 1 day
Aggregate intrinsic value of outstanding stock options | $	$ 921	$ 53,455
Aggregate intrinsic value of outstanding of exercisable stock options | $	$ 921

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Weighted Average Grant Date Fair Value and Intrinsic Value of Options Exercised (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangements [Abstract]
Weighted average grant date fair value (per share) of stock option units granted (in dollars per share)	$ 2.59	$ 7.39
Intrinsic value of stock option units exercised, using market price at exercise date	$ 5,106	$ 21,131

Share-Based Compensation - Su_3

Share-Based Compensation - Summary Of Fair Value Of Stock Options Granted Under the Plan (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items]
Expected annual dividend yield (in percent)	0%	0%
Bottom of range
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items]
Risk-free annual interest rate (in percent)	1.40%	0.40%
Expected stock price volatility (in percent)	74.90%	67%
Expected life of stock options (in years)	5 years 6 months	5 years
Forfeiture rate (in percent)	7.20%	7.50%
Fair value at grant date (in dollars per share)	$ 1.23	$ 4.47
Stock price at grant date (in dollars per share)	1.81	6.62
Exercise price range (in dollars per share)	$ 1.81	$ 6.62
Top of range
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items]
Risk-free annual interest rate (in percent)	3%	1.20%
Expected stock price volatility (in percent)	80.40%	82.20%
Expected life of stock options (in years)	7 years	7 years
Forfeiture rate (in percent)	28%	24.90%
Fair value at grant date (in dollars per share)	$ 4.9	$ 8.78
Stock price at grant date (in dollars per share)	6.91	13.1
Exercise price range (in dollars per share)	$ 6.91	$ 13.1

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Outstanding Restricted Stock Units (Details) - RSUs $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) shares $ / shares	Dec. 31, 2021 USD ($) shares $ / shares
Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]
Number of RSUs outstanding, beginning balance (in shares) | shares	1,093,000
Number of RSUs granted (in shares) | shares	4,438,000
Number of RSUs vested and settled (in shares) | shares	(452,000)
Number of RSUs forfeited (in shares) | shares	(821,000)
Number of RSUs outstanding, ending balance (in shares) | shares	4,258,000	1,093,000
Weighted average fair value of RSUs, beginning balance (in dollars per share) | $ / shares	$ 8.83
Weighted average fair value of RSUs, granted (in dollars per share) | $ / shares	5.36
Weighted average fair value of RSUs, vested and settled (in dollars per share) | $ / shares	5.31
Weighted average fair value of RSUs, forfeited (in dollars per share) | $ / shares	6.46
Weighted average fair value of RSUs, ending balance (in dollars per share) | $ / shares	$ 5.71	$ 8.83
Weighted average remaining contractual life of outstanding RSUs	4 years	3 years 6 months
Aggregate intrinsic value of outstanding RSUs | $	$ 24,330	$ 9,657

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of Total Fair Value of Restricted Stock Units Vested (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
RSUs
Total Fair Value Of Units Vested Other Equity Instruments [line Items]
Total fair value of RSUs vested, using market price at vest date	$ 2,396	$ 4,783

Share-Based Compensation - Su_6

Share-Based Compensation - Summary of Shares Movement (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) shares $ / shares
Disclosure Of Movement Of Shares [Line Items]
Compensation expense	$ 1,200	$ 200
Bluma replacement shares
Disclosure Of Movement Of Shares [Line Items]
Shares issued (in shares) | shares		814
Fair value (per share) (in dollars per share) | $ / shares		$ 12.17
Compensation expense		$ 239
Subscription award
Disclosure Of Movement Of Shares [Line Items]
Shares issued (in shares) | shares		62
Fair value (per share) (in dollars per share) | $ / shares		$ 11.25
Compensation expense		$ 694

Share-Based Compensation - Su_7

Share-Based Compensation - Summary of Expense from Share-Based Payment Transactions with Employees Related to Options (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	$ 10,011	$ 4,563
Cost of goods sold
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	1,984	2,958
Selling, general and administrative expense
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	11,749	17,743
Deferred Share Awards
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	$ 13,733	$ 20,701

Share-Based Compensation - Su_8

Share-Based Compensation - Summary of Expense from Share-Based Payment Transactions with Employees Related to Restricted Stock Units (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	$ 10,011	$ 4,563
RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	10,000	4,600
Cost of goods sold
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	1,984	2,958
Cost of goods sold | RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	2,097	579
Selling, general and administrative expense
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	11,749	17,743
Selling, general and administrative expense | RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Compensation expense	$ 7,914	$ 3,985

Acquisitions and Dispositions -

Acquisitions and Dispositions - Summary of Significant Business Combinations (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 09, 2021 USD ($) dispensary	Nov. 24, 2021 USD ($) dispensary	Sep. 30, 2021 USD ($)	Sep. 02, 2021 USD ($) dispensary	Apr. 14, 2021 USD ($) dispensary	Feb. 16, 2021 USD ($) dispensary
Total consideration
Common shares issued		$ 350,359
Cash		55,284
Cashless exercise option on loan		10,000
Settlement of leases		90
Loan settlement		37,831
Warrants issued		18,415
Replacement RSU awards		10,048
Payment of acquisition-related transaction costs on behalf of the acquiree		7,840
Payment of 3rd-party debt on behalf of the acquiree		20,125
Deferred consideration		48,483
Contingent consideration		29,642
Total consideration		588,117
Net identifiable assets (liabilities) acquired
Cash		7,609
Accounts receivable		6,527
Inventory		49,094
Loans receivable, short-term		1,600
Other current assets		2,113
Property & equipment		70,994
Right-of-use assets		17,833
Other non-current assets		47
Customer relationships		24,250
License		314,960
Trade name		1,400
Non-compete agreements		1,150
Investments		693
Total identifiable assets acquired		498,270
Short-term liabilities		(21,256)
Lease liability		(17,809)
Contract liability-loyalty program		(811)
Deferred tax liability		(82,258)
Total identifiable liabilities acquired		(122,134)
Net identifiable assets acquired		376,136
Purchase price allocation
Net identifiable assets acquired		376,136
Goodwill		211,981
Total consideration		588,117
OHIO
Purchase price allocation
Number of dispensaries in state | dispensary								5
FLORIDA
Purchase price allocation
Number of dispensaries in state | dispensary							8
MASSACHUSETTS
Purchase price allocation
Number of dispensaries in state | dispensary						4
PENNSYLVANIA
Purchase price allocation
Number of dispensaries in state | dispensary			9	8
Verdant
Total consideration
Common shares issued		2,000
Cash		1,500
Cashless exercise option on loan		10,000
Settlement of leases		90
Loan settlement		11,414
Total consideration		25,004
Net identifiable assets (liabilities) acquired
Cash		1,360
Inventory		1,519
Other current assets		76
Property & equipment		996
Right-of-use assets		127
Other non-current assets		47
Customer relationships		1,370
License		16,320
Total identifiable assets acquired		21,815
Short-term liabilities		(1,601)
Lease liability		(127)
Deferred tax liability		(3,968)
Total identifiable liabilities acquired		(5,696)
Net identifiable assets acquired		16,119
Purchase price allocation
Net identifiable assets acquired		16,119
Goodwill		8,885
Total consideration		25,004
Ownership interest (in percent)								100%
Net reduction in goodwill		200
Verdant | Subordinate Voting Shares (SVS)
Total consideration
Total consideration								$ 100
Purchase price allocation
Total consideration								$ 100
Bluma
Total consideration
Common shares issued		183,262
Loan settlement		21,226
Warrants issued		18,415
Replacement RSU awards		10,048
Payment of acquisition-related transaction costs on behalf of the acquiree		3,373
Deferred consideration		1,806
Total consideration		238,130
Net identifiable assets (liabilities) acquired
Cash		1,623
Inventory		19,244
Loans receivable, short-term		1,600
Other current assets		1,205
Property & equipment		26,152
Right-of-use assets		13,709
Customer relationships		6,700
License		117,000
Investments		693
Total identifiable assets acquired		187,926
Short-term liabilities		(3,733)
Lease liability		(13,685)
Contract liability-loyalty program		(456)
Deferred tax liability		(36,940)
Total identifiable liabilities acquired		(54,814)
Net identifiable assets acquired		133,112
Purchase price allocation
Net identifiable assets acquired		133,112
Goodwill		105,018
Total consideration		238,130
Ownership interest (in percent)							100%
Net reduction in goodwill		500
Net increase (decrease) in goodwill	$ 1,800
Bluma | Selling, general and administrative expense
Purchase price allocation
Transaction costs		1,500
Bluma | Subordinate Voting Shares (SVS)
Total consideration
Total consideration							$ 15,100
Purchase price allocation
Total consideration							$ 15,100
Cultivate
Total consideration
Common shares issued		46,643
Loan settlement		1,852
Payment of acquisition-related transaction costs on behalf of the acquiree		1,001
Payment of 3rd-party debt on behalf of the acquiree		20,125
Contingent consideration		29,642			$ 34,000
Total consideration		99,263
Net identifiable assets (liabilities) acquired
Cash		2,938
Accounts receivable		6,494
Inventory		24,862
Other current assets		662
Property & equipment		30,128
Right-of-use assets		1,304
Customer relationships		13,600
License		12,000
Trade name		1,400
Non-compete agreements		800
Total identifiable assets acquired		94,188
Short-term liabilities		(14,585)
Lease liability		(1,304)
Deferred tax liability		(10,597)
Total identifiable liabilities acquired		(26,486)
Net identifiable assets acquired		67,702
Purchase price allocation
Net identifiable assets acquired		67,702
Goodwill		31,561
Total consideration		99,263
Ownership interest (in percent)						100%
Net reduction in goodwill		700
Net increase (decrease) in goodwill	400
Cultivate | Selling, general and administrative expense
Purchase price allocation
Transaction costs		1,600
Cultivate | Subordinate Voting Shares (SVS)
Total consideration
Total consideration						$ 4,800
Purchase price allocation
Total consideration						$ 4,800
Cure Penn
Total consideration
Common shares issued		52,610
Cash		33,304
Payment of acquisition-related transaction costs on behalf of the acquiree		3,135
Total consideration		89,049
Net identifiable assets (liabilities) acquired
Cash		751
Accounts receivable		33
Inventory		2,963
Other current assets		134
Property & equipment		1,845
Right-of-use assets		1,834
Customer relationships		2,320
License		70,950
Non-compete agreements		270
Total identifiable assets acquired		81,100
Short-term liabilities		(1,186)
Lease liability		(1,834)
Contract liability-loyalty program		(355)
Total identifiable liabilities acquired		(3,375)
Net identifiable assets acquired		77,725
Purchase price allocation
Net identifiable assets acquired		77,725
Goodwill		11,324
Total consideration		89,049
Ownership interest (in percent)				100%
Net increase (decrease) in goodwill	100
Cure Penn | Subordinate Voting Shares (SVS)
Total consideration
Total consideration				$ 6,200
Purchase price allocation
Total consideration				$ 6,200
Laurel Harvest
Total consideration
Common shares issued		65,844
Cash		20,480
Loan settlement		3,339
Payment of acquisition-related transaction costs on behalf of the acquiree		331
Deferred consideration		46,677
Total consideration		136,671
Net identifiable assets (liabilities) acquired
Cash		937
Inventory		506
Other current assets		36
Property & equipment		11,873
Right-of-use assets		859
Customer relationships		260
License		98,690
Non-compete agreements		80
Total identifiable assets acquired		113,241
Short-term liabilities		(151)
Lease liability		(859)
Deferred tax liability		(30,753)
Total identifiable liabilities acquired		(31,763)
Net identifiable assets acquired		81,478
Purchase price allocation
Net identifiable assets acquired		81,478
Goodwill		55,193
Total consideration		136,671
Ownership interest (in percent)			100%
Net increase (decrease) in goodwill	$ (1,500)
Laurel Harvest | Selling, general and administrative expense
Purchase price allocation
Transaction costs		$ 1,100
Laurel Harvest | Subordinate Voting Shares (SVS)
Total consideration
Total consideration			$ 8,400
Purchase price allocation
Total consideration			$ 8,400

Acquisitions and Dispositions_2

Acquisitions and Dispositions - Summary of Contributed Revenue and Net Income (Loss) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Disclosure Contributed Revenue And Net income (Loss) [Line Items]
Contributed revenue	$ 85,762
Net income (loss)	11,728
Verdant
Disclosure Contributed Revenue And Net income (Loss) [Line Items]
Contributed revenue	26,547
Net income (loss)	5,352
Bluma
Disclosure Contributed Revenue And Net income (Loss) [Line Items]
Contributed revenue	26,642
Net income (loss)	(8,382)
Cultivate
Disclosure Contributed Revenue And Net income (Loss) [Line Items]
Contributed revenue	29,279
Net income (loss)	14,944
Cure Penn
Disclosure Contributed Revenue And Net income (Loss) [Line Items]
Contributed revenue	2,966
Net income (loss)	(50)
Laurel Harvest
Disclosure Contributed Revenue And Net income (Loss) [Line Items]
Contributed revenue	328
Net income (loss)	$ (136)

Acquisitions and Dispositions_3

Acquisitions and Dispositions - Summary of Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition Pro Forma Information [Line Items]
Pro forma revenue	$ 902,545	$ 555,869
Pro forma adjustments:
Total pro forma net income	(295,531)	(124,587)
Cresco Labs Inc.
Business Acquisition Pro Forma Information [Line Items]
Pro forma revenue	821,682	476,251
Pro forma adjustments:
Total pro forma net income	(296,834)	(92,771)
Verdant
Business Acquisition Pro Forma Information [Line Items]
Pro forma revenue	2,677	15,195
Pro forma net income:
Pre-acquisition net income	(846)	(1,982)
Pro forma adjustments:
(a) Transaction costs	399	(399)
(c) Intangible amortization	(150)	(171)
Total pro forma adjustments	250	(571)
Total pro forma net income	(596)	(2,553)
Bluma
Business Acquisition Pro Forma Information [Line Items]
Pro forma revenue	7,906	12,338
Pro forma net income:
Pre-acquisition net income	(13,784)	(25,998)
Pro forma adjustments:
(a) Transaction costs	1,461	(1,461)
(b) Post-acquisition share-based compensation	2,440	(2,440)
(c) Intangible amortization	(599)	(853)
Total pro forma adjustments	3,302	(4,754)
Total pro forma net income	(10,482)	(30,752)
Cultivate
Business Acquisition Pro Forma Information [Line Items]
Pro forma revenue	39,033	22,965
Pro forma net income:
Pre-acquisition net income	4,550	772
Pro forma adjustments:
(a) Transaction costs	1,555	(1,555)
(c) Intangible amortization	(860)	(3,483)
Total pro forma adjustments	695	(5,037)
Total pro forma net income	5,245	(4,266)
Cure Penn
Business Acquisition Pro Forma Information [Line Items]
Pro forma revenue	29,281	29,119
Pro forma net income:
Pre-acquisition net income	8,161	8,384
Pro forma adjustments:
(a) Transaction costs	439	(439)
(c) Intangible amortization	(355)	(387)
Total pro forma adjustments	84	(826)
Total pro forma net income	8,245	7,558
Laurel Harvest
Business Acquisition Pro Forma Information [Line Items]
Pro forma revenue	1,966	1
Pro forma net income:
Pre-acquisition net income	(2,121)	(650)
Pro forma adjustments:
(a) Transaction costs	1,081	(1,081)
(c) Intangible amortization	(68)	(73)
Total pro forma adjustments	1,013	(1,153)
Total pro forma net income	$ (1,109)	$ (1,803)

Acquisitions and Dispositions_4

Acquisitions and Dispositions - Summary of Deferred and Contingent Consideration Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Detailed Information Of Deferred Consideration Contingent And Consideration [Line Items]
Cultivate contingent consideration, short-term	$ 0	$ 33,969
Total Deferred and contingent consideration, short-term	47,821	71,816
Laurel Harvest
Disclosure of Detailed Information Of Deferred Consideration Contingent And Consideration [Line Items]
Laurel Harvest deferred consideration, short-term	$ 47,821	$ 37,847

Acquisitions and Dispositions_5

Acquisitions and Dispositions - Additional Information (Details) $ in Thousands		3 Months Ended		12 Months Ended
	Nov. 04, 2022 USD ($)	Jun. 30, 2022 USD ($) shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) dispensary	Dec. 31, 2021 USD ($)	Mar. 23, 2022 shares	Sep. 30, 2021 USD ($)	Mar. 30, 2021 USD ($)
Disclosure of detailed information about business combination [line items]
Contingent consideration recognised as of acquisition date					$ 29,642
Payment of acquisition related contingent consideration classified as financing activities				$ (4,927)	0
Short-term deferred consideration					37,900
Long-term deferred consideration					9,000
Total deferred consideration					46,900
Long-term deferred consideration, reclassified amount			$ 9,000
Total estimated liability				7,770	8,577
Portion of consideration to be received upon closing of divestiture	$ 185,000
Portion of cash consideration to be received upon closing of divestiture	110,000
Portion of seller notes consideration to be received upon closing of divestiture	$ 45,000
Spider Cannabis And Plant Based Investment Corp | Discontinued operations | 180 Smoke and related intercompany receivables
Disclosure of detailed information about business combination [line items]
Discontinued operations consideration receivable on disposal								$ 1,100
Loss on disposal of business					800
Reclassification from accumulated foreign currency loss to income statement due to disposal of business				300
Cultivate
Disclosure of detailed information about business combination [line items]
Entitled earnout (up to)				$ 68,000
Contingent consideration recognised as of acquisition date					$ 29,642		$ 34,000
Contingent liabilities recognised in business combination			39,600
Payment of acquisition related contingent consideration		$ 39,600
Payment of acquisition related contingent consideration classified as financing activities		$ 4,900
Contingent liabilities settled (in shares) | shares		5,300,000
Laurel Harvest
Disclosure of detailed information about business combination [line items]
Total deferred consideration, payable period				18 months
Accelerated payment of deferred consideration required on each number of dispensaries opened (in dispensaries) | dispensary				5
Total deferred payment				$ 47,800
Interest expense on deferred consideration				900
Long-term deferred consideration reclassified to short-term			$ 9,000
Valley Agriceuticals, LLC
Disclosure of detailed information about business combination [line items]
Total estimated liability				7,800
Decrease in deferred consideration				$ 800
Columbia Care Inc.
Disclosure of detailed information about business combination [line items]
Equity interests of acquirer to be received per acquiree share upon closing of acquisition (in shares) | shares						0.5579

Acquisitions and Dispositions_6

Acquisitions and Dispositions - Summary of Long-Term Deferred Consideration (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Business Combinations And Discontinued Operations [Abstract]
Valley Agriceuticals, LLC (“Valley Ag”) operating cash flows deferred consideration	$ 7,770	$ 8,577
Laurel Harvest deferred consideration	0	9,074
Total Long-term deferred and contingent consideration	$ 7,770	$ 17,651

Long-term Notes and Loans Pay_3

Long-term Notes and Loans Payable, Net - Summary of Loans Payable Balances as Follows (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Aug. 12, 2021
Disclosure of detailed information about borrowings [line items]
Interest payable	$ 9,500	$ 9,711
Financing liability	96,917	97,797
Total borrowings and interest payable	506,417	507,508
Less: Unamortized debt issuance costs	(18,550)	(22,501)
Less: Short-term borrowings and interest payable	(9,500)	(9,711)
Less: Current portion of financing liability	(9,312)	(10,217)
Total Long-term notes and loans payable, net	469,055	465,079
Senior Loan
Disclosure of detailed information about borrowings [line items]
Senior Loan	$ 400,000	$ 400,000	$ 400,000

Long-term Notes and Loans Pay_4

Long-term Notes and Loans Payable, Net - Additional Information (Details)				3 Months Ended	12 Months Ended
	Aug. 12, 2021 USD ($)	Dec. 11, 2020 USD ($)	Feb. 02, 2020 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Disclosure of detailed information about borrowings [line items]
Payments for debt issue costs					$ 0	$ 6,461,000
Adjustments for finance income (cost)					(3,951,000)	(11,304,000)
Gain (loss) on extinguishment of debt					$ 0	$ (17,987,000)
Bottom of range
Disclosure of detailed information about borrowings [line items]
Weighted average lessee's incremental borrowing rate (in percent)					11.30%	11.20%
Weighted average remaining lease term (in years)					10 years 4 months 24 days	8 years 1 month 6 days
Top of range
Disclosure of detailed information about borrowings [line items]
Weighted average lessee's incremental borrowing rate (in percent)					17.50%	17.50%
Weighted average remaining lease term (in years)					17 years 6 months	18 years 6 months
Term Loan | Loan commitments
Disclosure of detailed information about borrowings [line items]
Borrowings			$ 100,000,000
Term Loan | Bottom of range
Disclosure of detailed information about borrowings [line items]
Borrowings			100,000,000
Term Loan | Top of range
Disclosure of detailed information about borrowings [line items]
Option to increase principal amount of borrowings			$ 200,000,000
Term Loan, Tranche A Commitment
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate (in percent)			12.70%
Borrowings, maturity			July 22, 2021
Effective interest rate (in percent)			17%
Borrowing costs capitalised			$ 5,500,000
Term Loan, Tranche A Commitment | Loan commitments
Disclosure of detailed information about borrowings [line items]
Borrowings			$ 92,400,000
Term Loan, Tranche B Commitment
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate (in percent)			13.20%
Borrowings, maturity			January 22, 2022
Effective interest rate (in percent)			16.10%
Borrowing costs capitalised			$ 400,000
Term Loan, Tranche B Commitment | Loan commitments
Disclosure of detailed information about borrowings [line items]
Borrowings			$ 7,600,000
Amended Term Loan
Disclosure of detailed information about borrowings [line items]
Amended term loan						$ 0
Borrowing costs recognised as expense		$ 200,000
Payments for debt issue costs		800,000
Amended Term Loan | Loan commitments
Disclosure of detailed information about borrowings [line items]
Borrowings		200,000,000
Amended Term Loan, Non-Extending Lenders Commitment
Disclosure of detailed information about borrowings [line items]
Borrowings		$ 11,700,000
Borrowings, interest rate (in percent)		12.70%
Effective interest rate (in percent)		17.70%
Amended Term Loan, Extending Lenders Commitment
Disclosure of detailed information about borrowings [line items]
Borrowings		$ 97,300,000
Amended Term Loan, Increasing Lenders Commitment
Disclosure of detailed information about borrowings [line items]
Borrowings		91,000,000
OCN Term Loan Lender
Disclosure of detailed information about borrowings [line items]
Repayments of current borrowings		5,400,000
Term Loan Lenders
Disclosure of detailed information about borrowings [line items]
Repayments of current borrowings		$ 1,000,000
Amended Term Loan, Extending and Increasing Lenders Commitment
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate (in percent)		12%
Effective interest rate (in percent)		15.80%
Senior Loan
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 400,000,000				$ 400,000,000	$ 400,000,000
Borrowings, interest rate (in percent)	9.50%
Borrowings, maturity	August 12, 2026
Effective interest rate (in percent)	11%
Borrowing costs capitalised	$ 10,900,000
Adjustments for finance income (cost)	(13,000,000)
Gain (loss) on extinguishment of debt	(18,000,000)
Principal repayment of the Senior Loan	$ 7,000,000			$ 16,600,000
Minimum cash balance required to be maintained					$ 50,000,000
Fixed charge coverage ratio					2

Revenues and Loyalty Programs -

Revenues and Loyalty Programs - Summary of Disaggregated Revenue by Source (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Revenues	$ 842,681	$ 821,682
Wholesale
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Revenues	367,222	414,908
Dispensary
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Revenues	$ 475,459	$ 406,774

Revenues and Loyalty Programs_2

Revenues and Loyalty Programs - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Sales discounts (in percent)	107	70
Loyalty points outstanding	126,100,000	94,100,000
Loyalty points outstanding value	$ 2,100,000	$ 1,300,000
Loyalty point expected redemption period	1 year
Bottom of range
Disclosure of disaggregation of revenue from contracts with customers [line items]
Discount on future purchases	$ 0.01
Revenue reduction per loyalty point	0.01
Top of range
Disclosure of disaggregation of revenue from contracts with customers [line items]
Discount on future purchases	$ 0.1
Revenue reduction per loyalty point	0.04

Other Income , Net - Summary of

Other Income , Net - Summary of Other Income, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Other Operating Income (Expense) [Abstract]
Unrealized gain on derivative liabilities - warrants	$ 1,184	$ 16,669
(Loss) gain on derivative instruments	(5,698)	23,909
Gain (loss) on provision - loan receivable	572	(753)
Unrealized loss on investments held at fair value	(4,609)	(7,135)
Loss on debt extinguishment	0	(17,987)
Gain (loss) on conversion of investment	22	(880)
Gain (loss) on disposition of assets	14,711	(6)
Gain (loss) on foreign currency	931	(1,228)
Gain (loss) on lease termination	4,876	(43)
Other income, net	3,238	485
Total Other income, net	$ 15,227	$ 13,031

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) redeemableUnit in Millions		3 Months Ended		12 Months Ended
	Aug. 12, 2021 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2022 USD ($) redeemableUnit	Dec. 31, 2021 USD ($)
Disclosure of transactions between related parties [line items]
Non-controlling interests				$ (39,356,000)	$ 42,182,000
Interest expense				57,837,000	51,211,000
Interest payable				12,900,000	12,600,000
Right-of-use assets				128,264,000	88,017,000
Interest expense on finance liabilities				$ 3,952,000	4,053,000
Cultivation Facility And Production Facility, California
Disclosure of transactions between related parties [line items]
Right-of-use assets		$ 0
Gain (loss) on termination of lease		$ 4,900,000
Joe Caltabiano
Disclosure of transactions between related parties [line items]
Ownership interest (in percent)				11.80%
Individuals
Disclosure of transactions between related parties [line items]
Ownership interest (in percent)				21.90%
Borrowings with Related Parties
Disclosure of transactions between related parties [line items]
Interest expense				$ 0	1,200,000
Interest payable				$ 0	0
Amended Term Loan
Disclosure of transactions between related parties [line items]
Amended term loan					$ 0
Senior Loan
Disclosure of transactions between related parties [line items]
Principal repayment of the Senior Loan	$ 7,000,000		$ 16,600,000
Key management personnel of entity or parent
Disclosure of transactions between related parties [line items]
Number of redeemable units held by related party | redeemableUnit				89.9
Non-controlling interests				$ 24,700,000
Tax distribution payments to related party (in percent)				74.40%	84.70%
Reimbursements of tenant improvement allowance				$ 1,400,000
Expected reimbursements of tenant improvement allowance				800,000
MVS shareholder
Disclosure of transactions between related parties [line items]
Interest expense on finance liabilities				300,000	300,000
Finance liabilities				$ 1,500,000	$ 1,500,000
Incremental borrowing rate (in percent)				17.20%	17.20%

Related Party Transactions - Su

Related Party Transactions - Summary of Expense Resulting From The Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [line items]
Interest expense on finance liabilities	$ 3,952	$ 4,053
MVS shareholder
Disclosure of transactions between related parties [line items]
Interest expense on finance liabilities	300	300
MVS shareholder | Operating Leases
Disclosure of transactions between related parties [line items]
Rent expense	1,187	1,168
MVS shareholder | Finance Leases
Disclosure of transactions between related parties [line items]
Depreciation expense	81	74
Interest expense on finance liabilities	76	88
SLO Cultivation Inc. | Subsidiaries | Operating Leases
Disclosure of transactions between related parties [line items]
Rent expense	513	1,563
MedMar Inc. | Subsidiaries | Operating Leases
Disclosure of transactions between related parties [line items]
Rent expense	288	238
MedMar Inc. | Subsidiaries | Finance Leases
Disclosure of transactions between related parties [line items]
Depreciation expense	306	277
Interest expense on finance liabilities	$ 270	$ 310

Related Party Transactions - _2

Related Party Transactions - Summary of ROU Assets And Lease Liabilities Attributable To Related Party Transactions (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [line items]
Right-of-use assets	$ 128,264	$ 88,017
Present value of lease liabilities	182,304
Finance Leases
Disclosure of transactions between related parties [line items]
Right-of-use assets	22,137	25,688
Present value of lease liabilities	29,585
MVS shareholder | Operating Leases
Disclosure of transactions between related parties [line items]
Right-of-use assets	5,849	6,314
Present value of lease liabilities	5,907	4,867
MVS shareholder | Finance Leases
Disclosure of transactions between related parties [line items]
Right-of-use assets	596	616
Present value of lease liabilities	555	1,063
SLO Cultivation Inc. | Subsidiaries | Operating Leases
Disclosure of transactions between related parties [line items]
Right-of-use assets	0	6,996
Present value of lease liabilities	0	11,938
MedMar Inc. | Subsidiaries | Operating Leases
Disclosure of transactions between related parties [line items]
Right-of-use assets	1,415	1,525
Present value of lease liabilities	1,456	1,549
MedMar Inc. | Subsidiaries | Finance Leases
Disclosure of transactions between related parties [line items]
Right-of-use assets	2,034	2,137
Present value of lease liabilities	$ 2,452	$ 2,457

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Commitments And Contingencies [Line Items]
Loss contingency, damages awarded		$ 1,300
Contingent liabilities					$ 13,600
Selling, general and administrative expense			$ 350,653	$ 317,804
Severance costs			4,600
Construction projects
Commitments And Contingencies [Line Items]
Total commitments			19,000
Illinois Company, Secured Craft Grower Licenses
Commitments And Contingencies [Line Items]
Loans issued	$ 200
Groups Identified by State of Illinois, Opportunity To Receive Conditional Adult Use Dispensing Organization Licenses
Commitments And Contingencies [Line Items]
Loans issued	$ 1,000
Subordinate Voting Shares (SVS)
Commitments And Contingencies [Line Items]
Increase through other contributions by owners, equity				15,800
Amortisation, intangible assets other than goodwill				3,000
Litigation accrual adjustment				$ 800
Subordinate Voting Shares (SVS) | Bottom of range
Commitments And Contingencies [Line Items]
Selling, general and administrative expense			$ 12,800

Financial Instruments And Fin_3

Financial Instruments And Financial Risk Management - Summary Of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounts payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	$ 28,093	$ 32,278
Financial liabilities, fair value	28,093	32,278
Accrued liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	65,161	95,442
Financial liabilities, fair value	65,161	95,442
Short-term borrowings
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	18,812	19,928
Financial liabilities, fair value	18,812	19,928
Current portion of lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	26,124	20,792
Financial liabilities, fair value	26,124	20,792
Deferred consideration, contingent consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost		5
Financial liabilities, fair value		71,833
Derivative liabilities, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost		0
Financial liabilities, fair value		1,172
Deferred consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	6
Financial liabilities, fair value	47,834
Lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	156,180	118,936
Financial liabilities, fair value	156,180	118,936
Deferred consideration, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	0	0
Financial liabilities, fair value	7,770	17,651
Long-term notes payable and loans payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	469,055	465,079
Financial liabilities, fair value	469,055	465,079
Other long-term liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	7,000	7,001
Financial liabilities, fair value	7,000	7,001
Level 1 | Accounts payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Accrued liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Short-term borrowings
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Current portion of lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Deferred consideration, contingent consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value		12
Level 1 | Derivative liabilities, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value		0
Level 1 | Deferred consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	7
Level 1 | Lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Deferred consideration, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Long-term notes payable and loans payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Other long-term liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Accounts payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Accrued liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Short-term borrowings
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Current portion of lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Deferred consideration, contingent consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value		0
Level 2 | Derivative liabilities, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value		0
Level 2 | Deferred consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0
Level 2 | Lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Deferred consideration, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Long-term notes payable and loans payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Other long-term liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Accounts payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Accrued liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Short-term borrowings
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Current portion of lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Deferred consideration, contingent consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	47,821	71,816	$ 19,093
Level 3 | Derivative liabilities, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	1,172	0
Level 3 | Deferred consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	47,821
Level 3 | Lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Deferred consideration, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	7,770	17,651	7,247
Level 3 | Long-term notes payable and loans payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Other long-term liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Cash and cash equivalents
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	119,341	223,543
Financial assets, fair value	119,341	223,543
Cash and cash equivalents | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Cash and cash equivalents | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Cash and cash equivalents | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Restricted cash
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	2,169	2,559
Financial assets, fair value	2,169	2,559
Restricted cash | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Restricted cash | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Restricted cash | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Security deposits
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	4,367	3,941
Financial assets, fair value	4,367	3,941
Security deposits | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Security deposits | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Security deposits | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Accounts receivable, net
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	56,492	43,379
Financial assets, fair value	56,492	43,379
Accounts receivable, net | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Accounts receivable, net | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Accounts receivable, net | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	447	747
Financial assets, fair value	447	1,312
Loans receivable, short-term | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, short-term | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, short-term | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	565	1,517
Loans receivable, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	823	505
Financial assets, fair value	823	505
Loans receivable, long-term | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, long-term | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, long-term | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0	20,019
Investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	0	0
Financial assets, fair value	1,228	5,912
Investments | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	136	4,710
Investments | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	432	542
Investments | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	$ 660	$ 660	$ 119

Financial Instruments And Fin_4

Financial Instruments And Financial Risk Management - Rollforward of Level 3 Amounts Measured At Fair Value On Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred consideration, contingent consideration and other payables, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	$ 71,833
Ending balance		$ 71,833
Derivative liabilities, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	1,172
Ending balance		1,172
Deferred consideration, long-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	17,651
Ending balance	7,770	17,651
Level 3 | Deferred consideration, contingent consideration and other payables, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	71,816	19,093
Additions		69,099
Change in fair value	900
Payments	(39,542)	(1,829)
Settlement		0
Other	9,000	0
Ending balance	47,821	71,816
Level 3 | Deferred consideration, contingent consideration and other payables, short-term | Other Income
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value	5,647	(14,743)
Level 3 | Deferred consideration, contingent consideration and other payables, short-term | Selling, general and administrative expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value	0	0
Level 3 | Deferred consideration, contingent consideration and other payables, short-term | Interest Expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value		196
Level 3 | Derivative liabilities, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	1,172	0
Additions		0
Change in fair value	0
Payments	0	0
Settlement		0
Other	0	13,042
Ending balance	0	1,172
Level 3 | Derivative liabilities, short-term | Other Income
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value	(1,172)	(11,897)
Level 3 | Derivative liabilities, short-term | Selling, general and administrative expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value	0	0
Level 3 | Derivative liabilities, short-term | Interest Expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value		27
Level 3 | Derivative liabilities, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	0	17,505
Additions		0
Payments		0
Settlement		(9)
Other		(13,042)
Ending balance		0
Level 3 | Derivative liabilities, short-term | Other Income
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value		(4,231)
Level 3 | Derivative liabilities, short-term | Selling, general and administrative expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value		0
Level 3 | Derivative liabilities, short-term | Interest Expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value		(223)
Level 3 | Deferred consideration, long-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	17,651	7,247
Additions		9,026
Change in fair value	(881)
Payments	0	0
Settlement		0
Other	(9,000)	0
Ending balance	7,770	17,651
Level 3 | Deferred consideration, long-term | Other Income
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value	0	0
Level 3 | Deferred consideration, long-term | Selling, general and administrative expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value	0	0
Level 3 | Deferred consideration, long-term | Interest Expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value		1,378
Loans receivable, short-term
Changes in fair value measurement, assets [abstract]
Beginning balance	1,312
Ending balance	447	1,312
Loans receivable, short-term | Level 3
Changes in fair value measurement, assets [abstract]
Beginning balance	565	1,517
Additions		0
Change in fair value	0
Payments	(1,837)	(400)
Settlement		0
Other	0	0
Ending balance	0	565
Loans receivable, short-term | Level 3 | Other Income
Changes in fair value measurement, assets [abstract]
Change in fair value	0	0
Loans receivable, short-term | Level 3 | Selling, general and administrative expense
Changes in fair value measurement, assets [abstract]
Change in fair value	1,272	(552)
Loans receivable, short-term | Level 3 | Interest Expense
Changes in fair value measurement, assets [abstract]
Change in fair value		0
Loans receivable, long-term
Changes in fair value measurement, assets [abstract]
Beginning balance	505
Ending balance	823	505
Loans receivable, long-term | Level 3
Changes in fair value measurement, assets [abstract]
Beginning balance	0	20,019
Additions		0
Payments		0
Settlement		(20,019)
Other		0
Ending balance	0	0
Loans receivable, long-term | Level 3 | Other Income
Changes in fair value measurement, assets [abstract]
Change in fair value		0
Loans receivable, long-term | Level 3 | Selling, general and administrative expense
Changes in fair value measurement, assets [abstract]
Change in fair value		0
Loans receivable, long-term | Level 3 | Interest Expense
Changes in fair value measurement, assets [abstract]
Change in fair value		0
Investments
Changes in fair value measurement, assets [abstract]
Beginning balance	5,912
Ending balance	1,228	5,912
Investments | Level 3
Changes in fair value measurement, assets [abstract]
Beginning balance	660	119
Additions		593
Change in fair value	0
Payments	0	0
Settlement		(52)
Other	0	0
Ending balance	660	660
Investments | Level 3 | Other Income
Changes in fair value measurement, assets [abstract]
Change in fair value	0	0
Investments | Level 3 | Selling, general and administrative expense
Changes in fair value measurement, assets [abstract]
Change in fair value	$ 0	0
Investments | Level 3 | Interest Expense
Changes in fair value measurement, assets [abstract]
Change in fair value		$ 0

Financial Instruments And Fin_5

Financial Instruments And Financial Risk Management - Summary of Loans Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Loans receivable, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	$ 447	$ 1,312
Financial assets, amortized cost	447	747
Interest receivable	0	747
Financial assets	447	1,312
Loans receivable, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	823	505
Financial assets, amortized cost	823	505
Financial assets	823	505
Loans receivable, long-term | Origin House
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets		400
Lighthouse | Loans receivable, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	565
Illinois Incubator, Net Of Expected Credit Loss | Loans receivable, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	823	100
Other, Net Of Expected Credit Loss | Loans receivable, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	447	0
Other, Net Of Expected Credit Loss | Loans receivable, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	$ 0	$ 405

Financial Instruments And Fin_6

Financial Instruments And Financial Risk Management - Additional Information (Details) - USD ($) shares in Millions				3 Months Ended	12 Months Ended
	Mar. 21, 2022	Jul. 20, 2021	Aug. 12, 2019	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Aug. 12, 2021
Disclosure of detailed information about financial instruments [line items]
Derivative liabilities, short-term					$ 0	$ 1,172,000
Gain (loss) on foreign currency					931,000	(1,228,000)
Expenses for bad and doubtful debt					400,000	1,000,000
Bad debts write-offs					1,900,000	300,000
Senior Loan
Disclosure of detailed information about financial instruments [line items]
Borrowings, interest rate (in percent)								9.50%
Effective interest rate (in percent)								11%
Liquidity risk
Disclosure of detailed information about financial instruments [line items]
Working capital					$ 43,000,000
Currency risk
Disclosure of detailed information about financial instruments [line items]
Gain (loss) on foreign currency						$ (1,200,000)
Average rate of hedging instrument					0%	0%
Share purchase warrants
Disclosure of detailed information about financial instruments [line items]
Derivative liabilities, short-term						$ 4,200,000	$ 0
Increase (decrease) in share price					$ 1,200,000	16,700,000
Gain (loss) on foreign currency						(300,000)
Share purchase warrants | Historical volatility for shares, measurement input
Disclosure of detailed information about financial instruments [line items]
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities						$ 5,200,000
Share purchase warrants | September 2019 Financing
Disclosure of detailed information about financial instruments [line items]
Warrants outstanding (in shares)					0	9.8
Derivative liabilities, short-term						$ 3,700,000
Illinois Company, Secured Craft Grower Licenses
Disclosure of detailed information about financial instruments [line items]
Loans issued				$ 200,000
Groups Identified by State of Illinois, Opportunity To Receive Conditional Adult Use Dispensing Organization Licenses
Disclosure of detailed information about financial instruments [line items]
Loans issued				$ 1,000,000
Loans receivable, long-term
Disclosure of detailed information about financial instruments [line items]
Financial assets					$ 823,000	505,000
Financial assets at amortised cost, category | Loans and receivables, category
Disclosure of detailed information about financial instruments [line items]
Loans issued, fully funded	$ 1,200,000
Financial assets at amortised cost, category | Illinois Company, Secured Craft Grower Licenses | Loans and receivables, category
Disclosure of detailed information about financial instruments [line items]
Loans issued					300,000
Loans issued, fully funded		$ 100,000
Financial assets at amortised cost, category | Groups Identified by State of Illinois, Opportunity To Receive Conditional Adult Use Dispensing Organization Licenses | Loans and receivables, category
Disclosure of detailed information about financial instruments [line items]
Loans issued					$ 1,000,000
Lighthouse
Disclosure of detailed information about financial instruments [line items]
Ownership interest in subsidiaries (in percent)			1%
Origin House | Loans receivable, long-term
Disclosure of detailed information about financial instruments [line items]
Financial assets						$ 400,000

Financial Instruments And Fin_7

Financial Instruments And Financial Risk Management - Disclosure of Liability-Classified Warrants Fair Value Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets and Liabilities [Line Items]
Expected annual dividend yield	0%	0%
Share purchase warrants
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets and Liabilities [Line Items]
Risk-free annual interest rate		0.15%
Expected annual dividend yield		0%
Expected stock price volatility		47.30%
Expected life of stock warrants (in years) (less than)		1 year
Forfeiture rate		0%
Share price at period end (in dollars per share)		$ 6.62
Strike price at period end (in dollars per share)		9.86

Financial Instruments And Fin_8

Financial Instruments And Financial Risk Management - Summary of Aging Accounts Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, gross	$ 59,119	$ 45,599
Allowance for doubtful accounts	2,627	2,220
Total accounts receivable, net	56,492	43,379
0 to 60 days
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, gross	49,303	37,750
61 to 120 days
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, gross	6,118	4,309
120 days +
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, gross	$ 3,698	$ 3,540

Financial Instruments And Fin_9

Financial Instruments And Financial Risk Management - Summary of Contractual Obligations (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	$ 643,725
Less Than One Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	159,900
1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	7,770
3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	476,055
Accounts payable & Accrued liabilities
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	93,254
Accounts payable & Accrued liabilities | Less Than One Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	93,254
Accounts payable & Accrued liabilities | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Accounts payable & Accrued liabilities | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Deferred consideration, contingent consideration and other payables, short-term
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	47,834
Deferred consideration, contingent consideration and other payables, short-term | Less Than One Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	47,834
Deferred consideration, contingent consideration and other payables, short-term | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Deferred consideration, contingent consideration and other payables, short-term | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Deferred consideration, long-term
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	7,770
Deferred consideration, long-term | Less Than One Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Deferred consideration, long-term | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	7,770
Deferred consideration, long-term | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Long-term notes payable and loans payable and Short-term borrowings
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	487,867
Long-term notes payable and loans payable and Short-term borrowings | Less Than One Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	18,812
Long-term notes payable and loans payable and Short-term borrowings | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Long-term notes payable and loans payable and Short-term borrowings | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	469,055
Other long-term liabilities
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	7,000
Other long-term liabilities | Less Than One Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations
Other long-term liabilities | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations
Other long-term liabilities | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	$ 7,000

Variable Interest Entities - Su

Variable Interest Entities - Summary of Assets Liabilities and Networth of Variable Interest Entities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Summary of Assets Liabilities and Networth of Variable Interest Entities [line Items]
Current assets	$ 326,046	$ 421,755
Non-current assets	1,257,646	1,358,708
Current liabilities	(280,866)	(288,394)
Non-current liabilities	(715,143)	(694,333)
Deficit attributable to Cresco Labs Inc.	627,039	755,554
Cresco Labs Michigan, LLC
Summary of Assets Liabilities and Networth of Variable Interest Entities [line Items]
Current assets	17,506	9,850
Non-current assets	63,212	63,320
Current liabilities	(3,158)	(9,476)
Non-current liabilities	(108,113)	(86,124)
Deficit attributable to Cresco Labs Inc.	$ (30,553)	$ (22,430)

Variable Interest Entities - _2

Variable Interest Entities - Summary of Income Expenses and Net Income Loss of Variable Interest Entities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Summary of Income Expenses and Net Income Loss of Variable Interest Entities [line Items]
Revenue	$ 842,681	$ 821,682
Net income (loss) attributable to Cresco Labs Inc.	(212,047)	(319,597)
Net income (loss)	(215,843)	(296,834)
Cresco Labs Michigan, LLC
Summary of Income Expenses and Net Income Loss of Variable Interest Entities [line Items]
Revenue	12,659	4,031
Net income (loss) attributable to Cresco Labs Inc.	(8,617)	(9,120)
Net income (loss)	$ (8,617)	$ (9,120)

Segment Information - Additiona

Segment Information - Additional Information (Detail) - segment	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of operating segments [line items]
Number of operating segments	1
USA
Disclosure of operating segments [line items]
Percentage of entity's revenue	100%	99.60%

Interest Expense, Net - Summary

Interest Expense, Net - Summary of Interest Expense, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Interest Income (Expense) [Abstract]
Interest expense – leases	$ (3,952)	$ (4,053)
Interest expense – notes and loans payable	(38,528)	(29,661)
Accretion of debt discount and amortization of deferred financing fees	(3,951)	(5,153)
Interest expense – financing activities and sale and leasebacks	(11,887)	(11,586)
Other interest expense	(198)	(1,696)
Interest income	679	938
Total Interest expense, net	$ (57,837)	$ (51,211)

Provision For Income Taxes An_3

Provision For Income Taxes And Deferred Income Taxes - Summary of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current	$ 93,581	$ 75,152
Deferred	(17,000)	(37,729)
Change in valuation allowance	12,357	2,684
Total	88,938	40,107
Federal
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current	69,240	51,815
Deferred	(8,332)	(29,445)
State
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current	24,341	23,337
Deferred	(9,858)	(14,043)
Foreign
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current	0	0
Deferred	$ 1,190	$ 5,759

Provision For Income Taxes An_4

Provision For Income Taxes And Deferred Income Taxes - Summary of Components of Deferred Tax Assets And Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	$ 75,711	$ 67,397
Deferred tax liabilities	(107,381)	(115,418)
Valuation allowance	(43,442)	(31,085)
Net deferred tax liabilities	(75,112)	(79,105)
Share-based compensation
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	1,381	1,029
Financing fees
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	1,291	2,542
Net operating losses
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	43,629	36,096
Inventory
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	662	239
Lease liabilities
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	28,362	26,761
Other
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	386	730
Deferred tax liabilities	(1,329)	(1,948)
ROU assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	(9,560)	(7,824)
Property, plant and equipment
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	(12,393)	(11,885)
Intangible assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	$ (84,099)	$ (93,761)

Provision For Income Taxes An_5

Provision For Income Taxes And Deferred Income Taxes - Summary of Reconciliation Between The Effective Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Expected income tax expense at statutory tax rate	$ (26,650)	$ (53,912)
Tax rate differences	(2,296)	(1,109)
Pass through and non-controlling entities	(2,183)	(7,373)
State tax expense, net	6,782	8,697
IRC Section 280E disallowance	50,521	47,100
Changes in value of deferred consideration	699	(10,103)
Loss on debt modification	0	7,554
Uncertain tax treatment (including penalties and interest)	13,245	(4,749)
Share-based compensation	2,097	3,941
Goodwill impairment	25,334	45,314
Accrued current tax penalties and interest	4,155	563
Change in valuation allowance	12,357	2,684
Change in state tax rates	4,520	622
Other	357	876
Total	$ 88,938	$ 40,107
Effective tax rate	(70.10%)	(15.60%)

Provision For Income Taxes An_6

Provision For Income Taxes And Deferred Income Taxes - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Increase (decrease) through business combinations, deferred tax liability (asset)	$ 1.2
Deferred tax liability (asset)	0.6	$ 5.6
Increase (decrease) in deferred tax liability (asset)	0.4
Unrecognized tax benefits reserve	12.7
Unrecognized tax benefits, penalties and interest	0.5
Canadian non-capital
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Operating loss carryforward, offset by valuation allowance	63.5	66.1
U.S Federal
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Operating loss carryforward, offset by valuation allowance	45.7	0.4
Operating loss carryforward	52.2	30.8
State and Local Jurisdiction
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Operating loss carryforward, offset by valuation allowance	180.8	128
Operating loss carryforward	$ 184.3	$ 138.3

Provision For Income Taxes An_7

Provision For Income Taxes And Deferred Income Taxes - Schedule Of Reconciliation Of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation Of Unrecognized Tax Benefits [Roll Forward]
Balance at January 1	$ 0	$ 4,749
Additions based on tax positions related to the current year	7,380	0
Additions for tax positions of prior years	5,366	0
Reductions for tax positions of prior years	0	(4,749)
Balance at the end of the year	$ 12,746	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Forecast
Disclosure of non-adjusting events after reporting period [table]
Payment of previous tax obligations	$ 30.9